Methods for the degradation of HIF-1b (ARNT) via a CRBN / ARNT / small molecule ternary complex
A ternary complex of CRBN, ARNT, and a small molecule induces ARNT degradation, addressing the challenge of regulating HIF-1β levels, thereby treating diseases associated with hypoxia-induced pathways and angiogenesis.
Patent Information
- Application Number
- PCT/US2026/027217
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods fail to effectively degrade HIF-1β (ARNT) protein levels, which are crucial for regulating cellular responses to hypoxia and are implicated in various diseases, including cancer and angiogenic disorders, due to the lack of specific small molecules that can induce conformational changes necessary for ubiquitination and degradation.
Formation of a ternary complex between CRBN, ARNT, and a small molecule induces a non-natural conformational change in ARNT, facilitating its ubiquitination and subsequent degradation by the CRL4-CRBN E3 ubiquitin ligase.
This approach effectively reduces ARNT protein levels, potentially treating a range of diseases by modulating hypoxia-induced pathways and angiogenesis, offering therapeutic benefits for conditions like cancer, cardiovascular diseases, and ocular conditions.
Smart Images

Figure IMGF000112_0001 
Figure IMGF000116_0001 
Figure IMGF000120_0001
Abstract
Description
[0001] Attorney Docket No.: N2109-7007WO
[0002] METHODS FOR THE DEGRADATION OF HIF-1B (ARNT) VIA A CRBN / ARNTZ SMALL MOLECULE TERNARY COMPLEX CLAIM OF PRIORITY
[0003] The present application claims priority to U. S. Application No. 63 / 801,740, filed May 7, 2025, and U. S. Application No. 64 / 041,463, filed April 16, 2026. The entire contents of the foregoing applications are incorporated herein by reference.
[0004] FIELD OF THE DISCLOSURE
[0005] The present disclosure relates to methods for the degradation of hypoxia inducible factor 1 beta (HIF-ip, also known as ARNT) via the formation of a ternary complex comprising CRBN, ARNT, and a small molecule via specific ARNT / ARNT, CRBN / ARNT and ARNT / CRBN / small molecule interactions as well as methods for identifying small molecules that cause CRBN mediated degradation of ARNT.
[0006] BACKGROUND OF THE DISCLOSURE
[0007] The HIF transcription factors are master regulators of the cellular response to hypoxia. The HIF transcriptional regulator acts as a heterodimeric complex consisting of the constitutively expressed hypoxia inducible factor 1 beta (HIF-ip, also known as ARNT) and either of the two HIF-a isoforms, HIF-la or HIF-2a. HIF-ip is a key player in both the hypoxic-response pathway and the aryl hydrocarbon receptor (AHR) pathway. The first evidence provided that the HIF heterodimer not only activates the erythropoietin gene but is also part of a widespread oxygen-sensing and signal transduction mechanism was demonstrated when HIF activity was detected in various non-erythropoietin-producing cell lines cultured under hypoxic conditions (Wang and Semenza, Proc. Natl. Acad. Sci. USA, 1993, 90, 4304-4308; Maxwell et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 2423-2427).
[0008] Oxygen supply to tissues is essential in maintaining mammalian cell function and physiology and a deficiency in oxygen supply to tissues is a characteristic of a number of conditions in which there is insufficient blood flow to provide adequate oxygenation. Examples of diseases affected by inadequate oxygen supply include ischemic disorders, cancer, and atherosclerosis. Activation of a signaling cascade occurs in response to this hypoxic environment in tissues which drives the induction or repression of the transcription of a multitude of genes implicated in events such as angiogenesis (neo-vascularization), glucose metabolism, and cell survival / death. A key to this hypoxic transcriptional response lies in the transcription factors, the hypoxia inducible factors (HIF).
[0009] It has been shown that both HIF-a isoforms are rapidly degraded under normoxic conditions due to the oxygen-dependent hydroxylation of specific proline residues that mark the proteins for proteasomal degradation (Jewell, et al., Faseb. J, 2001, 15, 1312-1314; Gorlach, et al., Biochim. Biophys. Acta, 2000, 1493, 125-134) and that under hypoxic conditions this hydroxylation is reversed, and the protein is furtherAttorney Docket No.: N2109-7007WO
[0010] stabilized by phosphorylation (Wang et al., Biochem. Biophys. Res. Commun, 1995, 216, 669-675). Consequently, the HIF-a proteins are then translocated to the nucleus, where they interact with HIF-ip to form a heterodimeric transcription factor (Kallio et al., Embo J, 1998, 17, 6573-6586). The dimerization step has been shown in HIF- 1 p deficient cells to be an absolute requirement for the transcriptional activation of hypoxia response element genes (Wood et al., J. Biol. Chem., 1996, 271, 15117-15123). As a result, there are categories of genes that are activated by the HIF dimer which include oxygen transport genes, such as erythropoietin (Semenza, et al., J. Biol. Chem., 1994, 269, 23757- 23763) and transferrin (Rolfs et al., J. Biol. Chem., 1997, 272, 20055-20062); as well as genes involved in angiogenesis, such as VEGF (Levy et al., J. Biol. Chem., 1995, 270, 13333-13340); and genes involved in anaerobic metabolism, such as glucose transporter 1 (Ebert et al., J. Biol. Chem., 1995, 270, 29083-29089). It is thought that hypoxia-induced genes such as VEGF play a role in promoting angiogenesis and subsequent tumor growth (Harris, Nat. Rev. Cancer, 2002, 2, 38-47).
[0011] Cellular oxygen concentration precisely regulates HIF transcriptional activity. While changes in oxygen levels do not affect HIF-ip protein levels, the abundance of the HIF-a subunits is markedly increased upon exposure of cells to hypoxia, primarily due to stabilization of the alpha subunits (Safran and Kaelin, J. Clin. Invest., 2003, 111, 779-783). The HIF-2a / HIF-ip heterodimer protein, which contains the core recognition sequence 5'-TACGTG-3', binds to the hypoxic response element and is found in the cis-rcgulatory regions of hypoxia-regulated genes (Ema, et al., Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 4273-4278; Hogenesch, et al., J. Biol. Chem., 1997, 272, 8581-8593). It has been shown that binding of the heterodimer to the hypoxia-responsive element (HRE) induces gene expression (Wiesener, et al., Blood, 1998, 92, 2260-2268).
[0012] A range of other genes regulated by the dioxin response element (DRE) can also be activated by HIF dimers resulting in some of the toxic and carcinogenic effects associated with many of the AHR ligands, such as immunotoxicity, developmental and reproductive toxicity, disruption of endocrine pathways, wasting syndrome, and tumor promotion Safe, Toxicol. Lett., 2001, 120, 1-7). It has been demonstrated that the AHR / HIF-ip heterodimer directly associates with the estrogen receptors ER-a and ER-P and that this association results in the recruitment of unliganded estrogen receptor and coactivator p300 to estrogen-responsive gene promoters. This association has been shown to lead the activation of transcription and estrogenic effects and to give rise to the adverse estrogen-related actions of dioxin-type environmental contaminants (Ohtake et al., Nature, 2003, 423, 545-550).
[0013] In summary, HIF-ip plays an important role in both the hypoxia-induced and AHR signaling pathways, w hich have been linked to various forms of malignancies (Harris, Nat. Rev. Cancer, 2002, 2, 38-47; Safe, Toxicol. Lett., 2001, 120, 1-7). The angiogenic promoting capabilities of HIF-ip also make it aAttorney Docket No.: N2109-7007WO
[0014] potential therapeutic target for a variety of angiogenic disorders, such as arthritis, cardiovascular diseases, skin conditions, aberrant wound healing and ocular conditions (e.g., macular degeneration, diabetic retinopathy, diabetic macular edema and retinopathy of prematurity). Reduction of HIF- 1 p levels with small molecule modulators therefore has the potential to be a treatment for a range of diseases, including cancers, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases and other HIF-related diseases.
[0015] SUMMARY OF THE DISCLOSURE
[0016] We have discovered that certain synthetic small molecules bind to CRBN and ARNT to form a ternary complex with a previously unobserved induced structure of the ARNT protein. The induced structure of tire ARNT protein is a non-natural conformational change in the ARNT protein which is observed as a result of intramolecular interactions between the PAS-1 and PAS-2 domains of the ARNT protein. Without being bound by theory, the formation of the ternary complex and the non-natural conformational change enables the ubiquitination of the ARNT protein by the CRL4-CRBN E3 ubiquitin ligase resulting in degradation of ARNT. There is no evidence for a biologically meaningful level of recruitment of ARNT to CRBN in the absence of specific synthetic small molecules, and clinical CRBN binders do not exhibit significant recruitment or degradation of ARNT. As described herein, the formation of the ternary complex and the non-natural conformational change are necessary for the ubiquitination and degradation of the ARNT protein to occur. As shown herein, mutations of specific CRBN amino acids and / or ARNT amino acids interfere with the change in conformation of ARNT which results in the ARNT protein not being ubiquitinated and thus not degraded.
[0017] A first aspect of the present disclosure relates to a method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising: (i) contacting CRBN with a small molecule; (ii) inducing a change in the conformation of the CRBN, wherein said CRBN conformational change results in recruitment of ARNT; (iii) forming of a ternary complex between the CRBN, the ARNT and the small molecule; and (iv) ubiquitination of the ARNT; wherein the ubiquitination of the ARNT leads to degradation of the ARNT. In some embodiments, the present disclosure features a method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary’ complex comprising ccrcblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising: (i) contacting CRBN with a small molecule; (ii) inducing a change in the conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change orAttorney Docket No.: N2109-7007WO
[0018] alteration results in recruitment of ARNT; (iii) forming of a ternary complex between the CRBN, the ARNT and the small molecule; and (iv) ubiquitination of the ARNT; wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0019] Another aspect of the present disclosure relates to a method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising:(i) contacting CRBN with a small molecule;(ii) inducing a change in the conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(iii) forming of a ternary complex between the CRBN, the ARNT and the small molecule, wherein steps (i)-(iii) result in the induction of a change in conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and the PAS-2 domains of ARNT, wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0020] (iv) ubiquitination of the ARNT;
[0021] wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0022] In another aspect, the present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0023] (1) binding of a small molecule to cereblon (CRBN);
[0024] (2) inducing a change in the confonnation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT:
[0025] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0026] (4) forming of a ternary complex comprising the ARNT. the small molecule and the CRBN, wherein the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;Attorney Docket No.: N2109-7007WO
[0027] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0028] Another aspect of the present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0029] (4) forming of a ternary complex comprising tire ARNT, the small molecule and tire CRBN, wherein the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;
[0030] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0031] In another aspect, tire present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0032] (1) binding of a small molecule to cereblon (CRBN);
[0033] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT;
[0034] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT amino acids E398, N395, G393, I372, K245, G242, T241, K240, L239, or L237 mediate interactions of the ARNT with the CRBN in the ternary complex;Attorney Docket No.: N2109-7007WO
[0035] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0036] Another aspect of the present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0037] (4) forming of a ternary complex comprising the ARNT, the small molecule and tire CRBN, wherein the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 mediate the interactions of the ARNT with the CRBN to form the ternary complex;
[0038] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0039] In another aspect, the present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), tire method comprising:
[0040] (1) binding of a small molecule to cereblon (CRBN);
[0041] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0042] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371,Attorney Docket No.: N2109-7007WO
[0043] V388, H397, W386, W400, N351, Y355, H357, or S420, interacts with at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 to form the ternary complex;
[0044] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0045] Another aspect of the present disclosure relates to a method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0046] (1) binding of a small molecule to cereblon (CRBN);
[0047] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT; and
[0048] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0049] (4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT and the CRBN interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT E398 and CRBN F150; ARNT N395 and CRBN I152; ARNT G393 and CRBN H353; ARNT I372 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN I371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353;
[0050] wherein the ARNT intramolecular interactions and the ARNT-CRBN interactions mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
[0051] In another aspect, the present disclosure relates to a method for the design of a compound that causes the degradation of the aryl hydrocarbon nuclear translocator (ARNT) protein, the method comprising:
[0052] (1) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound;Attorney Docket No.: N2109-7007WO
[0053] (2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound from step (1) wherein the compound is designed by (i) predicting or identifying potential ligand-protein interactions of the ternary complex with the compound and modifying the compound to form said interactions, (ii) identifying existing ligand-protein interactions of the ternary complex with the compound and modifying the compound to enhance said interactions, (iii) predicting or identifying CRBN / ARNT interactions and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains and modifying the compound to enhance these interactions and to enhance compound / CRBN, CRBN / ARNT interactions, ARNT intramolecular interactions, and / or compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof, (iv) identifying empty cavities in the vicinity of the compound to fill and increase ligand / protein nonspecific interactions and modifying the compound to fill said cavities, (v) identifying areas of the compound that do not form interactions or are solvent exposed and modifying the compound in these areas to improve ADME / PK properties, (vi) identifying solvating molecules that are near the compound in the complex to target for destabilization or replacement and modifying the compound to target said areas, and / or, and (vii) use a combination of (i) through (vi) to improve potency and / or ADME / PK properties;
[0054] (3) synthesizing one or more of the designed compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier; and
[0055] (4) quantify ing the degradation activity of the synthesized compounds with at least one of biochemical assays, cellular assays or molecular dynamics simulations and / or other computational approaches to determine if the one or more designed compounds degrade ARNT or cause the formation of the ternary complex.
[0056] Another aspect of the present disclosure relates to a method for designing of a chemical library of cereblon (CRBN) binding compounds that form a ternary complex comprising CRBN, the compounds and aryl hydrocarbon nuclear translocator (ARNT) and that are predicted to form ARNT intramolecular interactions between the PAS-1 and PAS-2 domains when ARNT is recruited to cereblon (CRBN), wherein the method comprises:
[0057] (1) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound;
[0058] (2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound from step (1) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactionsAttorney Docket No.: N2109-7007WO
[0059] and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains of the complex and modifying tire compound to enhance these interactions and to enhance compound / CRBN, CRBN / ARNT interactions, and / or compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof, (ii) identify ing empty cavities in the vicinity of tire compound to fill and increase ligand / protein nonspecific interactions and modifying the compound to fill said cavities, (iii) identifying areas of the compound that do not form interactions or are solvent exposed and modifying the compound in these areas to improve ADME / PK properties, (iv) identifying solvating molecules that are near the compound in the complex to target for destabilization or replacement and modifying the compound to target said areas, and (v) use a combination of (i) through (iv) to improve potency and / or ADME / PK properties;
[0060] (3) synthesizing one or more of the designed compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier; and
[0061] (4) quantifying the degradation activity of the synthesized compounds with at least one of biochemical assays, cellular assays or molecular dynamics simulations and / or other computational approaches to determine if the one or more designed compounds degrade ARNT or enhance ternary complex formation.
[0062] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0063] (1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0064] (2) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound in the screening assay in step (1):
[0065] (3) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound identified in the screening assay in step (1) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to form or enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and modifyingAttorney Docket No.: N2109-7007WO
[0066] the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;
[0067] (4) synthesizing one or more compounds designed in step (3) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;
[0068] (5) testing said compounds synthesized in step (4) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0069] (6) testing said compounds in an assay to assess whether the compounds synthesized in step (4) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0070] wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (3), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
[0071] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0072] (1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0073] (2) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;
[0074] (3) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2);
[0075] (4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2) wherein the compound is designed by (i) predicting or identifying tire ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245. G242, T241, K240. L239, or L237 with at leastAttorney Docket No.: N2109-7007WO
[0076] one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;
[0077] (5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;
[0078] (6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0079] (7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0080] wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (4), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
[0081] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0082] (1) synthesizing a compound library comprising one or more compounds in an individual or pooled fonnat, wherein the compounds are optionally tagged with an identifier;
[0083] (2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0084] (3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in tire screening assay in step (2);
[0085] (4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) wherein tire compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, andAttorney Docket No.: N2109-7007WO
[0086] modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;
[0087] (5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled fomrat and wherein tire compounds are optionally tagged with an identifier;
[0088] (6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0089] (7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0090] wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (4), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
[0091] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0092] (1) synthesizing a compound library' comprising one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;
[0093] (2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0094] (3) confirming the screening data from step (2) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;
[0095] (4) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) and confirmed in step (3);
[0096] (5) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) and confirmed in step (3) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, and (ii) determining whetherAttorney Docket No.: N2109-7007WO
[0097] ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one ofthe ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;
[0098] (6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;
[0099] (7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0100] (8) testing the compounds in an assay to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0101] wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (5), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
[0102] In another aspect, tire present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0103] (1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0104] (2) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in tire screening assay in step (1);
[0105] (3) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in tire screening assay in step (1) wherein the compound is designed by (i) predicting or identify ing the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, (ii) determining whether said compound identified in the screening assay in step (1) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2), and (iii) identifying the specific ARNTAttorney Docket No.: N2109-7007WO
[0106] intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;
[0107] (4) synthesizing one or more compounds designed in step (3) wherein the compounds are synthesized in an individual or pooled fomiat and wherein tire compounds are optionally tagged with an identifier;
[0108] (5) testing said compounds synthesized in step (4) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0109] (6) testing said compounds in an assay to assess whether the compounds synthesized in step (4) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0110] wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (3), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via tire specific intramolecular interactions in step (3), (iii) result in degradation of ARNT.
[0111] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0112] (1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0113] (2) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;
[0114] (3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2);
[0115] (4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, a compound identified in the screening assay in step (1) and confirmed in step (2) wherein the compound is designed by (i) predicting and identify ing the ARNT / CRBN / compound interactions of the complex and modifying the compound enhance said interactions, (ii) determining whether said compoundAttorney Docket No.: N2109-7007WO
[0116] identified in the screening assay in step (1) and confirmed in step (2) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions ofthe PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2). (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;
[0117] (5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled fomiat and wherein the compounds are optionally tagged with an identifier;
[0118] (6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0119] (7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0120] wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (4), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (4), (iii) result in degradation of ARNT.
[0121] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0122] (1) synthesizing a compound library comprising one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;
[0123] (2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0124] (3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2);
[0125] (4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, a compound identified in the screening assay in step (2)Attorney Docket No.: N2109-7007WO
[0126] wherein the compound is designed by (i) determining whether said compound identified in the screening assay in step (2) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2), and (ii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the complex;
[0127] (5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled fomrat and wherein the compounds are optionally tagged with an identifier;
[0128] (6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0129] (7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0130] wherein the compounds that form the complex with ARNT and CRBN and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (4), (ii) between the ARNT amino acids result in degradation of ARNT.
[0131] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0132] (1) synthesizing a compound library comprising one or more compounds in an individual or pooled fonnat, wherein the compounds are optionally tagged with an identifier;
[0133] (2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;
[0134] (3) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;Attorney Docket No.: N2109-7007WO
[0135] (4) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) and confirmed in step (3);
[0136] (5) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, a compound identified in the screening assay in step (2) and confirmed in step (3) wherein the compound is designed by (i) identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, (ii) determining whether said compound identified in the screening assay in step (2) and confirmed in step (3) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.
[0137] 2), (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;
[0138] (6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;
[0139] (7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0140] (8) testing tire compounds in an assay to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0141] wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (5), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (5), (iii) result in degradation of ARNT.
[0142] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0143] (1) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound;
[0144] (2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally detemiined or computationally predicted atomicAttorney Docket No.: N2109-7007WO
[0145] structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the ARNT degrader compound is designed by predicting or identifying the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compounds to (a) to enhance said ARNT intramolecular interactions of the PAS-1 and PAS-2 domains and (b) to optionally cause additional ARNT intramolecular interactions of the PAS-1 and PAS-2 domains;
[0146] (3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;
[0147] (4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0148] (5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0149] wherein the compounds that form the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex comprising cereblon (CRBN), ARNT, and the compound result in degradation of ARNT.
[0150] Another aspect of the present disclosure relates to a method of identifying a compound that degrades and hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0151] (1) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound;
[0152] (2) performing structural modeling, using a suitably programmed computer, to identify a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the compound is designed by (i) identifying the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, (ii) determining if the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex occur through the specific interaction of ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237: ARNT F375 and ARNT E247: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244, and (in) modifying the compound to (a) enhance said ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in (ii) and (b) optionally cause additional ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;Attorney Docket No.: N2109-7007WO
[0153] (3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;
[0154] (4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0155] (5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0156] wherein the compounds that form the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in step (2) result in degradation of ARNT.
[0157] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0158] (1) experimentally determining or computationally predicting tire atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound;
[0159] (2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex, (ii) determining whether the ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and (iii) modifying the compound to (a) enhance said specific interactions between ARNT, CRBN and the compound, (b) optionally cause additional ARNT / CRBN / compound interactions and (c) optionally increase ARNT / CRBN / compound nonspecific interactions in the complex;
[0160] (3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;
[0161] (4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0162] (5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;
[0163] wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (2) between the ARNT amino acids and tire CRBN amino acids result in degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0164] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0165] (1) synthesizing one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;
[0166] (2) testing said compounds synthesized in step (1) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, engineered protein domain swaps, saturating mutagenesis assays, phenotypic screening assays or evaluation of the downregulation or disappearance of ARNT;
[0167] (3) experimentally determining or computationally predicting tire atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound tested in step (2) having ARNT modulation activity;
[0168] (4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound tested in step (2) having ARNT modulation activity, wherein the compound is designed by (i) identifying the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains formed in the complex, (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, (lii) modifying the compound to enhance said specific interactions between ARNT, CRBN and the compound and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains and optionally cause additional ARNT / CRBN / compound interactions and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains of the complex:
[0169] (5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;
[0170] (6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0171] (7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;Attorney Docket No.: N2109-7007WO
[0172] wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in between the ARNT amino acids and the CRBN amino acids and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains in step (4) result in degradation of ARNT.
[0173] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0174] (1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format; and
[0175] (2) screening said one or more compounds from step (1) in an individual or pooled format using a screening method comprising proteomics, cellular proximity screen, AlphaLisa / Alpha Screen, or luciferase-based proximity screens, or a combination thereof to determine the ability of the compounds to modulate ARNT;
[0176] (3) evaluating whether said one or more compounds induces a change in the conformation of the CRBN or otherwise alters the properties of the CRBN surface such that a ternary complex is formed between the CRBN, the ARNT and the small molecule;
[0177] (4) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.
[0178] 2); and
[0179] (5) testing said one or more compounds in a biochemical or cellular assay, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded;
[0180] wherein a CRBN confirmational change or alteration results in recruitment of ARNT, wherein ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the E3 ubiquitin ligase ternary complex and ubiquitination of ARNT, and wherein ARNT is not ubiquitinated by an E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0181] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0182] (1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format: and
[0183] (2) screening said one or more compounds from step (1) in an individual or pooled format using a screening method comprising proteomics, cellular proximity screen, AlphaLisa / Alpha Screen, or luciferase-based proximity screens, or a combination thereof to determine the ability of the compounds to modulate ARNT;Attorney Docket No.: N2109-7007WO
[0184] (3) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.
[0185] 2);
[0186] (4) testing said one or more compounds in a biochemical or cellular assay, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded:
[0187] wherein ARNT intramolecular interactions mediate the formation of the E3 ubiquitin ligase ternary complex and ubiquitination of ARNT, and wherein ARNT is not ubiquitinated by an E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0188] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0189] (1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format;
[0190] (2) contacting said one or more compounds with cereblon (CRBN);
[0191] (3) testing in a biochemical or cellular assay in an individual or pooled format, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded;
[0192] (4) evaluating whether said one or more compounds induces a change in the conformation of the CRBN or otherwise alters the properties of the CRBN surface such that a ternary complex is formed between the CRBN, the ARNT and the small molecule;
[0193] (5) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.
[0194] 2);
[0195] (6) modifying said one or more compounds to (i) enhance said specific interactions between the ARNT, CRBN and the compound, and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains, (ii) optionally cause additional ARNT / CRBN / compound interactions, ARNT intramolecular interactions, or enhance compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof; and (iii) optionally increase ARNT / CRBN / compound nonspecific interactions;
[0196] (7) synthesizing one or more compounds designed in step (6) wherein the compounds are synthesized in an individual or pooled format;Attorney Docket No.: N2109-7007WO
[0197] (8) testing said compounds synthesized in step (7) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0198] (9) testing the compounds in step (7) in a biochemical or cellular assay in an individual or pooled format to assess whether the compounds synthesized in step (7) are modulating ARNT via CRBN mediated degradation of the ARNT protein.
[0199] Another aspect of the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:
[0200] (1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format;
[0201] (2) contacting said one or more compounds with cereblon (CRBN);
[0202] (3) testing in a biochemical or cellular assay in an individual or pooled format, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded:
[0203] (4) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.
[0204] 2);
[0205] (5) modifying said one or more compounds to (i) enhance said the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains, and (ii) optionally cause additional ARNT intramolecular interactions, or enhance ARNT / CRBN / compound interactions, and / or cause compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof;
[0206] (6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled format;
[0207] (7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and
[0208] (8) testing the compounds in step (6) in a biochemical or cellular assay in an individual or pooled format to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein.
[0209] In another aspect, the present disclosure relates to a method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:Attorney Docket No.: N2109-7007WO
[0210] ( 1 ) developing is a biochemical or cellular assay to identify compounds that induce an ARNT-CRBN interaction wherein said biochemical or cellular assay can measure a compound’s ability to downregulate ARNT, to degrade ARNT, to ubiquitinate ARNT, to reduced protein levels wherein said reduced protein levels are measured by proteomics, fluorescence / luminescence read-out, or western blot, or to promote ARNT-CRBN proximity;
[0211] (2) screening one or more compounds in an individual or pooled format in an assay developed in step (1) wherein the compounds are optionally tagged with an identifier:
[0212] (3) analyzing the data from screening the compounds in step (2) to identify molecules that induce an ARNT-CRBN interaction in the assay;
[0213] (4) confirming the screening data from step (2) by testing the individual compounds in the same biochemical or cellular assay or additional biochemical and cellular assays;
[0214] (5) using the data obtained in step (2) and confirmed in step (4) to create a ternary complex model: and
[0215] (6) using said ternary complex model created in step (5) to design compounds compatible with the binding mode of ARNT.
[0216] Another aspect of the present disclosure relates to a small molecule (e.g., an ARNT degrader compound) capable of: (i) binding to CRBN; (ii) upon binding to CRBN, inducing a change in the conformation of the CRBN, wherein said CRBN conformational change results in recruitment of ARNT; and (iii) upon recruitment of the ARNT, forming of a ternary complex between the CRBN, the ARNT and the small molecule. In some embodiments, further comprising (iv) forming of a ternary complex between the CRBN, the ARNT, and the small molecule, inducing ubiquitination of the ARNT. In some embodiments, further comprising (v) degradation of the ARNT. In some embodiments, the ternary complex between the CRBN. the ARNT and the small molecule results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and the PAS-2 domains of ARNT. In some embodiments, the amino acids within the PAS-1 domain of ARNT that interact to form specific intramolecular interactions comprise amino acids 173-344 of ARNT (SEQ ID NO. 1). In some embodiments, the amino acids within the PAS-2 domain of ARNT that interact to form specific intramolecular interactions comprise amino acids 362-464 of ARNT (SEQ ID NO. 2). In some embodiments, the change in the conformation of the ARNT comprises amino acids K394, G393, L237 or V244 of the ARNT. In some embodiments, the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex. In some embodiments, the interaction of the ARNT with the CRBN in the ternary complex comprises at least one of amino acids K394, G393, L237 or V244 of the ARNT. In some embodiments, the interaction of the ARNT with the CRBN in the ternary complexAttorney Docket No.: N2109-7007WO
[0217] comprises ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237. In some embodiments, the interaction of the ARNT with the CRBN in the ternary complex comprises at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, interacting with at least one of the ARNT amino acids E398, N395, G393, 1372, K245. G242, T241, K240. L239, or L237. In some embodiments, forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT and the CRBN interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT E398 and CRBN F150; ARNT N395 and CRBN I152; ARNT G393 and CRBN H353; ARNT 1372 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN 1371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.;
[0218] In some embodiments in any and all of the preceding aspects, the small molecule is an ARNT degrader compound, e.g., a compound capable of inducing the degradation of ARNT, e.g., as described herein. In some embodiments, the small molecule is a compound capable of recruiting ARNT to CRBN. In some embodiments, the small molecule is a compound of any one of Formulas (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, e.g., as described herein.
[0219] The present disclosure provides methods for the degradation of hypoxia inducible factor 1 beta (HIF-ip, also known as ARNT) via the formation of a ternary complex comprising CRBN, ARNT, and a small molecule via specific ARNT / ARNT, CRBN / ARNT and ARNT / CRBN / small molecule interactions as well as methods for identifying small molecules that cause CRBN mediated degradation of ARNT as well as methods for designing and identifying all molecules that cause CRBN mediated degradation of ARNT. Ultimately the present disclosure provides the medical community with a novel pharmacological strategy for the design and identification of agents for the treatment of diseases and disorders associated with HIF-ip proteins.
[0220] BRIEF DESCRIPTION OF THE FIGURES FIG. 1 depicts an overview of glue-induced ARNT ubiquitination and degradation. On the left, the E3 ligase and substrate are depicted. In the middle of the figure, upon addition of the small molecule (i.e, termed ‘“glue” in the figure), a ternary complex is formed which comprises an intramolecular interaction of the ARNT PAS-1 and PAS-2 domains and the substrate (ARNT) is ubiquitinated. On the left, the ubiquitinated substrate is degraded by the proteasome.Attorney Docket No.: N2109-7007WO
[0221] FIG. 2 shows the glue-induced CRBN-glue-ARNT ternary complex observed by cryo-EM. On the left, the cryo-EM density of the ternary interface between CRBN, the small molecule (i.e., '‘glue”), and ARNT is shown. On the right, the glue-induced intramolecular ARNT interface comprising the PAS-1 domain and the PAS-2 domain is shown. CRBN is hidden for clarity. The arrows point to amino acid residues at the glue-induced ARNT intramolecular interface. The labels denote residue name (1-letter code) and number.
[0222] FIG. 3 depicts the differences observed in the expansion of small molecule (i.e., '‘glue’’)-induced ARNT conformation by cryo-EM versus the AlphaFold prediction of ARNT’s conformation. The top of the figure shows the ARNT conformation predicted by AlphaFold in the absence of a glue. The bottom of the figure shows the cryo-EM density for the glue-induced ARNT conformation observed in the ternary complex with glue and CRBN. As can been seen in the top panel at the bottom of the figure, the PAS-1 loop interacts with the PAS-2 domain in the presence of the glue and CRBN.
[0223] FIG. 4 depicts the differences observed in the small molecule (i.e., '‘glue:’)-induced ARNT conformation by cryo-EM versus the experimentally determined X-ray crystallography structure of the ARNT: HIF-2a heterodimer (PDB 4ZPH). The top of the figure shows the ARNT conformation observed by X-ray crystallography in the absence of a glue. The PAS-1 loop is not resolved in the crystal structure suggesting the loop is disordered and / or flexible. The bottom of the figure shows the cryo-EM density for the glue-induced ARNT conformation observed in tire ternary complex with glue and CRBN. As can been seen in the top panel at the bottom of the figure, the PAS-1 loop interacts with the PAS-2 domain in the presence of the molecular glue and CRBN.
[0224] FIGS. 5A-5G shows the results obtained from the ARNT-Glue-CRBN Ternary Complex Formation Homogeneous Time-Resolved Fluorescence (HTRF) Assay with Compound 110. Each panel shown in FIG 5A, FIG. 5B, FIG. 5C, FIG. 5D, FIG. 5E, FIG. 5F, and FIG. 5G shows the assay readout for a wildtype (WT), L237A, L239A, G242A, I372A, F375A, and L392A ARNT construct as dose-response curve. The title of each panel denotes the ARNT construct being assayed. Single-point mutants are denoted by 1-letter residue name, residue number, 1-letter residue name.
[0225] FIGS. 6A-6G shows the results obtained from the ARNT Degradation (HiBiT) Assay Compound 110. Each panel shown in FIG 6A, FIG. 6B, FIG. 6C, FIG. 6D, FIG. 6E, FIG. 6F, and FIG. 6G shows the assay readout for a wildtype (WT), L237A, L239A, G242A, 1372 A, F375A, and L392A ARNT construct as dose-response curve. The title of each panel denotes the ARNT construct being assayed. Single-point mutants are denoted by 1-letter residue name, residue number, 1-letter residue name.
[0226] FIGS. 7A-7D shows interactions between exemplary compounds described herein, e.g., compounds of Formulas (I), (II). (III). (IV) (e.g., glues) and the CRBN-ARNT ternary complex. TheAttorney Docket No.: N2109-7007WO
[0227] interactions were calculated with Schrodinger Maestro Ligand Interaction Diagram. All four ligand-protein complexes were determined experimentally by cryo-electron microscopy single-particle analysis. Single letters denote amino acid residue names. “Letter: number” denotes “protein chain: residue number”. Chains A and B correspond to ARNT and CRBN respectively. A default interaction distance cut-off of 4 Å was used for all diagrams. FIG. 7A shows interactions for Compound 213. FIG. 7B shows interactions for Compound 214. FIG. 7C shows interactions for Compound 211. FIG. 7D shows interactions for Compound 212.
[0228] FIGS. 8A-8B shows experimentally determined ternary complex cryo-electron microscopy density. FIG. 8A shows the ternary complex between Compound 211, ARNT, CRBN, and DDB1 is shown.
[0229] FIG.8B shows close-up view of the ternary complex interface showing Compound 211, ARNT, and CRBN colored as in panel A.
[0230] FIGS. 9A-9D shows cryo-electron microscopy atomic models of the ternary complex interface.
[0231] FIG. 9A shows Compound 213 is shown at the ternary complex interface with CRBN and ARNT. FIG.
[0232] 9B shows Compound 214 is shown at the ternary complex interface with CRBN and ARNT. FIG. 9C shows Compound 211 is shown at the ternary complex interface with CRBN and ARNT. FIG. 9D shows Compound 212 is shown at the ternary complex interface with CRBN and ARNT. Heteroatoms are colored using standard convention.
[0233] DETAILED DESCRIPTION OF THE DISCLOSURE
[0234] The present disclosure relates to methods for tire degradation of hypoxia inducible factor 1 beta (HIF-ip, also known as ARNT) via the fonnation of a ternary complex comprising CRBN, ARNT, and a small molecule via specific ARNT / ARNT, CRBN / ARNT and ARNT / CRBN / small molecule interactions as well as methods for identifying small molecules that cause CRBN mediated degradation of ARNT. We have discovered that our synthetic small molecules bind to CRBN and ARNT to form a ternary complex with a previously unobserved induced structure of tire ARNT protein. The induced structure of the ARNT protein is a non-natural conformational change in the ARNT protein which is observed as a result of intramolecular interactions between the PAS-1 and PAS-2 domains of the ARNT protein. The formation of the ternary complex and the non-natural conformational change enables the ubiquitination of the ARNT protein by the CRL4-CRBN E3 ubiquitin ligase resulting in degradation of ARNT. There is no evidence for a biologically meaningfi.il level of recruitment of ARNT to CRBN in the absence of specific synthetic small molecules, and clinical CRBN binders do not exhibit significant recruitment or degradation of ARNT. We have shown that the formation of the ternary complex and the non-natural confirmation change are necessary for the ubiquitination and degradation of the ARNT protein to occur. As we show herein,Attorney Docket No.: N2109-7007WO
[0235] mutations of specific CRBN amino acids and / or ARNT amino acids interfere with the change in conformation of ARNT which results in the ARNT protein not being ubiquitinated and thus not degraded.
[0236] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from tire description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
[0237] Definition of Terms and Conventions Used
[0238] Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification and appended claims, however, unless specified to the contrary, the following terms have the meaning indicated and tire following conventions are adhered to.
[0239] A. Chemical Nomenclature, Terms, and Conventions
[0240] In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, (Ci-Cio)alkyl means an alkyl group or radical having 1 to 10 carbon atoms. In general, for groups comprising two or more subgroups, the last-named group is the radical attachment point, for example, "alkylaryl" means a monovalent radical of the formula alkyl-aryl-, while "arylalkyl" means a monovalent radical of the formula aryl-alkyl-. Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of tenns control and conventional stable atom valences are presumed and achieved in all formulas and groups. The articles "a" and "an" refer to one or more than one (eg., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0241] Tire term "and / or" means either "and" or "or" unless indicated otherwise.
[0242] The term ‘‘amino acid”, as used herein, refers to naturally occurring amino acids, unnatural amino acids, amino acid analogues and amino acid mimetics that function in a manner similar to the naturally occurring amino acids, all in their D and L stereoisomers if their structure allows such stereoisomeric forms. Amino acids are referred to herein by either their name, their commonly known three letter symbols or by the one - letter symbols recommended by the IUPAC - IUB Biochemical Nomenclature Commission.Attorney Docket No.: N2109-7007WO
[0243] The term “naturally occurring” refers to materials which are found in nature and are not manipulated by man. Similarly, “non - naturally occurring”, “un - natural, " and the like, as used herein, refers to a material that is not found in nature or that has been structurally modified or synthesized by man. When used in connection with amino acids, the term “naturally occurring” refers to the 20 conventional amino acids ( i.e., alanine (A or Ala ), cysteine (C or Cys), aspartic acid (D or Asp), glutamic acid (E or Gl), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or lie), lysine ( K or Lys, leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gin), arginine (R or Arg), serine (S or Ser), threonine (T or Thr), valine (V or Vai), try ptophan (W or Trp), and tyrosine (Y or Tyr ).
[0244] Tire terms “non - natural amino acid” and “unnaturalamino acid", as used herein, are interchangeably intended to represent amino acid structures that cannot be generated biosynthetically in any organism using unmodified or modified genes from any organism, whether the same or different. These include, but are not limited to, modified amino acids and / or amino acid analogues that are not one of the 20 naturally occurring amino acids, selenocysteine, pyrrolysine (Pyl), or pyrroline - carboxy - lysine (Pci, e.g., as described in PCT patent publication WO2010 / 48582), etc.
[0245] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded other substituents (e.g., heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups but does not necessarily have any further functional groups. Suitable substituents used in tire optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(Ci-Ce)alkyl, (Ci-C6)alkyl, (Ci-Ce)alkoxy, (Ci-Celhaloalkyl, (Ci-Ce)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6)alkyl, -C(O)(Ci-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2,
[0246] -NH((Ci-C6)alkyl), -N((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -C(O)NH(C!-C6)alkyl, -S(O)2(Ci-C6)alkyl, -S(O)NH(Ci-C6)alkyl, and S(O)N((Ci-C6)alkyl)2. The substituents can themselves be optionally substituted. " Optionally substituted" as used herein also refers to substituted or unsubstituted whose meaning is described below.
[0247] The term "substituted" means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.Attorney Docket No.: N2109-7007WO
[0248] The term "unsubstituted" means that the specified group bears no substituents.
[0249] Unless otherwise specifically defined, "aryl" means a cyclic, aromatic hydrocarbon group having 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), tire aromatic rings of the aryl group are optionally joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). Hie aryl group is optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(Ci-Ce)alkyl, (Cl-C5)alkyl, -O-(C2-C5)alkenyl, -O-(C2-C6)alkynyl, (C2-C5)alkenyl, (C2-Ce)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C5)alkyl, -C(O)(Ci-C6)alkyl, -OC(O)O(Ci-C6) alkyl, NH2, NH((Ci-C6)alkyl), N((Ci-C6)alkyl)2, -S(O)2-(Ci-C6)alkyl,
[0250] -S(O)NH(Ci-C6)alkyl, and S(O)N((Ci-C6)alkyl)2. The substituents are themselves optionally substituted. Furthermore, when containing two fused rings, the aryl groups optionally have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.
[0251] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical, containing one or more ring heteroatoms selected from N, 0. or S, the remaining ring atoms being C. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, 0, or S. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno [3,2-b]thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl. imidazo[l,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo [3,2-c]pyridinyl, pyrazolo [3,4-c]pyridinyl, thieno [3,2-c]pyridinyl, thieno[2,3 -c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b ][l,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2.3-b]pyridinyl. pyrrolo[3,4-b]pyridinyl, pyrrolo [3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1λ²-pyrrolo[2,1-b]pyrimidine, dibenzo [b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5 -naphthyridinyl, faro [3,2-b]pyridinc, [ 1,2,4]triazolo [1,5 -a]pyridinyl, benzo[l,2,3]triazolyl, imidazo[l,2a]pyrimidinyl, [l,2,4]triazolo[4,3-b]pyridazinyl. benzo[c]Attorney Docket No.: N2109-7007WO
[0252] [1,2,5]thiadiazoly 1, benzo[c][l,2,5]oxadiazole, l,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo [1,5-b] [l,2]oxazinyl,4,5,6, 7-tetrahydropyrazolo [l,5-a]pyridinyl, thiazolo[5,4d]thiazolyl, imidazo[2,l-b] [l,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two fused rings the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl. dihydrobenzothiophenyl. dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro- IH-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
[0253] " Alkyl" means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. Examples of a (Ci-C6)alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
[0254] " Alkoxy" means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal " O" in the chain, e.g., -O(alkyl). Examples of alkoxy groups include, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
[0255] " Alkenyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. Tire "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted and may be straight or branched.
[0256] " Alkynyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in tire chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.
[0257] " Alkylene" or "alkylenyl" means a divalent alkyl radical. Any of tire above-mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a (Ci-C5)alkylene. An alkylene may further be a (Ci-C^alkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CEI2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH-, and the like.
[0258] " Amino" means a substituent containing at least one nitrogen atom (e.g., NEI2).
[0259] " Cyano" means a substituent having a carbon atom joined to a nitrogen atom by a triple bond. i.e., C^N
[0260] " Cycloalkyl" or "carbocyclyl" means a monocyclic or polycyclic saturated or partially unsaturated non-aromatic carbon ring containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl,Attorney Docket No.: N2109-7007WO
[0261] norborenyl, bicyclo[2.2.2]octanyl, or bicyclo [2.2.2] octenyl and derivatives thereof. A (C3-Cs)cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. A cycloalkyl group can be fused (e g., decalin) or bridged (e.g., norbomane).
[0262] " Deuteroalkyl" means an alkyl group substituted with one or more deuterium (“D”). Examples of deuteroalkyl groups include -CDH2, -CD3, -CHD2, -CD2CH3. -CD2CD3, CH2CD3, -CHDCH3, -CD2CH2CD3, etc.
[0263] " Halogen" or "halo" mean fluorine, chlorine, bromine, or iodine.
[0264] " Haloalkyl" means an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
[0265] " Haloalkoxy" means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to. trifluoromethoxy. difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.
[0266] “Halohydroxyalkyl” means an alkyl group substituted with at least one halogen and at least one -OH group. Examples of halohydroxyalkyl groups include, but are not limited to, HO-C(H)F-, HO-CH(F)-CH2-, CF3-CH(OH)-CH2-, and CH3-CH(OH)-, etc.
[0267] " Heterocyclyl" or "heterocycloalkyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, or sulfur (O, N, or S) and wherein there is not delocalized n electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. Examples of heterocycloalkyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl. tetrahydropyranyl. dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide. piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.
[0268] " Hydroxyalkyl" means an alkyl group substituted with one or more -OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2CH2-, and CH3-CH(OH)-.
[0269] " Spirocarbocyclyl " or "spirocycloalkyl" means carbogenic bicyclic ring systems with both rings connected through a single atom. The rings can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or hctcroaromatic ring. A (C3-Ci2)spirocarbocyclyl is a spirocyclc containing between 3 and 12 carbon atoms.Attorney Docket No.: N2109-7007WO
[0270] " Spiroheterocyclyl" or "spiroheterocycloalkyl" means a spirocycle wherein at least one of the rings is a heterocycle one or more of the carbon atoms can be substituted with a heteroatom (e.g., one or more of the carbon atoms can be substituted with a heteroatom in at least one of the rings). One or both of the rings in a spiroheterocyclyl can be fused to another ring, e.g., carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
[0271] B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions
[0272] " Prodrug" or "prodrug derivative" means a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s). In general, such prodrugs have metabolically cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds. Hie prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased aqueous solubility), and / or decreased side effects (e.g.. toxicity). In general, prodrugs themselves have weak or no biological activity and are stable under ordinary conditions. Prodmgs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: " Design and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker. 1998; Methods in Enzymology, K. Widder et al. (eds.). Vol. 42, Academic Press, 1985, particularly pp. 309-396; Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed ), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987, each of which is incorporated herein by reference in their entireties.
[0273] " Pharmaceutically acceptable prodrug" as used herein means a prodrug of a compound of the disclosure which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic fonns, where possible.
[0274] " Salt" means an ionic fonn of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound. Salts of the compounds of the present disclosure can be synthesized from the parent compounds w'hich contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared byAttorney Docket No.: N2109-7007WO
[0275] reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
[0276] " Pharmaceutically acceptable salt" means a salt of a compound of the disclosure which is, within the scope of sound medical judgment, suitable for use in contact w ith the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use. The term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. As the compounds of the present disclosure are usefill in both free base and salt form, in practice, the use of the salt form amounts to use of the base form. Lists of suitable salts are found in, e.g., S. M. Birge et al., J. Pharm. Set., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety.
[0277] " Pharmaceutically-acceptable acid addition salt" means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methane sulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalene sulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3 -phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and tire like.
[0278] " Pharmaceutically-acceptable base addition salt" means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmacally-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylaminc, cthanolaminc. diethanolamine, 2-dimcthylaminocthanol, 2-dicthylaminocthanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine,Attorney Docket No.: N2109-7007WO
[0279] glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N, N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N, N-dibenzylphenethylamine, 1 -ephenamine, N, N'-dibenzylethylenediamine, polyamine resins, and tire like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0280] " Solvate" means a complex of variable stoichiometry formed by a solute, for example, a Compound of Formula (I)) and solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. In general, such solvents selected for tire purpose of the disclosure do not interfere with the biological activity of the solute. Solvates encompasses both solution -phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
[0281] " Hydrate" means a solvate wherein the solvent molecule(s) is / are water.
[0282] The compounds of tire present disclosure as discussed below include the free base or acid thereof, their salts, solvates, and prodrugs and may include oxidized sulfur atoms or quatemized nitrogen atoms in their structure, although not explicitly stated or shown, particularly the pharmaceutically acceptable fonns thereof Such forms, particularly the pharmaceutically acceptable forms, are intended to be embraced by the appended claims.
[0283] C. Jsomer Terms and Conventions
[0284] " Isomers" means compounds having the same number and kind of atoms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.
[0285] " Stereoisomer" or "optical isomer" mean a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the disclosure which may give rise to stereoisomerism, the disclosure contemplates stereoisomers and mixtures thereof. The compounds of the disclosure and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. As discussed in more detail below,Attorney Docket No.: N2109-7007WO
[0286] individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recry stallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well known in the art.
[0287] “Enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of each other.
[0288] " Diastereoisomers" or "diastereomers" mean optical isomers, which are not mirror images of each other.
[0289] " Racemic mixture" or "racemate" mean a mixture containing equal parts of individual enantiomers. " Non-racemic mixture" means a mixture containing unequal parts of individual enantiomers.
[0290] " Geometrical isomer" means a stable isomer, which results from restricted freedom of rotation about double bonds (e.g., cis-2-butene and trans-2-butene) or in a cyclic structure (e.g., cis-1,3-dichlorocyclobutane and trans-l,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, cyclic structures, and the like may be present in tire compounds of the disclosure, the disclosure contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these cyclic structures. Tire substituents and the isomers are designated using the cis / trans convention or using the E or Z system, wherein the term " E" means higher order substituents on opposite sides of the double bond, and the term " Z" means higher order substituents on tire same side of the double bond. A thorough discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions. Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, which is hereby incorporated by reference in its entirety. Several of the following examples represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of the E and Z isomers can be done by analytical methods such as x-ray crystallography, 'El NMR, and13C NMR.
[0291] Some of tire compounds of the disclosure can exist in more than one tautomeric form. As mentioned above, the compounds of tire disclosure include all such tautomers.
[0292] It is well known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound. Thus, for example, enantiomers often exhibit strikingly different biological activity including differences in pharmacokinetic properties, including metabolism, protein binding, and the like, and pharmacological properties, including tire type of activity displayed, the degree of activity’, toxicity, and the like. Tirus, one skilled in the art will appreciate that one enantiomer may be more active or may exhibit beneficial effects when enriched relative to the other enantiomer or whenAttorney Docket No.: N2109-7007WO
[0293] separated from the other enantiomer. Additionally, one skilled in the art would know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the disclosure from this disclosure and the knowledge of the prior art.
[0294] Tirus, although the racemic form of drug may be used, it is often less effective than administering an equal amount of enantiomerically pure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and would merely serve as a simple diluent. For example, although ibuprofen had been previously administered as a racemate, it has been shown that only the S-isomer of ibuprofen is effective as an anti-inflammatory agent (in the case of ibuprofen, however, although the R-isomer is it is converted in vivo to the S-isomer, thus, the rapidity of action of the racemic form of the drug is less than that of the pure S-isomer). Furthermore, the pharmacological activities of enantiomers may have distinct biological activity. For example. S-penicillamine is a therapeutic agent for chronic arthritis, while inactive, R-penicillamine is toxic. Indeed, some purified enantiomers have advantages over the racemates, as it has been reported that purified individual isomers have faster transdermal penetration rates compared to the racemic mixture. See U. S. Pat. Nos. 5,114,946 and 4,818,541.
[0295] Tirus, if one enantiomer is pharmacologically more active, less toxic, or has a preferred disposition in the body than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way. the patient undergoing treatment would be exposed to a lower total dose of the drug and to a lower dose of an enantiomer that is possibly toxic or an inhibitor of the other enantiomer.
[0296] Preparation of pure enantiomers or mixtures of desired enantiomeric excess (ee) or enantiomeric purity are accomplished by one or more of the many methods of (a) separation or resolution of enantiomers, or (b) enantioselective synthesis known to those of skill in the art, or a combination thereof. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and nonenzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are disclosed generally in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T. E. Beesley and R. P. W. Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc.. 2000. Furthermore, there are equally well-known methods for the quantitation of enantiomeric excess or purity, for example, GC, HPLC, CE, or NMR, and assignment of absolute configuration and conformation, for example, CD ORD, X-ray crystal lography, or NMR.
[0297] In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or stereoisomers or racemic or non-raccmic mixtures, of a chemical structure or compound isAttorney Docket No.: N2109-7007WO
[0298] intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.
[0299] D. Pharmaceutical Administration and Treatment Terms and Conventions
[0300] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or nonhuman primate, such as a monkey, chimpanzee, baboon or, rhesus. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
[0301] An "effective amount" or "therapeutically effective amount" when used in connection with a compound means an amount of a compound of the present disclosure that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
[0302] The terms "pharmaceutically effective amount" or "therapeutically effective amount" means an amount of a compound according to the disclosure which, when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue, system, or patient that is sought by a researcher or clinician. The amount of a compound of according to the disclosure which constitutes a therapeutically effective amount will vary' depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the disclosure, and the age, body weight, general health, sex, and diet of the patient. Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.
[0303] As used herein, the term "pharmaceutical composition" refers to a compound of the disclosure, or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.
[0304] " Carrier" encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in earn ing or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject. A subject is "hi need of’ a treatment if such subject would benefit biologically, medically, or in quality of life from such treatment (preferably, a human).
[0305] As used herein, the term "inhibit", "inhibition", or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.Attorney Docket No.: N2109-7007WO
[0306] As used herein, the tenn "treat", "treating", or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.
[0307] As used herein, the term "prevent", "preventing", or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
[0308] " Pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a fonnulation, and / or tire mammal being treated therewith.
[0309] " Disorder" means, and is used interchangeably with, the temrs disease, condition, or illness, unless otherwise indicated.
[0310] " Administer", "administering", or "administration" means to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of tire compound or pharmacally acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
[0311] " Prodrug" means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound. " Compounds of the present disclosure", "compounds of the disclosure", and equivalent expressions (unless specifically identified otherwise) refer to compounds of Formulae (I), (II), (III), and (IV) as herein described including tire tautomers, the prodrugs, salts particularly tire pharmacally acceptable salts, and the solvates and hydrates thereof, where tire context so permits thereof, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labelled compounds (including deuterium substitutions), as well as inherently formed moieties (e.g., polymorphs, solvates and / or hydrates). For the purposes of this disclosure, solvates and hydrates are generally considered compositions. In general and preferably, the compounds of the disclosure and the fonnula designating the compounds of the disclosure are understood to only include stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts and solvates, where the context so permits. For the sake of clarity, particular instances when the context so pennits are sometimes indicated in the text, but these instances arc purely illustrative, and it is not intended to exclude other instances when the context so permits.Attorney Docket No.: N2109-7007WO
[0312] " Stable compound" or "stable structure" means a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, a compound, which would have a "dangling valency" or is a carbanion is not a compound contemplated by the disclosure.
[0313] In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%. and more preferably within 5% of a given value or range.
[0314] The yield of each of the reactions described herein is expressed as a percentage of the theoretical yield.
[0315] " HIF-ip-dcpcndcnt disease or disorder" means any disease or disorder which is directly or indirectly affected by the modulation of HIF-ip protein levels.
[0316] The term 'von Hippel-Lindau disease” or “VHL disease” or “VHL syndrome” or “von Hippel-Lindau syndrome”, as used herein, refers to a rare disease caused by a mutation in the von Hippel-Lindau (VHL) tumor suppressor leading to an aberrant non-functional VHL protein and to an absence of VHL protein. VHL gene mutations associated with this condition either prevent the production of any VHL protein or lead to the production of an abnormal version of the protein, with more than 370 inherited mutations in the VHL gene having been identified in people with von Hippel-Lindau disease (http: / / www.umd.be / VHL / ). VHL disease is characterized by the formation of multiple benign and malignant tumors and fluid-filled sacs (cysts) in many different parts of the body, including: retinal hemangioblastoma, CNS hemangioblastoma, clear cell renal cell carcinoma (CCRCC), pheochromocytoma, pancreatic islet tumor, endolymphatic sac tumors and cysts in testes and broad ligament.
[0317] " Colitis" is an inflammation of the colon. The colitis may be acute or chronic. As used herein, colitis includes ulcerative colitis, microscopic colitis, lymphocytic colitis, collagenous colitis, diversion colitis, chemical colitis, ischemic colitis, infections colitis, pancolitis, left-sided colitis, extensive colitis, segmental colitis, microscopic colitis, radiation-induced colitis, medication-induced colitis and proctitis. E. Specific Embodiments of the Methods of the Present Disclosure
[0318] The present disclosure relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of modulating HIF-ip protein levels, which are useful for the treatment of diseases and disorders associated with modulation of HIF-ip protein levels. The disclosure further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which arc useful for reducing or decreasing HIF-ip protein levels.Attorney Docket No.: N2109-7007WO
[0319] Embodiment 1: A method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising:
[0320] (i) contacting CRBN with a small molecule;
[0321] (ii) inducing a change in the conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0322] (iii) forming of the ternary complex between the CRBN, the ARNT and the small molecule; and (iv) ubiquitination of the ARNT;
[0323] wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0324] Embodiment 2: A method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising:
[0325] (i) contacting CRBN with a small molecule;
[0326] (ii) inducing a change in the conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0327] (iii) forming of the ternary complex between the CRBN, the ARNT and the small molecule, wherein steps (i)-(iii) result in the induction of a change in conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and the PAS-2 domains of ARNT, wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO.
[0328] 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0329] (iv) ubiquitination of the ARNT;
[0330] wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
[0331] Embodiment 3: The method of Embodiment 2, wherein the contact between ARNT and the small molecule in the ternary complex occurs through the interaction of the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT.
[0332] Embodiment 4: The method of Embodiment 2 or 3, wherein the formation of the ternary complex comprising the CRBN, ARNT and the small molecule is mediated through the interaction of CRBN amino acids GI51, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 with ARNT, and wherein the formation of tire ternary complex leads to degradation of the ARNT.Attorney Docket No.: N2109-7007WO
[0333] Embodiment 5: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0334] (1) binding of a small molecule to cereblon (CRBN);
[0335] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT;
[0336] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0337] (4) forming of a ternary complex comprising the ARNT. the small molecule and the CRBN, wherein the CRBN amino acids G151, 1152, F150. H353, F102, H103, Q390, A395, 1371, V388, H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;
[0338] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0339] Embodiment 6: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0340] (1) binding of a small molecule to cereblon (CRBN);
[0341] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0342] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0343] (4) forming of a ternary complex comprising the ARNT. the small molecule and the CRBN, wherein the CRBN amino acids G151, 1152, F150. H353, F102, H103, Q390, A395, 1371, V388. H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;Attorney Docket No.: N2109-7007WO
[0344] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0345] Embodiment 7: The method of anyone of Embodiments 2-6, wherein the CRBN amino acids in the ternary complex interact with at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237.
[0346] Embodiment 8: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0347] (1) binding of a small molecule to cereblon (CRBN);
[0348] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT;
[0349] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0350] (4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT amino acids E398, N395, G393, I372, K245, G242, T241, K240, L239, or L237 mediate interactions of the ARNT with the CRBN in the ternary complex;
[0351] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0352] Embodiment 9: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0353] (1) binding of a small molecule to cereblon (CRBN);
[0354] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0355] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); andAttorney Docket No.: N2109-7007WO
[0356] (4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT amino acids E398, N395, G393, I372, K245, G242, T241, K240, L239, or L237 mediate the interactions of the ARNT with the CRBN to form the ternary complex;
[0357] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0358] Embodiment 10: The method of Embodiment 8 or 9, wherein the ARNT amino acids in the ternary complex interact with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, 1371, V388, H397, W386, W400, N351, Y355, H357, or S420.
[0359] Embodiment 11: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0360] (1) binding of a small molecule to cereblon (CRBN);
[0361] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;
[0362] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0363] (4) forming of a ternary complex comprising the ARNT, the small molecule and tire CRBN, wherein at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, interacts with at least one of the ARNT amino acids E398, N395. G393, 1372, K245. G242, T241, K240. L239, or L237 to form the ternary complex;
[0364] wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0365] Embodiment 12: The method of anyone of Embodiments 2-10, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT E398 and CRBN F150; ARNT N395 and CRBN I152; ARNT G393 and CRBN H353; ARNT 1372 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN 1371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 andAttorney Docket No.: N2109-7007WO
[0366] CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.
[0367] Embodiment 13: A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:
[0368] (1) binding of a small molecule to cereblon (CRBN);
[0369] (2) inducing a change in the conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of K394, G393, L237 or V244 amino acids of the ARNT; and
[0370] (3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and
[0371] (4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT and the CRBN interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT E398 and CRBN F150; ARNT N395 and CRBN I152; ARNT G393 and CRBN H353; ARNT 1372 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN 1371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353;
[0372] wherein the ARNT intramolecular interactions and the ARNT-CRBN interactions mediate the formation of the ternary complex and wherein the formation of the ternary complex leads to degradation of the ARNT.
[0373] Embodiment 14: The method of anyone of Embodiments 2-12, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT N395 and CRBN I152; ARNT I372 and CRBN H353; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.Attorney Docket No.: N2109-7007WO
[0374] Embodiment 15: The method of anyone of Embodiments 2-12, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT E398 and CRBN F150; ARNT G393 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; or ARNT K245 and CRBN 1371.
[0375] Embodiment 16: The method of anyone of Embodiments 2-13, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT N395 and CRBN 1152; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; or ARNT K240 and CRBN S420.
[0376] Embodiment 17: The method of anyone of Embodiments 2-13, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT I372 and CRBN H353; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.
[0377] Embodiment 18: The method of anyone of Embodiments 2-13 or 17, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT I372 and CRBN H353; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.
[0378] Embodiment 19: The method of anyone of Embodiments 2-13 or 17, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the following ARNT-CRBN amino acid interaction: ARNT I372 and CRBN H353.
[0379] Embodiment 20: The method of anyone of Embodiments 2-13 or 17, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.
[0380] Embodiment 21: The method of anyone of Embodiments 2-13, 17 or 20, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; or ARNT T241.Attorney Docket No.: N2109-7007WO
[0381] Embodiment 22: The method of anyone of Embodiments 2-13, 17 or 20, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.
[0382] Embodiment 23: The method of anyone of Embodiments 2-22, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of tire PAS-1 and PAS-2 domains: ARNT R235 and ARNT V376; ARNT R235 and ARNT D377; ARNT R235 and ARNT P388; ARNT R235 and ARNT Q389; ARNT I236 and ARNT R366; ARNT L237 and ARNT G393; ARNT L239 and ARNT N368; ARNT L239 and ARNT G393; ARNT V244 and ARNT Q389; ARNT R366 and ARNT E247; ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT D377 and ARNT T233; ARNT D377 and ARNT G234; ARNT D377 and ARNT R235; ARNT H378 and ARNT T233; ARNT H378 and ARNT G234; ARNT H378 and ARNT K246; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0383] Embodiment 24: The method of anyone of Embodiments 2-23, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; ARNT L392 and ARNT V244; ARNT L239 and ARNTN368; or ARNT L239 and ARNT G393.
[0384] Embodiment 25: The method of anyone of Embodiments 2-24, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO
[0385] Embodiment 26: The method of anyone of Embodiments 2-25, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237 and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT 1372 and ARNT L239; ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0386] Embodiment 27: The method of anyone of Embodiments 2-26, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0387] Embodiment 28: The method of anyone of Embodiments 2-27, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239: ARNT T374 and ARNT 1236; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0388] Embodiment 29: The method of anyone of Embodiments 2-28, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0389] Embodiment 30: The method of anyone of Embodiments 2-29, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interactionAttorney Docket No.: N2109-7007WO
[0390] of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0391] Embodiment 31: The method of anyone of Embodiments 2-30, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0392] Embodiment 32: The method of anyone of Embodiments 2-31, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0393] Embodiment 33: The method of anyone of Embodiments 2-32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0394] Embodiment 34: The method of anyone of Embodiments 2-33, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375Attorney Docket No.: N2109-7007WO
[0395] and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0396] Embodiment 35: The method of anyone of Embodiments 2-34, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0397] Embodiment 36: The method of anyone of Embodiments 2-35, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT I236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0398] Embodiment 37: The method of anyone of Embodiments 2-36, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0399] Embodiment 38: The method of anyone of Embodiments 2-37, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction ofthe PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNTAttorney Docket No.: N2109-7007WO
[0400] L392 and ARNT I236;and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0401] Embodiment 39: The method of anyone of Embodiments 2-38, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236: ARNT T374 and ARNT L237: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
[0402] Embodiment 40: Tire method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237: and ARNT 1372 and ARNT L239.
[0403] Embodiment 41: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236.
[0404] Embodiment 42: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction ofthe PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236: and ARNT T374 and ARNT L237.
[0405] Embodiment 43: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction ofthe PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; and ARNT T374 and ARNT L239.
[0406] Embodiment 44: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233.
[0407] Embodiment 45: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; and ARNT F375 and ARNT G234.
[0408] Embodiment 46: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction ofthe PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and ARNT F375 and ARNT R235.Attorney Docket No.: N2109-7007WO
[0409] Embodiment 47: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and ARNT F375 and ARNT 1236.
[0410] Embodiment 48: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and ARNT F375 and ARNT L237.
[0411] Embodiment 49: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.
[0412] Embodiment 50: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235.
[0413] Embodiment 51: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; and ARNT L392 and ARNT 1236.
[0414] Embodiment 52: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and ARNT L392 and ARNT L237.
[0415] Embodiment 53: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
[0416] Embodiment 54: The method of anyone of Embodiments 2-22, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT 1372 and ARNT L237; or ARNT 1372 and ARNT L239.
[0417] Embodiment 55: The method of anyone of Embodiments 2-22, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interactionAttorney Docket No.: N2109-7007WO
[0418] between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; or ARNT T374 and ARNT L239.
[0419] Embodiment 56: The method of anyone of Embodiments 2-22, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to fonn the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0420] Embodiment 57: The method of anyone of Embodiments 2-22, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to fonn the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0421] Embodiment 58: The method of anyone of Embodiments 2-22, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to fonn the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L239 and ARNT N368; or ARNT L239 and ARNT G393.
[0422] Embodiment 59: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237: or ARNT T374 and ARNT L239.
[0423] Embodiment 60: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT L237; or ARNT T374 and ARNT L239.
[0424] Embodiment 61: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237: ARNT 1372 and ARNT L239: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; and ARNT T374 and ARNT L239.
[0425] Embodiment 62: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interactionAttorney Docket No.: N2109-7007WO
[0426] of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0427] Embodiment 63: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0428] Embodiment 64: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0429] Embodiment 65: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237: ARNT 1372 and ARNT L239: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0430] Embodiment 66: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237: ARNT 1372 and ARNT L239: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0431] Embodiment 67: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.Attorney Docket No.: N2109-7007WO
[0432] Embodiment 68: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of tire PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0433] Embodiment 69: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0434] Embodiment 70: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0435] Embodiment 71: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNTV244.
[0436] Embodiment 72: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of tire PAS-1 and PAS-2 domains: ARNT L239 and ARNT N368; or ARNT L239 and ARNT G393.
[0437] Embodiment 73: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L239 and ARNTN368; and ARNT L239 and ARNT G393.
[0438] Embodiment 74: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interactionAttorney Docket No.: N2109-7007WO
[0439] of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0440] Embodiment 75: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0441] Embodiment 76: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0442] Embodiment 77: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0443] Embodiment 78: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
[0444] Embodiment 79: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.Attorney Docket No.: N2109-7007WO
[0445] Embodiment 80: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0446] Embodiment 81: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNTL239; ARNT L392 and ARNTR235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0447] Embodiment 82: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0448] Embodiment 83: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
[0449] Embodiment 84: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L239 and ARNT N368; and ARNT L239 and ARNT G393.
[0450] Embodiment 85: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO
[0451] Embodiment 86: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0452] Embodiment 87: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247: ARNT L392 and ARNT R235: ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
[0453] Embodiment 88: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236: ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
[0454] Embodiment 89: Hie method of anyone of Embodiments 2-39, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236: ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L239 and ARNTN368; and ARNT L239 and ARNT G393.
[0455] Embodiment 90: The method of anyone of Embodiments 2-39, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; ARNT L392 and ARNT V244; ARNT L239 and ARNTN368; and ARNT L239 and ARNT G393.
[0456] Embodiment 91: The method of anyone of Embodiments 2-90, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine modifies or reduces the small molecule -induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[0457] Embodiment 92: The method of anyone of Embodiments 2-91, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0458] Embodiment 93: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
[0459] Embodiment 94: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0460] Embodiment 95: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0461] Embodiment 96: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0462] Embodiment 97: Tire method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0463] Embodiment 98: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
[0464] Embodiment 99: Tire method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0465] Embodiment 100: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0466] Embodiment 101: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the small molecule-induced confonnation change of ARNT.
[0467] Embodiment 102: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[0468] Embodiment 103: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0469] Embodiment 104: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0470] Embodiment 105: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0471] Embodiment 106: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the small molecule-induced confonnation change of ARNT.
[0472] Embodiment 107: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L237 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0473] Embodiment 108: Tire method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0474] Embodiment 109: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the small molecule-induced confonnation change of ARNT.
[0475] Embodiment 110: Tire method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0476] Embodiment 111: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the small molecule-induced confonnation change of ARNT.
[0477] Embodiment 112: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0478] Embodiment 113: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[0479] Embodiment 114: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0480] Embodiment 115: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0481] Embodiment 116: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0482] Embodiment 117: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0483] Embodiment 118: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0484] Embodiment 119: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374. F375, L237. and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0485] Embodiment 120: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0486] Embodiment 121: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239. F375, L237. and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0487] Embodiment 122: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0488] Embodiment 123: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0489] Embodiment 124: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[0490] Embodiment 125: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0491] Embodiment 126: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0492] Embodiment 127: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0493] Embodiment 128: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0494] Embodiment 129: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0495] Embodiment 130: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0496] Embodiment 131: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0497] Embodiment 132: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
[0498] Embodiment 133: The method of anyone of Embodiments 2-92, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
[0499] Embodiment 134: The method of anyone of Embodiments 2-90, wherein a mutation of any ARNT amino acid L239, 1372, T374. F375, L392, N368. G393, L237, 1236, T233, G234, R235. E247, or V244, or a combination thereof to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0500] Embodiment 135: The method of anyone of Embodiments 2-90 or 134, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0501] Embodiment 136: The method of anyone of Embodiments 2-90, 134. or 135, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0502] Embodiment 137: The method of anyone of Embodiments 2-90, 134. or 135. wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0503] Embodiment 138: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO
[0504] Embodiment 139: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0505] Embodiment 140: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0506] Embodiment 141: The method of anyone of Embodiments 2-90, 134. or 135. wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0507] Embodiment 142: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0508] Embodiment 143: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0509] Embodiment 144: The method of anyone of Embodiments 2-90, 134, or 135. wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0510] Embodiment 145: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0511] Embodiment 146: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0512] Embodiment 147: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0513] Embodiment 148: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0514] Embodiment 149: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0515] Embodiment 150: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L237 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0516] Embodiment 151: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0517] Embodiment 152: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0518] Embodiment 153: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO
[0519] Embodiment 154: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0520] Embodiment 155: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0521] Embodiment 156: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0522] Embodiment 157: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0523] Embodiment 158: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0524] Embodiment 159: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374. F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0525] Embodiment 160: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0526] Embodiment 161: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0527] Embodiment 162: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0528] Embodiment 163: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid T374, F375, L237. and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0529] Embodiment 164: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO
[0530] Embodiment 165: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0531] Embodiment 166: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0532] Embodiment 167: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0533] Embodiment 168: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0534] Embodiment 169: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0535] Embodiment 170: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, T374. F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0536] Embodiment 171: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0537] Embodiment 172: The method of anyone of Embodiments 2-90, 134. or 135, wherein a mutation of ARNT amino acid L239, 1372. T374, F375. L237, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0538] Embodiment 173: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0539] Embodiment 174: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0540] Embodiment 175: The method of anyone of Embodiments 2-90, 134, or 135. wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0541] Embodiment 176: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0542] Embodiment 177: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO
[0543] Embodiment 178: The method of anyone of Embodiments 2-90, 134, or 135, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
[0544] Embodiment 179: The method of anyone of Embodiments 2-90, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0545] Embodiment 180: The method of anyone of Embodiments 2-90 or 179, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0546] Embodiment 181: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239 and 1372 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0547] Embodiment 182: The method of anyone of Embodiments 2-90, 179, or 180. wherein a mutation of ARNT amino acid L239 and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0548] Embodiment 183: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0549] Embodiment 184: The method of anyone of Embodiments 2-90, 179, or 180. wherein a mutation of ARNT amino acid L239 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0550] Embodiment 185: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0551] Embodiment 186: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372 and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0552] Embodiment 187: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0553] Embodiment 188: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0554] Embodiment 189: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0555] Embodiment 190: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0556] Embodiment 191: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0557] Embodiment 192: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0558] Embodiment 193: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid F375 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0559] Embodiment 194: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid F375 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0560] Embodiment 195: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0561] Embodiment 196: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0562] Embodiment 197: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0563] Embodiment 198: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0564] Embodiment 199: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0565] Embodiment 200: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0566] Embodiment 201: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0567] Embodiment 202: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0568] Embodiment 203: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0569] Embodiment 204: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0570] Embodiment 205: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0571] Embodiment 206: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0572] Embodiment 207: The method of anyone of Embodiments 2-90, 179. or 180, wherein a mutation of ARNT amino acid T374, F375, L237. and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0573] Embodiment 208: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0574] Embodiment 209: The method of anyone of Embodiments 2-90, 179. or 180, wherein a mutation of ARNT amino acid L239, F375, L237. and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0575] Embodiment 210: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0576] Embodiment 211: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0577] Embodiment 212: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0578] Embodiment 213: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0579] Embodiment 214: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0580] Embodiment 215: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, T374, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0581] Embodiment 216: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0582] Embodiment 217: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0583] Embodiment 218: The method of anyone of Embodiments 2-90, 179. or 180, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0584] Embodiment 219: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L239 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0585] Embodiment 220: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid 1372 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0586] Embodiment 221: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0587] Embodiment 222: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0588] Embodiment 223: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0589] Embodiment 224: The method of anyone of Embodiments 2-90, 179, or 180, wherein a mutation of ARNT amino acid L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0590] Embodiment 225: The method of anyone of Embodiments 2-90, wherein a mutation of any ARNT amino acid L239, 1372, T374. F375, L392, N368. G393, L237, 1236, T233, G234, R235. E247, or V244, or a combination thereof to alanine modifies the cellular signaling effects mediated by ARNT.
[0591] Embodiment 226: The method of anyone of Embodiments 2-90 or 225, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine modifies the cellular signaling effects mediated by ARNT.
[0592] Embodiment 227: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies the cellular signaling effects mediated by ARNT.
[0593] Embodiment 228: The method of anyone of Embodiments 2-90, 225, or 226. wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
[0594] Embodiment 229: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0595] Embodiment 230: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0596] Embodiment 231: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0597] Embodiment 232: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
[0598] Embodiment 233: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0599] Embodiment 234: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0600] Embodiment 235: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[0601] Embodiment 236: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0602] Embodiment 237: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0603] Embodiment 238: Hie method of anyone of Embodiments 2-90, 225. or 226. wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0604] Embodiment 239: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0605] Embodiment 240: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0606] Embodiment 241: Hie method of anyone of Embodiments 2-90, 225, or 226. wherein a mutation of ARNT amino acid L239. 1372, and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
[0607] Embodiment 242: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0608] Embodiment 243: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0609] Embodiment 244: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0610] Embodiment 245: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0611] Embodiment 246: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0612] Embodiment 247: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0613] Embodiment 248: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[0614] Embodiment 249: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0615] Embodiment 250: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0616] Embodiment 251: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid F375, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0617] Embodiment 252: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0618] Embodiment 253: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0619] Embodiment 254: Tire method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374, F375. L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0620] Embodiment 255: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0621] Embodiment 256: Hie method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0622] Embodiment 257: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, F375, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0623] Embodiment 258: Tire method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0624] Embodiment 259: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[0625] Embodiment 260: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0626] Embodiment 261: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0627] Embodiment 262: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0628] Embodiment 263: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0629] Embodiment 264: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0630] Embodiment 265: Tire method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L239 to alanine modifies tire cellular signaling effects mediated by ARNT.
[0631] Embodiment 266: The method of anyone of Embodiments 2-90, 225, or 226. wherein a mutation of ARNT amino acid 1372 to alanine modifies the cellular signaling effects mediated by ARNT.
[0632] Embodiment 267: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid T374 to alanine modifies the cellular signaling effects mediated by ARNT.
[0633] Embodiment 268: Hie method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid F375 to alanine modifies the cellular signaling effects mediated by ARNT.
[0634] Embodiment 269: The method of anyone of Embodiments 2-90, 225, or 226. wherein a mutation of ARNT amino acid L237 to alanine modifies the cellular signaling effects mediated by ARNT.
[0635] Embodiment 270: The method of anyone of Embodiments 2-90, 225, or 226, wherein a mutation of ARNT amino acid L392 to alanine modifies the cellular signaling effects mediated by ARNT.
[0636] Embodiment 271: Tire method of anyone of Embodiments 2-90, wherein a mutation of any ARNT amino acid L239, 1372, T374. F375, L392, N368. G393, L237, 1236, T233, G234, R235. E247, or V244, or a combination thereof to alanine modifies or reduces the degradation of ARNT.
[0637] Embodiment 272: The method of anyone of Embodiments 2-90 or 271, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0638] Embodiment 273: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the degradation of ARNT.
[0639] Embodiment 274: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces tire degradation of ARNT.
[0640] Embodiment 275: Tire method of anyone of Embodiments 2-90, 271. or 272. wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the degradation of ARNT.
[0641] Embodiment 276: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the degradation of ARNT.
[0642] Embodiment 277: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces tire degradation of ARNT.
[0643] Embodiment 278: Tire method of anyone of Embodiments 2-90, 271. or 272. wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the degradation of ARNT.
[0644] Embodiment 279: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the degradation of ARNT.
[0645] Embodiment 280: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the degradation of ARNT.
[0646] Embodiment 281: The method of anyone of Embodiments 2-90, 271, or 272. wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the degradation of ARNT.
[0647] Embodiment 282: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the degradation of ARNT.
[0648] Embodiment 283: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the degradation of ARNT.
[0649] Embodiment 284: The method of anyone of Embodiments 2-90, 271, or 272. wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the degradation of ARNT.
[0650] Embodiment 285: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the degradation of ARNT.
[0651] Embodiment 286: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the degradation of ARNT.
[0652] Embodiment 287: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the degradation of ARNT.
[0653] Embodiment 288: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the degradation of ARNT.
[0654] Embodiment 289: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0655] Embodiment 290: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the degradation of ARNT.
[0656] Embodiment 291: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies or reduces the degradation of ARNT.
[0657] Embodiment 292: Tire method of anyone of Embodiments 2-90, 271. or 272. wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the degradation of ARNT.
[0658] Embodiment 293: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the degradation of ARNT.
[0659] Embodiment 294: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the degradation of ARNT.
[0660] Embodiment 295: Tire method of anyone of Embodiments 2-90, 271, or 272. wherein a mutation of ARNT amino acid T374, F375. and L238 to alanine modifies or reduces the degradation of ARNT.
[0661] Embodiment 296: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
[0662] Embodiment 297: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the degradation of ARNT.
[0663] Embodiment 298: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
[0664] Embodiment 299: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid 1372, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
[0665] Embodiment 300: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
[0666] Embodiment 301: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
[0667] Embodiment 302: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
[0668] Embodiment 303: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
[0669] Embodiment 304: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the degradation of ARNT.
[0670] Embodiment 305: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0671] Embodiment 306: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
[0672] Embodiment 307: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
[0673] Embodiment 308: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, and L392 to alanine modifies or reduces the degradation of ARNT.
[0674] Embodiment 309: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the degradation of ARNT.
[0675] Embodiment 310: The method of anyone of Embodiments 2-90, 271, or 272. wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the degradation of ARNT.
[0676] Embodiment 311: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the degradation of ARNT.
[0677] Embodiment 312: Tire method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the degradation of ARNT.
[0678] Embodiment 313: The method of anyone of Embodiments 2-90, 271, or 272. wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the degradation of ARNT.
[0679] Embodiment 314: The method of anyone of Embodiments 2-90, 271, or 272, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the degradation of ARNT.
[0680] Embodiment 315: Hie method of anyone of Embodiments 2-90, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof reduces recruitment of ARNT.
[0681] Embodiment 316: The method of anyone of Embodiments 2-90 or 315, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, orH357 or a combination thereof reduces recruitment of ARNT.
[0682] Embodiment 317: Hie method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 and V388 reduces recruitment of ARNT.
[0683] Embodiment 318: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid H353 and H397 reduces recruitment of ARNT.
[0684] Embodiment 319: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 and W400 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0685] Embodiment 320: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 and N351 reduces recruitment of ARNT.
[0686] Embodiment 321: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 and Y355 reduces recruitment of ARNT.
[0687] Embodiment 322: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H353 and H357 reduces recruitment of ARNT.
[0688] Embodiment 323: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 and E377 reduces recruitment of ARNT.
[0689] Embodiment 324: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, and H397 reduces recruitment of ARNT.
[0690] Embodiment 325: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H353. V388, and E377 reduces recruitment of ARNT.
[0691] Embodiment 326: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, and W400 reduces recruitment of ARNT.
[0692] Embodiment 327: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, and N351 reduces recruitment of ARNT.
[0693] Embodiment 328: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid H353, V388, and Y355 reduces recruitment of ARNT.
[0694] Embodiment 329: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, and H357 reduces recruitment of ARNT.
[0695] Embodiment 330: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and H397 reduces recruitment of ARNT.
[0696] Embodiment 331: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and E377 reduces recruitment of ARNT.
[0697] Embodiment 332: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and W400 reduces recruitment of ARNT.
[0698] Embodiment 333: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and N351 reduces recruitment of ARNT.
[0699] Embodiment 334: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and Y355 reduces recruitment of ARNT.
[0700] Embodiment 335: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 and H357 reduces recruitment of ARNT.
[0701] Embodiment 336: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397 and E377 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0702] Embodiment 337: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397 and W400 reduces recruitment of ARNT.
[0703] Embodiment 338: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397 and N351 reduces recruitment of ARNT.
[0704] Embodiment 339: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H397 and Y355 reduces recruitment of ARNT.
[0705] Embodiment 340: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397 and H357 reduces recruitment of ARNT.
[0706] Embodiment 341: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid E377 and W400 reduces recruitment of ARNT.
[0707] Embodiment 342: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid E377 and N351 reduces recruitment of ARNT.
[0708] Embodiment 343: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid E377 and Y355 reduces recruitment of ARNT.
[0709] Embodiment 344: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid E377 and H357 reduces recruitment of ARNT.
[0710] Embodiment 345: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid W400 and N351 reduces recruitment of ARNT.
[0711] Embodiment 346: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid W400 and Y355 reduces recruitment of ARNT.
[0712] Embodiment 347: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid W400 and H357 reduces recruitment of ARNT.
[0713] Embodiment 348: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid N351 and Y355 reduces recruitment of ARNT.
[0714] Embodiment 349: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid N351 and H357 reduces recruitment of ARNT.
[0715] Embodiment 350: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid Y355 and H357 reduces recruitment of ARNT.
[0716] Embodiment 351: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, and E377 reduces recruitment of ARNT.
[0717] Embodiment 352: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, and W400 reduces recruitment of ARNT.
[0718] Embodiment 353: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, and N351 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0719] Embodiment 354: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, and Y355 reduces recruitment of ARNT.
[0720] Embodiment 355: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, and H357 reduces recruitment of ARNT.
[0721] Embodiment 356: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H397. E377. and W400 reduces recruitment of ARNT.
[0722] Embodiment 357: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, E377, and N351 reduces recruitment of ARNT.
[0723] Embodiment 358: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, E377, and Y355 reduces recruitment of ARNT.
[0724] Embodiment 359: Hie method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid H397. E377, and H357 reduces recruitment of ARNT.
[0725] Embodiment 360: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid E377, W400, and N351 reduces recruitment of ARNT.
[0726] Embodiment 361: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid E377, W400, and Y355 reduces recruitment of ARNT.
[0727] Embodiment 362: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid E377, W400, and H357 reduces recruitment of ARNT.
[0728] Embodiment 363: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, W400, and N351 reduces recruitment of ARNT.
[0729] Embodiment 364: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, W400 and Y355 reduces recruitment of ARNT.
[0730] Embodiment 365: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, W400, and H357 reduces recruitment of ARNT.
[0731] Embodiment 366: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid W400, N351, and Y355, reduces recruitment of ARNT.
[0732] Embodiment 367: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid W400, N351, and H357 reduces recruitment of ARNT.
[0733] Embodiment 368: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid N351, Y355, and H357 reduces recruitment of ARNT.
[0734] Embodiment 369: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 reduces recruitment of ARNT.
[0735] Embodiment 370: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0736] Embodiment 371: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 reduces recruitment of ARNT.
[0737] Embodiment 372: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 reduces recruitment of ARNT.
[0738] Embodiment 373: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H353. V388, H397 and H357 reduces recruitment of ARNT.
[0739] Embodiment 374: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 reduces recruitment of ARNT.
[0740] Embodiment 375: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 reduces recruitment of ARNT.
[0741] Embodiment 376: Hie method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid V388. H397, E377, and Y355 reduces recruitment of ARNT.
[0742] Embodiment 377: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 reduces recruitment of ARNT.
[0743] Embodiment 378: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 reduces recruitment of ARNT.
[0744] Embodiment 379: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 reduces recruitment of ARNT.
[0745] Embodiment 380: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 reduces recruitment of ARNT.
[0746] Embodiment 381: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 reduces recruitment of ARNT.
[0747] Embodiment 382: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 reduces recruitment of ARNT.
[0748] Embodiment 383: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 reduces recruitment of ARNT.
[0749] Embodiment 384: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 reduces recruitment of ARNT.
[0750] Embodiment 385: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino H397, W400, N351, and H357 reduces recruitment of ARNT.
[0751] Embodiment 386: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino W400, N351, Y355, and H357 reduces recruitment of ARNT.
[0752] Embodiment 387: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0753] Embodiment 388: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 reduces recruitment of ARNT.
[0754] Embodiment 389: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 reduces recruitment of ARNT.
[0755] Embodiment 390: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H353. V388, H397, 11, and H357 reduces recruitment of ARNT.
[0756] Embodiment 391: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 reduces recruitment of ARNT.
[0757] Embodiment 392: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 reduces recruitment of ARNT.
[0758] Embodiment 393: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid H353. V388, H397, W400, and H357 reduces recruitment of ARNT.
[0759] Embodiment 394: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 reduces recruitment of ARNT.
[0760] Embodiment 395: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 reduces recruitment of ARNT.
[0761] Embodiment 396: The method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 reduces recruitment of ARNT.
[0762] Embodiment 397: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 reduces recruitment of ARNT.
[0763] Embodiment 398: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 reduces recruitment of ARNT.
[0764] Embodiment 399: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 reduces recruitment of ARNT.
[0765] Embodiment 400: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 reduces recruitment of ARNT.
[0766] Embodiment 401: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351. and H357 reduces recruitment of ARNT.
[0767] Embodiment 402: The method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 reduces recruitment of ARNT.
[0768] Embodiment 403: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H353 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO
[0769] Embodiment 404: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid V388 reduces recruitment of ARNT.
[0770] Embodiment 405: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H397 reduces recruitment of ARNT.
[0771] Embodiment 406: Hie method of anyone of Embodiments 2-90, 315. or 316. wherein a mutation of CRBN amino acid E377 reduces recruitment of ARNT.
[0772] Embodiment 407: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid W400 reduces recruitment of ARNT.
[0773] Embodiment 408: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid N351 reduces recruitment of ARNT.
[0774] Embodiment 409: Hie method of anyone of Embodiments 2-90, 315, or 316. wherein a mutation of CRBN amino Y355 reduces recruitment of ARNT.
[0775] Embodiment 410: The method of anyone of Embodiments 2-90, 315, or 316, wherein a mutation of CRBN amino acid H357 reduces recruitment of ARNT.
[0776] Embodiment 411: The method of anyone of Embodiments 2-90, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof modifies or reduces degradation of ARNT.
[0777] Embodiment 412: The method of anyone of Embodiments 2-90 or 411, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies or reduces degradation of ARNT.
[0778] Embodiment 413: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 and V388 modifies or reduces degradation of ARNT.
[0779] Embodiment 414: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H353 and H397 modifies or reduces degradation of ARNT.
[0780] Embodiment 415: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 and W400 modifies or reduces degradation of ARNT.
[0781] Embodiment 416: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 and N351 modifies or reduces degradation of ARNT.
[0782] Embodiment 417: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H353 and Y355 modifies or reduces degradation of ARNT.
[0783] Embodiment 418: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 and H357 modifies or reduces degradation of ARNT.
[0784] Embodiment 419: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 and E377 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0785] Embodiment 420: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, and H397 modifies or reduces degradation of ARNT.
[0786] Embodiment 421: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, and E377 modifies or reduces degradation of ARNT.
[0787] Embodiment 422: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid H353. V388, and W400 modifies or reduces degradation of ARNT.
[0788] Embodiment 423: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, and N351 modifies or reduces degradation of ARNT.
[0789] Embodiment 424: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, and Y355 modifies or reduces degradation of ARNT.
[0790] Embodiment 425: Hie method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H353. V388, and H357 modifies or reduces degradation of ARNT.
[0791] Embodiment 426: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388 and H397 modifies or reduces degradation of ARNT.
[0792] Embodiment 427: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388 and E377 modifies or reduces degradation of ARNT.
[0793] Embodiment 428: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid V388 and W400 modifies or reduces degradation of ARNT.
[0794] Embodiment 429: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388 and N351 modifies or reduces degradation of ARNT.
[0795] Embodiment 430: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388 and Y355 modifies or reduces degradation of ARNT.
[0796] Embodiment 431: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid V388 and H357 modifies or reduces degradation of ARNT.
[0797] Embodiment 432: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397 and E377 modifies or reduces degradation of ARNT.
[0798] Embodiment 433: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397 and W400 modifies or reduces degradation of ARNT.
[0799] Embodiment 434: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H397 and N351 modifies or reduces degradation of ARNT.
[0800] Embodiment 435: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397 and Y355 modifies or reduces degradation of ARNT.
[0801] Embodiment 436: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397 and H357 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0802] Embodiment 437: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377 and W400 modifies or reduces degradation of ARNT.
[0803] Embodiment 438: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377 and N351 modifies or reduces degradation of ARNT.
[0804] Embodiment 439: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid E377 and Y355 modifies or reduces degradation of ARNT.
[0805] Embodiment 440: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377 and H357 modifies or reduces degradation of ARNT.
[0806] Embodiment 441: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid W400 and N351 modifies or reduces degradation of ARNT.
[0807] Embodiment 442: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid W400 and Y355 modifies or reduces degradation of ARNT.
[0808] Embodiment 443: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid W400 and H357 modifies or reduces degradation of ARNT.
[0809] Embodiment 444: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid N351 and Y355 modifies or reduces degradation of ARNT.
[0810] Embodiment 445: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid N351 and H357 modifies or reduces degradation of ARNT.
[0811] Embodiment 446: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid Y355 and H357 modifies or reduces degradation of ARNT.
[0812] Embodiment 447: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, and E377 modifies or reduces degradation of ARNT.
[0813] Embodiment 448: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid V388, H397, and W400 modifies or reduces degradation of ARNT.
[0814] Embodiment 449: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies or reduces degradation of ARNT.
[0815] Embodiment 450: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, and Y355 modifies or reduces degradation of ARNT.
[0816] Embodiment 451: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies or reduces degradation of ARNT.
[0817] Embodiment 452: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies or reduces degradation of ARNT.
[0818] Embodiment 453: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0819] Embodiment 454: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies or reduces degradation of ARNT.
[0820] Embodiment 455: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, and H357 modifies or reduces degradation of ARNT.
[0821] Embodiment 456: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid E377, W400, and N351 modifies or reduces degradation of ARNT.
[0822] Embodiment 457: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377, W400, and Y355 modifies or reduces degradation of ARNT.
[0823] Embodiment 458: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377, W400, and H357 modifies or reduces degradation of ARNT.
[0824] Embodiment 459: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid H397. W400, and N351 modifies or reduces degradation of ARNT.
[0825] Embodiment 460: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, W400 and Y355 modifies or reduces degradation of ARNT.
[0826] Embodiment 461: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, W400, and H357 modifies or reduces degradation of ARNT.
[0827] Embodiment 462: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid W400, N351, and Y355. modifies or reduces degradation of ARNT.
[0828] Embodiment 463: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid W400, N351, and H357 modifies or reduces degradation of ARNT.
[0829] Embodiment 464: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid N351, Y355, and H357 modifies or reduces degradation of ARNT.
[0830] Embodiment 465: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 modifies or reduces degradation of ARNT.
[0831] Embodiment 466: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 modifies or reduces degradation of ARNT.
[0832] Embodiment 467: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 modifies or reduces degradation of ARNT.
[0833] Embodiment 468: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 modifies or reduces degradation of ARNT.
[0834] Embodiment 469: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 modifies or reduces degradation of ARNT.
[0835] Embodiment 470: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0836] Embodiment 471: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 modifies or reduces degradation of ARNT.
[0837] Embodiment 472: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 modifies or reduces degradation of ARNT.
[0838] Embodiment 473: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid V388. H397, E377, and H357 modifies or reduces degradation of ARNT.
[0839] Embodiment 474: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 modifies or reduces degradation of ARNT.
[0840] Embodiment 475: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 modifies or reduces degradation of ARNT.
[0841] Embodiment 476: Hie method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid V388. H397, W400 and H357 modifies or reduces degradation of ARNT.
[0842] Embodiment 477: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 modifies or reduces degradation of ARNT.
[0843] Embodiment 478: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 modifies or reduces degradation of ARNT.
[0844] Embodiment 479: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H397, E377. W400, and H357 modifies or reduces degradation of ARNT.
[0845] Embodiment 480: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 modifies or reduces degradation of ARNT.
[0846] Embodiment 481: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino H397, W400, N351, and H357 modifies or reduces degradation of ARNT.
[0847] Embodiment 482: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino W400, N351, Y355, and H357 modifies or reduces degradation of ARNT.
[0848] Embodiment 483: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 modifies or reduces degradation of ARNT.
[0849] Embodiment 484: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 modifies or reduces degradation of ARNT.
[0850] Embodiment 485: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 modifies or reduces degradation of ARNT.
[0851] Embodiment 486: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and H357 modifies or reduces degradation of ARNT.
[0852] Embodiment 487: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0853] Embodiment 488: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 modifies or reduces degradation of ARNT.
[0854] Embodiment 489: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 modifies or reduces degradation of ARNT.
[0855] Embodiment 490: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid V388. H397, E377, W400, and N351 modifies or reduces degradation of ARNT.
[0856] Embodiment 491: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 modifies or reduces degradation of ARNT.
[0857] Embodiment 492: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 modifies or reduces degradation of ARNT.
[0858] Embodiment 493: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino acid V388. H397, W400. N351, and Y355 modifies or reduces degradation of ARNT.
[0859] Embodiment 494: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 modifies or reduces degradation of ARNT.
[0860] Embodiment 495: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 modifies or reduces degradation of ARNT.
[0861] Embodiment 496: The method of anyone of Embodiments 2-90, 411, or 412. wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 modifies or reduces degradation of ARNT.
[0862] Embodiment 497: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and H357 modifies or reduces degradation of ARNT.
[0863] Embodiment 498: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 modifies or reduces degradation of ARNT.
[0864] Embodiment 499: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H353 modifies or reduces degradation of ARNT.
[0865] Embodiment 500: Hie method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid V388 modifies or reduces degradation of ARNT.
[0866] Embodiment 501: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H397 modifies or reduces degradation of ARNT.
[0867] Embodiment 502: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid E377 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO
[0868] Embodiment 503: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid W400 modifies or reduces degradation of ARNT.
[0869] Embodiment 504: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid N351 modifies or reduces degradation of ARNT.
[0870] Embodiment 505: Hie method of anyone of Embodiments 2-90, 411. or 412. wherein a mutation of CRBN amino Y355 modifies or reduces degradation of ARNT.
[0871] Embodiment 506: The method of anyone of Embodiments 2-90, 411, or 412, wherein a mutation of CRBN amino acid H357 modifies or reduces degradation of ARNT.
[0872] Embodiment 507: The method of anyone of Embodiments 2-90, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0873] Embodiment 508: The method of anyone of Embodiments 2-90 or 507, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, orH357 or a combination thereof reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0874] Embodiment 509: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and V388 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0875] Embodiment 510: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0876] Embodiment 511: Hie method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0877] Embodiment 512: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0878] Embodiment 513: Hie method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0879] Embodiment 514: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0880] Embodiment 515: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0881] Embodiment 516: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388. and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0882] Embodiment 517: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0883] Embodiment 518: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0884] Embodiment 519: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0885] Embodiment 520: Tire method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388. and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0886] Embodiment 521: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0887] Embodiment 522: Hie method of anyone of Embodiments 2-90, 507. or 508, wherein a mutation of CRBN amino acid V388 and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0888] Embodiment 523: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0889] Embodiment 524: Hie method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0890] Embodiment 525: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0891] Embodiment 526: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0892] Embodiment 527: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0893] Embodiment 528: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0894] Embodiment 529: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0895] Embodiment 530: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0896] Embodiment 531: Tire method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0897] Embodiment 532: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0898] Embodiment 533: Hie method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0899] Embodiment 534: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0900] Embodiment 535: Tire method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0901] Embodiment 536: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0902] Embodiment 537: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0903] Embodiment 538: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0904] Embodiment 539: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid W400 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0905] Embodiment 540: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid N351 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0906] Embodiment 541: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid N351 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0907] Embodiment 542: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid Y355 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0908] Embodiment 543: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0909] Embodiment 544: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0910] Embodiment 545: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0911] Embodiment 546: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0912] Embodiment 547: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0913] Embodiment 548: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0914] Embodiment 549: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0915] Embodiment 550: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0916] Embodiment 551: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0917] Embodiment 552: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0918] Embodiment 553: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0919] Embodiment 554: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0920] Embodiment 555: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0921] Embodiment 556: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0922] Embodiment 557: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0923] Embodiment 558: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid W400, N351, and Y355, reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0924] Embodiment 559: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0925] Embodiment 560: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid N351, Y355. and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0926] Embodiment 561: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0927] Embodiment 562: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0928] Embodiment 563: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0929] Embodiment 564: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0930] Embodiment 565: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0931] Embodiment 566: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0932] Embodiment 567: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0933] Embodiment 568: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0934] Embodiment 569: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0935] Embodiment 570: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0936] Embodiment 571: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397. W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0937] Embodiment 572: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0938] Embodiment 573: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0939] Embodiment 574: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0940] Embodiment 575: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0941] Embodiment 576: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0942] Embodiment 577: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0943] Embodiment 578: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino W400, N351, Y355, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0944] Embodiment 579: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0945] Embodiment 580: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0946] Embodiment 581: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0947] Embodiment 582: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353. V388, H397. E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0948] Embodiment 583: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0949] Embodiment 584: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0950] Embodiment 585: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0951] Embodiment 586: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0952] Embodiment 587: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0953] Embodiment 588: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0954] Embodiment 589: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0955] Embodiment 590: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0956] Embodiment 591: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO
[0957] Embodiment 592: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0958] Embodiment 593: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397. E377, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0959] Embodiment 594: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0960] Embodiment 595: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H353 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0961] Embodiment 596: The method of anyone of Embodiments 2-90, 507. or 508. wherein a mutation of CRBN amino acid V388 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0962] Embodiment 597: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0963] Embodiment 598: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0964] Embodiment 599: The method of anyone of Embodiments 2-90, 507, or 508. wherein a mutation of CRBN amino acid W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0965] Embodiment 600: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0966] Embodiment 601: The method of anyone of Embodiments 2-90, 507, or 508, wherein a mutation of CRBN amino acid Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0967] Embodiment 602: The method of anyone of Embodiments 2-90, 507, or 508. wherein a mutation of CRBN amino acid H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
[0968] Embodiment 603: The method of anyone of Embodiments 2-90, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof modifies the cellular signaling effects mediated by ARNT.
[0969] Embodiment 604: The method of anyone of Embodiments 2-90 or 603, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies the cellular signaling effects mediated by ARNT.
[0970] Embodiment 605: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and V388 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[0971] Embodiment 606: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and H397 modifies the cellular signaling effects mediated by ARNT.
[0972] Embodiment 607: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and W400 modifies the cellular signaling effects mediated by ARNT.
[0973] Embodiment 608: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and N351 modifies the cellular signaling effects mediated by ARNT.
[0974] Embodiment 609: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and Y355 modifies the cellular signaling effects mediated by ARNT.
[0975] Embodiment 610: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and H357 modifies the cellular signaling effects mediated by ARNT.
[0976] Embodiment 611: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 and E377 modifies the cellular signaling effects mediated by ARNT.
[0977] Embodiment 612: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and H397 modifies the cellular signaling effects mediated by ARNT.
[0978] Embodiment 613: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and E377 modifies the cellular signaling effects mediated by ARNT.
[0979] Embodiment 614: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and W400 modifies the cellular signaling effects mediated by ARNT.
[0980] Embodiment 615: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and N351 modifies the cellular signaling effects mediated by ARNT.
[0981] Embodiment 616: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and Y355 modifies the cellular signaling effects mediated by ARNT.
[0982] Embodiment 617: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, and H357 modifies the cellular signaling effects mediated by ARNT.
[0983] Embodiment 618: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and H397 modifies the cellular signaling effects mediated by ARNT.
[0984] Embodiment 619: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and E377 modifies the cellular signaling effects mediated by ARNT.
[0985] Embodiment 620: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and W400 modifies the cellular signaling effects mediated by ARNT.
[0986] Embodiment 621: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and N351 modifies the cellular signaling effects mediated by ARNT.
[0987] Embodiment 622: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and Y355 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[0988] Embodiment 623: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 and H357 modifies the cellular signaling effects mediated by ARNT.
[0989] Embodiment 624: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397 and E377 modifies the cellular signaling effects mediated by ARNT.
[0990] Embodiment 625: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397 and W400 modifies the cellular signaling effects mediated by ARNT.
[0991] Embodiment 626: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397 and N351 modifies the cellular signaling effects mediated by ARNT.
[0992] Embodiment 627: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397 and Y355 modifies the cellular signaling effects mediated by ARNT.
[0993] Embodiment 628: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397 and H357 modifies the cellular signaling effects mediated by ARNT.
[0994] Embodiment 629: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377 and W400 modifies the cellular signaling effects mediated by ARNT.
[0995] Embodiment 630: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377 and N351 modifies the cellular signaling effects mediated by ARNT.
[0996] Embodiment 631: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377 and Y355 modifies the cellular signaling effects mediated by ARNT.
[0997] Embodiment 632: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377 and H357 modifies the cellular signaling effects mediated by ARNT.
[0998] Embodiment 633: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400 and N351 modifies the cellular signaling effects mediated by ARNT.
[0999] Embodiment 634: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400 and Y355 modifies the cellular signaling effects mediated by ARNT.
[1000] Embodiment 635: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400 and H357 modifies the cellular signaling effects mediated by ARNT.
[1001] Embodiment 636: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid N351 and Y355 modifies the cellular signaling effects mediated by ARNT.
[1002] Embodiment 637: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid N351 and H357 modifies the cellular signaling effects mediated by ARNT.
[1003] Embodiment 638: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid Y355 and H357 modifies the cellular signaling effects mediated by ARNT.
[1004] Embodiment 639: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, and E377 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[1005] Embodiment 640: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, and W400 modifies the cellular signaling effects mediated by ARNT.
[1006] Embodiment 641: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies the cellular signaling effects mediated by ARNT.
[1007] Embodiment 642: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1008] Embodiment 643: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies the cellular signaling effects mediated by ARNT.
[1009] Embodiment 644: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.
[1010] Embodiment 645: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
[1011] Embodiment 646: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1012] Embodiment 647: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
[1013] Embodiment 648: The method of anyone of Embodiments 2-90, 603, or 604. wherein a mutation of CRBN amino acid E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
[1014] Embodiment 649: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1015] Embodiment 650: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
[1016] Embodiment 651: The method of anyone of Embodiments 2-90, 603, or 604. wherein a mutation of CRBN amino acid H397, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
[1017] Embodiment 652: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, W400 and Y355 modifies the cellular signaling effects mediated by ARNT.
[1018] Embodiment 653: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
[1019] Embodiment 654: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400, N351, and Y355. modifies the cellular signaling effects mediated by ARNT.
[1020] Embodiment 655: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
[1021] Embodiment 656: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[1022] Embodiment 657: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 modifies the cellular signaling effects mediated by ARNT.
[1023] Embodiment 658: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 modifies the cellular signaling effects mediated by ARNT.
[1024] Embodiment 659: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 modifies the cellular signaling effects mediated by ARNT.
[1025] Embodiment 660: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 modifies the cellular signaling effects mediated by ARNT.
[1026] Embodiment 661: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 modifies the cellular signaling effects mediated by ARNT.
[1027] Embodiment 662: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.
[1028] Embodiment 663: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
[1029] Embodiment 664: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1030] Embodiment 665: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
[1031] Embodiment 666: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 modifies the cellular signaling effects mediated by ARNT.
[1032] Embodiment 667: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[1033] Embodiment 668: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 modifies the cellular signaling effects mediated by ARNT.
[1034] Embodiment 669: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
[1035] Embodiment 670: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1036] Embodiment 671: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
[1037] Embodiment 672: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1038] Embodiment 673: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino H397, W400. N351, and H357 modifies the cellular signaling effects mediated by ARNT.
[1039] Embodiment 674: The method of anyone of Embodiments 2-90, 603, or 604. wherein a mutation of CRBN amino W400, N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.
[1040] Embodiment 675: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.
[1041] Embodiment 676: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
[1042] Embodiment 677: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1043] Embodiment 678: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
[1044] Embodiment 679: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[1045] Embodiment 680: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1046] Embodiment 681: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388. H397, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
[1047] Embodiment 682: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
[1048] Embodiment 683: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, W400. and Y355 modifies the cellular signaling effects mediated by ARNT.
[1049] Embodiment 684: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
[1050] Embodiment 685: Tire method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397. W400, N3 1, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1051] Embodiment 686: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
[1052] Embodiment 687: Hie method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.
[1053] Embodiment 688: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 modifies the cellular signaling effects mediated by ARNT.
[1054] Embodiment 689: Tire method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
[1055] Embodiment 690: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN ammo acid H353, V388, H397, E377, W400, N351, Y355 and H357 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO
[1056] Embodiment 691: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H353 modifies the cellular signaling effects mediated by ARNT.
[1057] Embodiment 692: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid V388 modifies the cellular signaling effects mediated by ARNT.
[1058] Embodiment 693: Hie method of anyone of Embodiments 2-90, 603. or 604. wherein a mutation of CRBN amino acid H397 modifies the cellular signaling effects mediated by ARNT.
[1059] Embodiment 694: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid E377 modifies the cellular signaling effects mediated by ARNT.
[1060] Embodiment 695: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid W400 modifies the cellular signaling effects mediated by ARNT.
[1061] Embodiment 696: Hie method of anyone of Embodiments 2-90, 603, or 604. wherein a mutation of CRBN amino acid N351 modifies the cellular signaling effects mediated by ARNT.
[1062] Embodiment 697: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino Y355 modifies the cellular signaling effects mediated by ARNT.
[1063] Embodiment 698: The method of anyone of Embodiments 2-90, 603, or 604, wherein a mutation of CRBN amino acid H357 modifies the cellular signaling effects mediated by ARNT.
[1064] Embodiment 699: Hie method of anyone of Embodiments 2-90. wherein a mutation of any CRBN ammo acid G151. 1152. F150, H353, F102. H103, Q390. A395, 1371, V388. H397, E377, W386, W400, N351, Y355, H357, or S420 or a combination thereof modifies or reduces the small molecule-induced conformation change of ARNT.
[1065] Embodiment 700: The method of anyone of Embodiments 2-90 or 699, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies or reduces the small molecule-induced conformation change of ARNT.
[1066] Embodiment 701: The method of anyone of Embodiments 2-90, 699, or 700. wherein a mutation of CRBN amino acid H353 and V388 modifies or reduces the small molecule-induced conformation change of ARNT.
[1067] Embodiment 702: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and H397 modifies or reduces the small molecule-induced conformation change of ARNT.
[1068] Embodiment 703: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and W400 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[1069] Embodiment 704: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and N351 modifies or reduces the small molecule-induced conformation change ofARNT.
[1070] Embodiment 705: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and Y355 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1071] Embodiment 706: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and H357 modifies or reduces the small molecule-induced conformation change ofARNT.
[1072] Embodiment 707: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353 and E377 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1073] Embodiment 708: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388, and H397 modifies or reduces tire small molecule-induced confonnation change of ARNT.
[1074] Embodiment 709: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388. and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
[1075] Embodiment 710: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388, and W400 modifies or reduces the small molecule-induced confonnation change of ARNT.
[1076] Embodiment 711: Hie method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388. and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
[1077] Embodiment 712: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388, and Y355 modifies or reduces the small molecule-induced confonnation change of ARNT.
[1078] Embodiment 713: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H353, V388. and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
[1079] Embodiment 714: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and H397 modifies or reduces the small molecule-induced conformation change ofARNT.Attorney Docket No.: N2109-7007WO
[1080] Embodiment 715: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and E377 modifies or reduces the small molecule-induced conformation change ofARNT.
[1081] Embodiment 716: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and W400 modifies or reduces the small molecule -induced conformation change of ARNT.
[1082] Embodiment 717: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and N351 modifies or reduces the small molecule-induced conformation change ofARNT.
[1083] Embodiment 718: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and Y355 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1084] Embodiment 719: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388 and H357 modifies or reduces the small molecule-induced conformation change ofARNT.
[1085] Embodiment 720: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397 and E377 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1086] Embodiment 721: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397 and W400 modifies or reduces the small molecule-induced confonnation change of ARNT.
[1087] Embodiment 722: Hie method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397 and N3 1 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1088] Embodiment 723: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397 and Y355 modifies or reduces the small molecule-induced conformation change ofARNT.
[1089] Embodiment 724: Hie method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397 and H3 7 modifies or reduces the small molecule-induced confonnation change ofARNT.
[1090] Embodiment 725: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid E377 and W400 modifies or reduces the small molecule-induced conformation change ofARNT.Attorney Docket No.: N2109-7007WO
[1091] Embodiment 726: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid E377 and N3 1 modifies or reduces the small molecule-induced conformation change ofARNT.
[1092] Embodiment 727: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid E377 and Y355 modifies or reduces the small molecule-induced conformation change ofARNT.
[1093] Embodiment 728: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid E377 and H357 modifies or reduces the small molecule-induced conformation change ofARNT.
[1094] Embodiment 729: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid W400 and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
[1095] Embodiment 730: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid W400 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
[1096] Embodiment 731: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid W400 and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
[1097] Embodiment 732: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid N351 and Y355 modifies or reduces the small molecule-induced conformation change ofARNT.
[1098] Embodiment 733: Hie method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid N351 and H357 modifies or reduces tire small molecule-induced conformation change ofARNT.
[1099] Embodiment 734: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid Y355 and H357 modifies or reduces the small molecule-induced conformation change ofARNT.
[1100] Embodiment 735: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388, H397. and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
[1101] Embodiment 736: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388, H397, and W400 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO
[1102] Embodiment 737: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
[1103] Embodiment 738: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388, H397, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
[1104] Embodiment 739: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies or reduces tire small molecule-induced conformation change of ARNT.
[1105] Embodiment 740: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
[1106] Embodiment 741: The method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
[1107] Embodiment 742: Tire method of anyone of Embodiments 2-90, 699, or 700, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies or reduces the small molecule-induced confo...
Claims
Attorney Docket No.: N2109-7007WOCLAIMSWhat is claimed is:
1. A method of inducing ternary complex formation between aryl hydrocarbon nuclear translocator (ARNT), cereblon (CRBN), and a small molecule, said method comprising:(i) contacting either CRBN. ARNT. or both with a small molecule;(ii) forming a ternary complex between the CRBN, ARNT, and the small molecule resulting in conformation change within the structure of ARNT;(iii) evaluating the conformational change using a method suitable for detecting said conformational change,thereby inducing ternary complex formation.
2. The method of claim 1, wherein the conformational change in ARNT comprises formation of an intramolecular interaction between the PAS-1 and PAS-2 domains of ARNT.
3. The method of claim 1, wherein the PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1).
4. The method of claim 1, wherein the PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2).
5. The method of claim 1, wherein the formation of the ternary complex between the CRBN, ARNT, and the small molecule results in the ubiquitination of the ARNT.
6. The method of claim 5, wherein the ubiquitination of ARNT leads to degradation of ARNT.
7. The method of claim 5, wherein ARNT is not ubiquitinated to a sufficient level to reduce cellular ARNT protein levels in the absence of the small molecule.
8. The method of claim 1, wherein the method suitable for detecting the conformational change comprises cryo-electron microscopy (cryo-EM) or X-ray crystallography.Attorney Docket No.: N2109-7007WO9. The method of claim 1, wherein the contact between ARNT and tire small molecule in the ternary complex comprises an interaction of the small molecule with at least one of amino acids K394, G393, L237 and V244 of ARNT.
10. The method of claim 1, wherein the contact between ARNT and the small molecule in the ternary complex comprises an interaction of the small molecule with amino acid K394 ARNT.
11. The method of claim 1, wherein the contact between ARNT and the small molecule in the ternary complex comprises an interaction of the small molecule with amino acid G393 ARNT.
12. The method of claim 1, wherein the contact between ARNT and the small molecule in the ternary complex comprises an interaction of the small molecule with amino acid L237 ARNT.
13. The method of claim 1, wherein the contact between ARNT and the small molecule in the ternary complex comprises an interaction of the small molecule with amino acid V244 ARNT.
14. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule is mediated through the interaction of at least one of CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, and S420 with ARNT.
15. The method of claim 1, wherein the formation of a ternary- complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid G151 of CRBN with ARNT.
16. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid 1152 of CRBN with ARNT.
17. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid Fl 50 of CRBN with ARNT.
18. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid H353 of CRBN with ARNT.Attorney Docket No.: N2109-7007WO19. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid Fl 02 of CRBN with ARNT.
20. Tire method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid H103 of CRBN with ARNT.
21. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid Q390 of CRBN with ARNT.
22. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid A395 of CRBN with ARNT.
23. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid 1371 of CRBN with ARNT.
24. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid V388 of CRBN with ARNT.
25. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid H397 of CRBN with ARNT.
26. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid W386 of CRBN with ARNT27. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid W400 of CRBN with ARNT28. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid N351 of CRBN with ARNT.
29. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid Y355 of CRBN with ARNT.Attorney Docket No.: N2109-7007WO30. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid H357 of CRBN with ARNT.
31. The method of claim 1, wherein the formation of a ternary complex comprising the CRBN, ARNT and the small molecule comprises an interaction of amino acid S420 of CRBN with ARNT.
32. A method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising:(i) contacting CRBN with a small molecule;(ii) inducing a change in the conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(iii) forming of a ternary complex between the CRBN, the ARNT and the small molecule; and (iv) ubiquitination of the ARNT;wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
33. A method of recruiting ARNT for ubiquitination to an E3 ubiquitin ligase to form a ternary complex comprising cereblon (CRBN), aryl hydrocarbon nuclear translocator (ARNT) and a small molecule, said method comprising:(i) contacting CRBN with a small molecule;(ii) inducing a change in tire conformation of the CRBN or otherwise altering the properties of the CRBN surface, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(iii) forming of a ternary complex between the CRBN, the ARNT and the small molecule, w herein steps (i)-(iii) result in the induction of a change in conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and the PAS-2 domains of ARNT, wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(iv) ubiquitination of the ARNT;wherein the ubiquitination of the ARNT leads to degradation of the ARNT and wherein ARNT is not ubiquitinated by said E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.Attorney Docket No.: N2109-7007WO34. The method of claim 33, wherein the contact between ARNT and the small molecule in the ternary complex occurs through the interaction of the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT.
35. The method of claim 33. wherein tire fonnation of a ternary complex comprising the CRBN, ARNT and the small molecule is mediated through the interaction of at least one of CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 with ARNT, and wherein the formation of the ternary complex leads to degradation of the ARNT.
36. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of tire PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and tire CRBN, wherein at least one of CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
37. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in tire conformation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through tire interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNTAttorney Docket No.: N2109-7007WOwherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and tire CRBN, wherein at least one of CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355. H357, or S420 mediate interactions of the CRBN with the ARNT in the ternary complex;wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
38. The method of claim 32, wherein the CRBN amino acids in the ternary complex interact with at least one of the ARNT amino acids E398, N395, G393, 1372, K245. G242, T241, K240. L239, or L237.
39. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of tire CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394. G393, L237 or V244 of the ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT. tire small molecule and the CRBN, wherein at least one of ARNT amino acids E398. N395, G393. 1372. K245, G242, T241. K240, L239. or L237 mediate interactions of the ARNT with the CRBN in the ternary complex;wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the fomration of a ternary’ complex leads to degradation of the ARNT.
40. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small moleculeAttorney Docket No.: N2109-7007WOwith at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to fomi specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein at least one of ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 mediate the interactions of the ARNT with the CRBN to form the ternary complex;wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the fonnation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.
41. The method of claim 39, wherein the ARNT amino acids in the ternary complex interact with at least one of the CRBN ammo acids GI51, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420.
42. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the conformation of the CRBN or otherwise altering the properties of a CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394, G393, L237 or V244 of the ARNT, wherein said CRBN conformational change or alteration results in recruitment of ARNT;(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT. tire small molecule and the CRBN, wherein at least one of tire CRBN amino acids G151, 1152, F150, H353, F102, H103, Q390, A395, 1371, V388. H397, W386, W400. N351, Y355. H357, or S420. interacts with at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 to form the ternary complex;wherein the ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the ternary complex and wherein the formation of a ternary complex leads to degradation of the ARNT.Attorney Docket No.: N2109-7007WO43. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT E398 and CRBN F150; ARNT N395 and CRBN I152; ARNT G393 and CRBN H353; ARNT 1372 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN 1371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400: ARNT T241 and CRBN V388: ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N3 1; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.
44. A method for degrading aryl hydrocarbon nuclear translocator (ARNT), the method comprising:(1) binding of a small molecule to cereblon (CRBN);(2) inducing a change in the confonnation of the CRBN or otherwise altering the properties of an CRBN surface that specifically recruits ARNT through the interaction of the CRBN and the small molecule with at least one of amino acids K394. G393, L237 or V244 of tire ARNT; and(3) inducing a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2); and(4) forming of a ternary complex comprising the ARNT, the small molecule and the CRBN, wherein the ARNT and the CRBN interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT E398 and CRBN F150: ARNT N395 and CRBN 1152; ARNT G393 and CRBN H353; ARNT 1372 and CRBN H353: ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; ARNT K245 and CRBN 1371; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355: ARNT L239 and CRBN N351: or ARNT L237 and CRBN H353;wherein the ARNT intramolecular interactions and the ARNT-CRBN interactions mediate the formation of the ternary complex and wherein tire fonnation of a ternary complex leads to degradation of the ARNT.Attorney Docket No.: N2109-7007WO45. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT N395 and CRBN 1152; ARNT 1372 and CRBN H353; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357: ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400; ARNT K240 and CRBN S420; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.
46. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT E398 and CRBN F150; ARNT G393 and CRBN H353; ARNT K245 and CRBN Q390; ARNT K245 and CRBN A395; or ARNT K245 and CRBN 1371.
47. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acid interactions: ARNT N395 and CRBN 1152; ARNT K240 and CRBN N351; ARNT K240 and CRBN Y355; ARNT K240 and CRBN H357; ARNT K240 and CRBN W400: or ARNT K240 and CRBN S420.
48. Tire method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to fonn at least one of tire following ARNT-CRBN amino acid interactions: ARNT 1372 and CRBN H353; ARNT G242 and CRBN V388; ARNT G242 and CRBN W386; ARNT G242 and CRBN W400; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; ARNT L239 and CRBN N351; or ARNT L237 and CRBN H353.
49. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form at least one of the following ARNT-CRBN amino acids interactions: ARNT 1372 and CRBN H353; ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.Attorney Docket No.: N2109-7007WO50. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the following ARNT-CRBN amino acid interaction: ARNT 1372 and CRBN H353.
51. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; ARNT T241 and CRBN H357; ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.
52. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT T241 and CRBN W400; ARNT T241 and CRBN V388; ARNT T241 and CRBN H397; or ARNT T241.
53. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT amino acids ARNT I372 and CRBN H353 and at least one of following ARNT-CRBN amino acid interactions ARNT L239 and CRBN H353; ARNT L239 and CRBN Y355; or ARNT L239 and CRBN N351.
54. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT R235 and ARNT V376; ARNT R235 and ARNT D377: ARNT R235 and ARNT P388; ARNT R235 and ARNT Q389; ARNT I236 and ARNT R366: ARNT L237 and ARNT G393; ARNT L239 and ARNTN368; ARNT L239 and ARNT G393; ARNT V244 and ARNT Q389; ARNT R366 and ARNT E247; ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236: ARNT F375 and ARNT L237: ARNT F375 and ARNT E247; ARNT D377 and ARNT T233; ARNT D377 and ARNT G234; ARNT D377 and ARNT R235; ARNT H378 and ARNT T233; ARNT H378 and ARNT G234; ARNT H378 and ARNT K246; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO55. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; ARNT L392 and ARNT V244; ARNT L239 and ARNTN368; or ARNT L239 and ARNT G393.
56. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
57. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237 and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT 1372 and ARNT L239; ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236: ARNT L392 and ARNT L237: or ARNT L392 and ARNT V244.
58. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of tire PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239: and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO59. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
60. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT I236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT I236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
61. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
62. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; and at least one of tire following ARNT intramolecular interactions of tire PAS-1 and PAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNTAttorney Docket No.: N2109-7007WOL237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
63. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
64. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247: ARNT L392 and ARNT R235: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
65. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237: ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
66. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNTAttorney Docket No.: N2109-7007WOF375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
67. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
68. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fonn an intramolecular interaction of tire PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
69. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236;and at least one of the following ARNT intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
70. Tire method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of tire PAS-1 and PAS-2 domainsAttorney Docket No.: N2109-7007WObetween ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
71. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; and ARNT 1372 and ARNT L239.
72. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236.
73. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fonn an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; and ARNT T374 and ARNT L237.
74. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; and ARNT T374 and ARNT L239.
75. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233.
76. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233: and ARNT F375 and ARNT G234.
77. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domainsAttorney Docket No.: N2109-7007WObetween ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and ARNT F375 and ARNT R235.
78. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and ARNT F375 and ARNT 1236.
79. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236: and ARNT F375 and ARNT L237.
80. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.
81. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235.
82. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; and ARNT L392 and ARNT 1236.
83. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and ARNT L392 and ARNT L237.
84. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domainsAttorney Docket No.: N2109-7007WObetween ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
85. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to fonn the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT 1372 and ARNT L237; or ARNT 1372 and ARNT L239.
86. Tire method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; or ARNT T374 and ARNT L239.
87. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
88. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
89. The method of claim 32, wherein the ARNT amino acids and the CRBN amino acids in the ternary complex interact to form the ARNT-CRBN amino acid interaction between ARNT 1372 and CRBN H353 and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L239 and ARNT N368; or ARNT L239 and ARNT G393.
90. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of followingAttorney Docket No.: N2109-7007WOintramolecular interactions of the PAS-1 and PAS-2 domains: ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; or ARNT T374 and ARNT L239.
91. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; and at least one of following intramolecular interactions of tire PAS-1 and PAS-2 domains: ARNT T374 and ARNT L237; or ARNT T374 and ARNT L239.
92. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT I372 and ARNT L237; ARNT I372 and ARNT L239; ARNT T374 and ARNT I236; ARNT T374 and ARNT L237; and ARNT T374 and ARNT L239.
93. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fonn an intramolecular interaction of tire PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
94. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
95. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.Attorney Docket No.: N2109-7007WO96. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
97. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
98. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.
99. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
100. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO101. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
102. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
103. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L239 and ARNT N368; or ARNT L239 and ARNT G393.
104. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239; ARNT L239 and ARNT N368; and ARNT L239 and ARNT G393.
105. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236: ARNT T374 and ARNT L237; ARNT T374 and ARNT L239: and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
106. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; and at least one of following intramolecular interactions of the PAS-1 andAttorney Docket No.: N2109-7007WOPAS-2 domains: ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
107. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
108. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
109. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT F375 and ARNT L237; or ARNT F375 and ARNT E247.
110. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; and ARNT F375 and ARNT E247.
111. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392Attorney Docket No.: N2109-7007WOand ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
112. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L392 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
113. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
114. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
115. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT L239 and ARNT N368; and ARNT L239 and ARNT G393.
116. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.Attorney Docket No.: N2109-7007WO117. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
118. Tire method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to fomr an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236: ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; and at least one of following intramolecular interactions of the PAS-1 and PAS-2 domains: ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244.
119. The method of claim 32, wherein the ARNT undergoes a confonnational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247: ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; and ARNT L392 and ARNT V244.
120. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235: ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L239 and ARNT N368; and ARNT L239 and ARNT G393.
121. The method of claim 32, wherein the ARNT undergoes a conformational change that results in ARNT amino acids interacting to form an intramolecular interaction of the PAS-1 and PAS-2 domains between ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236: ARNT L392 and ARNT L237: ARNT L392 and ARNT V244; ARNT L239 and ARNTN368; and ARNT L239 and ARNT G393.Attorney Docket No.: N2109-7007WO122. The method of claim 32, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
123. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392. or a combination thereof to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
124. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the small molecule-induced confonnation change of ARNT.
125. The method of claim 32, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
126. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
127. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
128. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
129. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
130. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
131. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
132. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO133. The method of claim 32, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
134. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
135. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
136. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
137. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
138. The method of claim 32, wherein a mutation of ARNT amino acid L237 and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
139. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
140. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
141. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
142. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
143. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the small molcculc-induccd conformation change of ARNT.Attorney Docket No.: N2109-7007WO144. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
145. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
146. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
147. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
148. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
149. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
150. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, L237, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
151. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
152. The method of claim 32, wherein a mutation of ARNT amino acid L239, F375, L237, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
153. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
154. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO155. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
156. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
157. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
158. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, and L392 to alanine modifies or reduces the small molecule-induced conformation change of ARNT.
159. The method of claim 32, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
160. The method of claim 32, wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
161. The method of claim 32, wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
162. The method of claim 32, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
163. The method of claim 32, wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
164. The method of claim 32, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the small molecule -induced conformation change of ARNT.
165. The method of claim 32, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO166. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392, or a combination thereof to alanine modifies or reduces the recruitment of ARNT to CRBN.
167. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the recruitment of ARNT to CRBN.
168. The method of claim 32, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
169. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
170. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
171. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
172. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
173. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
174. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
175. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
176. The method of claim 32, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO177. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
178. Tire method of claim 32, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
179. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
180. Tire method of claim 32, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
181. The method of claim 32, wherein a mutation of ARNT amino acid L237 and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
182. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
183. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
184. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
185. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
186. The method of claim 32, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
187. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO188. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
189. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
190. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
191. Tire method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
192. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
193. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
194. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, L237, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
195. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
196. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
197. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
198. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO199. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
200. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
201. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
202. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
203. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, and L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.
204. The method of claim 32, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the recruitment of ARNT to CRBN.
205. The method of claim 32, wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the recruitment of ARNT to CRBN.
206. The method of claim 32, wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the recruitment of ARNT to CRBN.
207. The method of claim 32, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the recruitment of ARNT to CRBN.
208. The method of claim 32, wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the recruitment of ARNT to CRBN.
209. The method of claim 32, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the recruitment of ARNT to CRBN.Attorney Docket No.: N2109-7007WO210. The method of claim 32, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
211. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392. or a combination thereof to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
212. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and 1372 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
213. The method of claim 32, wherein a mutation of ARNT amino acid L239 and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
214. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
215. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
216. Tire method of claim 32, wherein a mutation of ARNT amino acid L239 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
217. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
218. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
219. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
220. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO221. The method of claim 32, wherein a mutation of ARNT amino acid T374 and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
222. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
223. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
224. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
225. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
226. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
227. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
228. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
229. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
230. The method of claim 32, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
231. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO232. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
233. Tire method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
234. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
235. Tire method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
236. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
237. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
238. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
239. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
240. The method of claim 32, wherein a mutation of ARNT amino acid L239, F375, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
241. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
242. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO243. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
244. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
245. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
246. Tire method of claim 32, wherein a mutation of ARNT amino acid L239, T374, L237, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
247. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
248. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
249. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237 and L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
250. The method of claim 32, wherein a mutation of ARNT amino acid L239 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
251. The method of claim 32, wherein a mutation of ARNT amino acid 1372 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
252. The method of claim 32, wherein a mutation of ARNT amino acid T374 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
253. The method of claim 32, wherein a mutation of ARNT amino acid F375 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO254. The method of claim 32, wherein a mutation of ARNT amino acid L237 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
255. Tire method of claim 32, wherein a mutation of ARNT amino acid L392 to alanine reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
256. The method of claim 32, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine modifies the cellular signaling effects mediated by ARNT.
257. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, or L392. or a combination thereof to alanine modifies the cellular signaling effects mediated by ARNT.
258. The method of claim 32, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies the cellular signaling effects mediated by ARNT.
259. The method of claim 32, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
260. The method of claim 32, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
261. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
262. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
263. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
264. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO265. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
266. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
267. The method of claim 32, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
268. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
269. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
270. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
271. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
272. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies the cellular signaling effects mediated by ARNT.
273. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
274. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
275. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO276. The method of claim 32, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
277. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
278. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
279. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
280. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
281. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
282. The method of claim 32, wherein a mutation of ARNT amino acid F375, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
283. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies the cellular signaling effects mediated by ARNT.
284. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
285. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
286. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO287. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
288. The method of claim 32, wherein a mutation of ARNT amino acid L239, F375, L237, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
289. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
290. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
291. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
292. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
293. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine modifies the cellular signaling effects mediated by ARNT.
294. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
295. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237 and L392 to alanine modifies the cellular signaling effects mediated by ARNT.
296. The method of claim 32, wherein a mutation of ARNT amino acid L239 to alanine modifies the cellular signaling effects mediated by ARNT.
297. The method of claim 32, wherein a mutation of ARNT amino acid 1372 to alanine modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO298. The method of claim 32, wherein a mutation of ARNT amino acid T374 to alanine modifies the cellular signaling effects mediated by ARNT.
299. The method of claim 32, wherein a mutation of ARNT amino acid F375 to alanine modifies the cellular signaling effects mediated by ARNT.
300. The method of claim 32, wherein a mutation of ARNT amino acid L237 to alanine modifies the cellular signaling effects mediated by ARNT.
301. The method of claim 32, wherein a mutation of ARNT amino acid L392 to alanine modifies the cellular signaling effects mediated by ARNT.
302. The method of claim 32, wherein a mutation of any ARNT amino acid L239, 1372, T374, F375, L392, N368, G393, L237, 1236, T233, G234, R235, E247, or V244, or a combination thereof to alanine modifies or reduces the degradation of ARNT.
303. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375. L237, or L392. or a combination thereof to alanine modifies or reduces the degradation of ARNT.
304. The method of claim 32, wherein a mutation of ARNT amino acid L239 and 1372 to alanine modifies or reduces the degradation of ARNT.
305. The method of claim 32, wherein a mutation of ARNT amino acid L239 and T374 to alanine modifies or reduces the degradation of ARNT.
306. The method of claim 32, wherein a mutation of ARNT amino acid L239 and F375 to alanine modifies or reduces the degradation of ARNT.
307. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L237 to alanine modifies or reduces the degradation of ARNT.
308. The method of claim 32, wherein a mutation of ARNT amino acid L239 and L392 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO309. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and T374 to alanine modifies or reduces the degradation of ARNT.
310. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and F375 to alanine modifies or reduces the degradation of ARNT.
311. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L237 to alanine modifies or reduces the degradation of ARNT.
312. The method of claim 32, wherein a mutation of ARNT amino acid 1372 and L392 to alanine modifies or reduces the degradation of ARNT.
313. The method of claim 32, wherein a mutation of ARNT amino acid T374 and F375 to alanine modifies or reduces the degradation of ARNT.
314. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L237 to alanine modifies or reduces the degradation of ARNT.
315. The method of claim 32, wherein a mutation of ARNT amino acid T374 and L392 to alanine modifies or reduces the degradation of ARNT.
316. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L237 to alanine modifies or reduces the degradation of ARNT.
317. The method of claim 32, wherein a mutation of ARNT amino acid F375 and L392 to alanine modifies or reduces the degradation of ARNT.
318. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and T374 to alanine modifies or reduces the degradation of ARNT.
319. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and F375 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO320. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L392 to alanine modifies or reduces the degradation of ARNT.
321. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, and L237 to alanine modifies or reduces the degradation of ARNT.
322. The method of claim 32, wherein a mutation of ARNT amino acid L239, L237, and L392 to alanine modifies or reduces the degradation of ARNT.
323. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and F375 to alanine modifies or reduces the degradation of ARNT.
324. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L237 to alanine modifies or reduces the degradation of ARNT.
325. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, and L392 to alanine modifies or reduces the degradation of ARNT.
326. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L238 to alanine modifies or reduces the degradation of ARNT.
327. The method of claim 32, wherein a mutation of ARNT amino acid T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
328. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and F375 to alanine modifies or reduces the degradation of ARNT.
329. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
330. The method of claim 32, wherein a mutation of ARNT amino acid 1372, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO331. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
332. The method of claim 32, wherein a mutation of ARNT amino acid L239, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
333. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
334. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
335. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L237 to alanine modifies or reduces the degradation of ARNT.
336. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, and L392 to alanine modifies or reduces the degradation of ARNT.
337. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L237 to alanine modifies or reduces the degradation of ARNT.
338. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, and L392 to alanine modifies or reduces the degradation of ARNT.
339. The method of claim 32, wherein a mutation of ARNT amino acid L239, 1372, T374, F375, L237, and L392 to alanine modifies or reduces the degradation of ARNT.
340. The method of claim 32, wherein a mutation of ARNT amino acid L239 to alanine modifies or reduces the degradation of ARNT.
341. The method of claim 32, wherein a mutation of ARNT amino acid 1372 to alanine modifies or reduces the degradation of ARNT.Attorney Docket No.: N2109-7007WO342. The method of claim 32, wherein a mutation of ARNT amino acid T374 to alanine modifies or reduces the degradation of ARNT.
343. The method of claim 32, wherein a mutation of ARNT amino acid F375 to alanine modifies or reduces the degradation of ARNT.
344. The method of claim 32, wherein a mutation of ARNT amino acid L237 to alanine modifies or reduces the degradation of ARNT.
345. The method of claim 32, wherein a mutation of ARNT amino acid L392 to alanine modifies or reduces the degradation of ARNT.
346. The method of claim 32, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof reduces recruitment of ARNT.
347. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, E377, W400, N351, Y355, or H357 or a combination thereof reduces recruitment of ARNT.
348. The method of claim 32, wherein a mutation of CRBN amino acid H353 and V388 reduces recruitment of ARNT.
349. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H397 reduces recruitment of ARNT.
350. The method of claim 32, wherein a mutation of CRBN amino acid H353 and W400 reduces recruitment of ARNT.
351. The method of claim 32, wherein a mutation of CRBN amino acid H353 and N351 reduces recruitment of ARNT.
352. The method of claim 32, wherein a mutation of CRBN amino acid H353 and Y355 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO353. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H357 reduces recruitment of ARNT.
354. The method of claim 32, wherein a mutation of CRBN amino acid H353 and E377 reduces recruitment of ARNT.
355. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H397 reduces recruitment of ARNT.
356. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and E377 reduces recruitment of ARNT.
357. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and W400 reduces recruitment of ARNT.
358. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and N351 reduces recruitment of ARNT.
359. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and Y355 reduces recruitment of ARNT.
360. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and H357 reduces recruitment of ARNT.
361. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H397 reduces recruitment of ARNT.
362. The method of claim 32, wherein a mutation of CRBN amino acid V388 and E377 reduces recruitment of ARNT.
363. The method of claim 32, wherein a mutation of CRBN amino acid V388 and W400 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO364. The method of claim 32, wherein a mutation of CRBN amino acid V388 and N351 reduces recruitment of ARNT.
365. The method of claim 32, wherein a mutation of CRBN amino acid V388 and Y355 reduces recruitment of ARNT.
366. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H357 reduces recruitment of ARNT.
367. The method of claim 32, wherein a mutation of CRBN amino acid H397 and E377 reduces recruitment of ARNT.
368. The method of claim 32, wherein a mutation of CRBN amino acid H397 and W400 reduces recruitment of ARNT.
369. The method of claim 32, wherein a mutation of CRBN amino acid H397 and N351 reduces recruitment of ARNT.
370. The method of claim 32, wherein a mutation of CRBN amino acid H397 and Y355 reduces recruitment of ARNT.
371. The method of claim 32, wherein a mutation of CRBN amino acid H397 and H357 reduces recruitment of ARNT.
372. The method of claim 32, wherein a mutation of CRBN amino acid E377 and W400 reduces recruitment of ARNT.
373. The method of claim 32, wherein a mutation of CRBN amino acid E377 and N351 reduces recruitment of ARNT.
374. The method of claim 32, wherein a mutation of CRBN amino acid E377 and Y355 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO375. The method of claim 32, wherein a mutation of CRBN amino acid E377 and H357 reduces recruitment of ARNT.
376. Tire method of claim 32, wherein a mutation of CRBN amino acid W400 and N351 reduces recruitment of ARNT.
377. The method of claim 32, wherein a mutation of CRBN amino acid W400 and Y355 reduces recruitment of ARNT.
378. Tire method of claim 32, wherein a mutation of CRBN amino acid W400 and H357 reduces recruitment of ARNT.
379. The method of claim 32, wherein a mutation of CRBN amino acid N351 and Y355 reduces recruitment of ARNT.
380. The method of claim 32, wherein a mutation of CRBN amino acid N351 and H357 reduces recruitment of ARNT.
381. The method of claim 32, wherein a mutation of CRBN amino acid Y355 and H357 reduces recruitment of ARNT.
382. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. and E377 reduces recruitment of ARNT.
383. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and W400 reduces recruitment of ARNT.
384. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. and N351 reduces recruitment of ARNT.
385. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and Y355 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO386. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and H357 reduces recruitment of ARNT.
387. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and W400 reduces recruitment of ARNT.
388. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and N351 reduces recruitment of ARNT.
389. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and Y355 reduces recruitment of ARNT.
390. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and H357 reduces recruitment of ARNT.
391. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and N351 reduces recruitment of ARNT.
392. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and Y355 reduces recruitment of ARNT.
393. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and H357 reduces recruitment of ARNT.
394. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and N351 reduces recruitment of ARNT.
395. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400 and Y355 reduces recruitment of ARNT.
396. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and H357 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO397. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and Y355, reduces recruitment of ARNT.
398. Tire method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and H357 reduces recruitment of ARNT.
399. The method of claim 32, wherein a mutation of CRBN amino acid N351, Y355, and H357 reduces recruitment of ARNT.
400. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 reduces recruitment of ARNT.
401. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 reduces recruitment of ARNT.
402. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 reduces recruitment of ARNT.
403. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 reduces recruitment of ARNT.
404. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397 and H357 reduces recruitment of ARNT.
405. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 reduces recruitment of ARNT.
406. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, and N351 reduces recruitment of ARNT.
407. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO408. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 reduces recruitment of ARNT.
409. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 reduces recruitment of ARNT.
410. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 reduces recruitment of ARNT.
411. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 reduces recruitment of ARNT.
412. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 reduces recruitment of ARNT.
413. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 reduces recruitment of ARNT.
414. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 reduces recruitment of ARNT.
415. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 reduces recruitment of ARNT.
416. The method of claim 32, wherein a mutation of CRBN amino H397, W400, N351, and H357 reduces recruitment of ARNT.
417. The method of claim 32, wherein a mutation of CRBN amino W400, N351, Y355, and H357 reduces recruitment of ARNT.
418. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO419. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 reduces recruitment of ARNT.
420. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 reduces recruitment of ARNT.
421. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and H357 reduces recruitment of ARNT.
422. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 reduces recruitment of ARNT.
423. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 reduces recruitment of ARNT.
424. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 reduces recruitment of ARNT.
425. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 reduces recruitment of ARNT.
426. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, W400, and Y355 reduces recruitment of ARNT.
427. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 reduces recruitment of ARNT.
428. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. W400, N351, and Y355 reduces recruitment of ARNT.
429. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO430. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 reduces recruitment of ARNT.
431. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 reduces recruitment of ARNT.
432. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and H357 reduces recruitment of ARNT.
433. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 reduces recruitment of ARNT.
434. The method of claim 32, wherein a mutation of CRBN amino acid H353 reduces recruitment of ARNT.
435. The method of claim 32, wherein a mutation of CRBN amino acid V388 reduces recruitment of ARNT.
436. The method of claim 32, wherein a mutation of CRBN amino acid H397 reduces recruitment of ARNT.
437. The method of claim 32, wherein a mutation of CRBN amino acid E377 reduces recruitment of ARNT.
438. The method of claim 32, wherein a mutation of CRBN amino acid W400 reduces recruitment of ARNT.
439. The method of claim 32, wherein a mutation of CRBN amino acid N351 reduces recruitment of ARNT.
440. The method of claim 32, wherein a mutation of CRBN amino Y355 reduces recruitment of ARNT.Attorney Docket No.: N2109-7007WO441. The method of claim 32, wherein a mutation of CRBN amino acid H357 reduces recruitment of ARNT.
442. Tire method of claim 32, wherein a mutation of any CRBN amino acid G151, 1152, F150, H353, F102, H103. Q390, A395, 1371, V388, H397, E377. W386, W400, N351, Y355, H357, or S420, or a combination thereof modifies or reduces degradation of ARNT.
443. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies or reduces degradation of ARNT.
444. The method of claim 32, wherein a mutation of CRBN amino acid H353 and V388 modifies or reduces degradation of ARNT.
445. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H397 modifies or reduces degradation of ARNT.
446. The method of claim 32, wherein a mutation of CRBN amino acid H353 and W400 modifies or reduces degradation of ARNT.
447. The method of claim 32, wherein a mutation of CRBN amino acid H353 and N351 modifies or reduces degradation of ARNT.
448. The method of claim 32, wherein a mutation of CRBN amino acid H353 and Y355 modifies or reduces degradation of ARNT.
449. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H357 modifies or reduces degradation of ARNT.
450. The method of claim 32, wherein a mutation of CRBN amino acid H353 and E377 modifies or reduces degradation of ARNT.
451. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H397 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO452. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and E377 modifies or reduces degradation of ARNT.
453. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and W400 modifies or reduces degradation of ARNT.
454. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and N351 modifies or reduces degradation of ARNT.
455. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and Y355 modifies or reduces degradation of ARNT.
456. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H357 modifies or reduces degradation of ARNT.
457. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H397 modifies or reduces degradation of ARNT.
458. The method of claim 32, wherein a mutation of CRBN amino acid V388 and E377 modifies or reduces degradation of ARNT.
459. The method of claim 32, wherein a mutation of CRBN amino acid V388 and W400 modifies or reduces degradation of ARNT.
460. The method of claim 32, wherein a mutation of CRBN amino acid V388 and N351 modifies or reduces degradation of ARNT.
461. The method of claim 32, wherein a mutation of CRBN amino acid V388 and Y355 modifies or reduces degradation of ARNT.
462. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H357 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO463. The method of claim 32, wherein a mutation of CRBN amino acid H397 and E377 modifies or reduces degradation of ARNT.
464. Tire method of claim 32, wherein a mutation of CRBN amino acid H397 and W400 modifies or reduces degradation of ARNT.
465. The method of claim 32, wherein a mutation of CRBN amino acid H397 and N351 modifies or reduces degradation of ARNT.
466. Tire method of claim 32, wherein a mutation of CRBN amino acid H397 and Y355 modifies or reduces degradation of ARNT.
467. The method of claim 32, wherein a mutation of CRBN amino acid H397 and H357 modifies or reduces degradation of ARNT.
468. The method of claim 32, wherein a mutation of CRBN amino acid E377 and W400 modifies or reduces degradation of ARNT.
469. The method of claim 32, wherein a mutation of CRBN amino acid E377 and N351 modifies or reduces degradation of ARNT.
470. The method of claim 32, wherein a mutation of CRBN amino acid E377 and Y355 modifies or reduces degradation of ARNT.
471. The method of claim 32, wherein a mutation of CRBN amino acid E377 and H357 modifies or reduces degradation of ARNT.
472. The method of claim 32, wherein a mutation of CRBN amino acid W400 and N351 modifies or reduces degradation of ARNT.
473. The method of claim 32, wherein a mutation of CRBN amino acid W400 and Y355 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO474. The method of claim 32, wherein a mutation of CRBN amino acid W400 and H357 modifies or reduces degradation of ARNT.
475. Tire method of claim 32, wherein a mutation of CRBN amino acid N351 and Y355 modifies or reduces degradation of ARNT.
476. The method of claim 32, wherein a mutation of CRBN amino acid N351 and H357 modifies or reduces degradation of ARNT.
477. The method of claim 32, wherein a mutation of CRBN amino acid Y355 and H357 modifies or reduces degradation of ARNT.
478. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and E377 modifies or reduces degradation of ARNT.
479. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and W400 modifies or reduces degradation of ARNT.
480. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies or reduces degradation of ARNT.
481. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. and Y355 modifies or reduces degradation of ARNT.
482. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies or reduces degradation of ARNT.
483. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies or reduces degradation of ARNT.
484. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO485. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies or reduces degradation of ARNT.
486. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and EI357 modifies or reduces degradation of ARNT.
487. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and N351 modifies or reduces degradation of ARNT.
488. Tire method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and Y355 modifies or reduces degradation of ARNT.
489. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and H357 modifies or reduces degradation of ARNT.
490. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and N351 modifies or reduces degradation of ARNT.
491. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400 and Y355 modifies or reduces degradation of ARNT.
492. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and H357 modifies or reduces degradation of ARNT.
493. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and Y355, modifies or reduces degradation of ARNT.
494. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and H357 modifies or reduces degradation of ARNT.
495. The method of claim 32, wherein a mutation of CRBN amino acid N351, Y355, and 14357 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO496. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 modifies or reduces degradation of ARNT.
497. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 modifies or reduces degradation of ARNT.
498. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 modifies or reduces degradation of ARNT.
499. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 modifies or reduces degradation of ARNT.
500. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 modifies or reduces degradation of ARNT.
501. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 modifies or reduces degradation of ARNT.
502. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 modifies or reduces degradation of ARNT.
503. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, and Y355 modifies or reduces degradation of ARNT.
504. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 modifies or reduces degradation of ARNT.
505. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. W400 and N351 modifies or reduces degradation of ARNT.
506. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO507. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 modifies or reduces degradation of ARNT.
508. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 modifies or reduces degradation of ARNT.
509. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 modifies or reduces degradation of ARNT.
510. Tire method of claim 32, wherein a mutation of CRBN amino acid EI397, E377, W400, and H357 modifies or reduces degradation of ARNT.
511. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 modifies or reduces degradation of ARNT.
512. The method of claim 32, wherein a mutation of CRBN amino H397, W400, N351, and H357 modifies or reduces degradation of ARNT.
513. The method of claim 32, wherein a mutation of CRBN amino W400, N351, Y355, and H357 modifies or reduces degradation of ARNT.
514. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 modifies or reduces degradation of ARNT.
515. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 modifies or reduces degradation of ARNT.
516. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, E377, and Y355 modifies or reduces degradation of ARNT.
517. The method of claim 32, wherein a mutation of CRBN amino acid EI353, V388, H397, E377, and H357 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO518. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 modifies or reduces degradation of ARNT.
519. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 modifies or reduces degradation of ARNT.
520. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 modifies or reduces degradation of ARNT.
521. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 modifies or reduces degradation of ARNT.
522. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 modifies or reduces degradation of ARNT.
523. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 modifies or reduces degradation of ARNT.
524. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 modifies or reduces degradation of ARNT.
525. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 modifies or reduces degradation of ARNT.
526. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 modifies or reduces degradation of ARNT.
527. The method of claim 32, wherein a mutation of CRBN amino acid 14353, V388, H397, E377, W400, N351, and Y355 modifies or reduces degradation of ARNT.
528. The method of claim 32, wherein a mutation of CRBN amino acid 14353, V388, H397, E377, W400, N351, and 14357 modifies or reduces degradation of ARNT.Attorney Docket No.: N2109-7007WO529. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 modifies or reduces degradation of ARNT.
530. Tire method of claim 32, wherein a mutation of CRBN amino acid H353 modifies or reduces degradation of ARNT.
531. The method of claim 32, wherein a mutation of CRBN amino acid V388 modifies or reduces degradation of ARNT.
532. Tire method of claim 32, wherein a mutation of CRBN amino acid H397 modifies or reduces degradation of ARNT.
533. The method of claim 32, wherein a mutation of CRBN amino acid E377 modifies or reduces degradation of ARNT.
534. The method of claim 32, wherein a mutation of CRBN amino acid W400 modifies or reduces degradation of ARNT.
535. The method of claim 32, wherein a mutation of CRBN amino acid N351 modifies or reduces degradation of ARNT.
536. The method of claim 32, wherein a mutation of CRBN amino Y355 modifies or reduces degradation of ARNT.
537. The method of claim 32, wherein a mutation of CRBN amino acid H357 modifies or reduces degradation of ARNT.
538. The method of claim 32, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386. W400. N351, Y355, H357, or S420, or a combination thereof reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
539. The method of claim 32, wherein a mutation of CRBN amino acid 14353, V388, 14397, E377, W400, N351, Y355, or 14357 or a combination thereof reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO540. The method of claim 32, wherein a mutation of CRBN amino acid H353 and V388 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
541. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
542. The method of claim 32, wherein a mutation of CRBN amino acid H353 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
543. The method of claim 32, wherein a mutation of CRBN amino acid H353 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
544. The method of claim 32, wherein a mutation of CRBN amino acid H353 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
545. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
546. The method of claim 32, wherein a mutation of CRBN amino acid H353 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
547. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
548. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
549. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
550. The method of claim 32, wherein a mutation of CRBN amino acid 14353, V388, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO551. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
552. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
553. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
554. Tire method of claim 32, wherein a mutation of CRBN amino acid V388 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
555. The method of claim 32, wherein a mutation of CRBN amino acid V388 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
556. The method of claim 32, wherein a mutation of CRBN amino acid V388 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
557. The method of claim 32, wherein a mutation of CRBN amino acid V388 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
558. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
559. The method of claim 32, wherein a mutation of CRBN amino acid H397 and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
560. The method of claim 32, wherein a mutation of CRBN amino acid H397 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
561. The method of claim 32, wherein a mutation of CRBN amino acid H397 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO562. The method of claim 32, wherein a mutation of CRBN amino acid H397 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
563. Tire method of claim 32, wherein a mutation of CRBN amino acid H397 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
564. The method of claim 32, wherein a mutation of CRBN amino acid E377 and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
565. Tire method of claim 32, wherein a mutation of CRBN amino acid E377 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
566. The method of claim 32, wherein a mutation of CRBN amino acid E377 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
567. The method of claim 32, wherein a mutation of CRBN amino acid E377 and 14357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
568. The method of claim 32, wherein a mutation of CRBN amino acid W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
569. The method of claim 32, wherein a mutation of CRBN amino acid W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
570. The method of claim 32, wherein a mutation of CRBN amino acid W400 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
571. The method of claim 32, wherein a mutation of CRBN amino acid N351 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
572. The method of claim 32, wherein a mutation of CRBN amino acid N351 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO573. The method of claim 32, wherein a mutation of CRBN amino acid Y355 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
574. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
575. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
576. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
577. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
578. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
579. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
580. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
581. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
582. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
583. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO584. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
585. Tire method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
586. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
587. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
588. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
589. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and Y355, reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
590. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
591. The method of claim 32, wherein a mutation of CRBN amino acid N351, Y355, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
592. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
593. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
594. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO595. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
596. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
597. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
598. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
599. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
600. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
601. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
602. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
603. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
604. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
605. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO606. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
607. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
608. The method of claim 32, wherein a mutation of CRBN amino H397, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
609. The method of claim 32, wherein a mutation of CRBN amino W400, N351, Y355, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
610. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
611. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
612. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
613. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, E377, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
614. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
615. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
616. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO617. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
618. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
619. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
620. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
621. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
622. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
623. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
624. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. 14397, E377, W400, N351, and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
625. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
626. The method of claim 32, wherein a mutation of CRBN amino acid H353 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
627. The method of claim 32, wherein a mutation of CRBN amino acid V388 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.Attorney Docket No.: N2109-7007WO628. The method of claim 32, wherein a mutation of CRBN amino acid H397 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
629. The method of claim 32, wherein a mutation of CRBN amino acid E377 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
630. The method of claim 32, wherein a mutation of CRBN amino acid W400 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
631. The method of claim 32, wherein a mutation of CRBN amino acid N351 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
632. The method of claim 32, wherein a mutation of CRBN amino Y355 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
633. The method of claim 32, wherein a mutation of CRBN amino acid H357 reduces ubiquitin transfer from CRL4-CRBN ubiquitin ligase to ARNT.
634. The method of claim 32, wherein a mutation of any CRBN amino acid G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, E377, W386, W400, N351, Y355, H357, or S420, or a combination thereof modifies the cellular signaling effects mediated by ARNT.
635. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies the cellular signaling effects mediated by ARNT.
636. The method of claim 32, wherein a mutation of CRBN amino acid H353 and V388 modifies the cellular signaling effects mediated by ARNT.
637. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H397 modifies the cellular signaling effects mediated by ARNT.
638. The method of claim 32, wherein a mutation of CRBN amino acid H353 and W400 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO639. The method of claim 32, wherein a mutation of CRBN amino acid H353 and N351 modifies the cellular signaling effects mediated by ARNT.
640. The method of claim 32, wherein a mutation of CRBN amino acid H353 and Y355 modifies the cellular signaling effects mediated by ARNT.
641. The method of claim 32, wherein a mutation of CRBN amino acid H353 and H357 modifies the cellular signaling effects mediated by ARNT.
642. The method of claim 32, wherein a mutation of CRBN amino acid H353 and E377 modifies the cellular signaling effects mediated by ARNT.
643. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H397 modifies the cellular signaling effects mediated by ARNT.
644. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and E377 modifies the cellular signaling effects mediated by ARNT.
645. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and W400 modifies the cellular signaling effects mediated by ARNT.
646. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and N351 modifies the cellular signaling effects mediated by ARNT.
647. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and Y355 modifies the cellular signaling effects mediated by ARNT.
648. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and H357 modifies the cellular signaling effects mediated by ARNT.
649. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H397 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO650. The method of claim 32, wherein a mutation of CRBN amino acid V388 and E377 modifies the cellular signaling effects mediated by ARNT.
651. The method of claim 32, wherein a mutation of CRBN amino acid V388 and W400 modifies the cellular signaling effects mediated by ARNT.
652. The method of claim 32, wherein a mutation of CRBN amino acid V388 and N351 modifies the cellular signaling effects mediated by ARNT.
653. The method of claim 32, wherein a mutation of CRBN amino acid V388 and Y355 modifies the cellular signaling effects mediated by ARNT.
654. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H357 modifies the cellular signaling effects mediated by ARNT.
655. The method of claim 32, wherein a mutation of CRBN amino acid H397 and E377 modifies the cellular signaling effects mediated by ARNT.
656. The method of claim 32, wherein a mutation of CRBN amino acid H397 and W400 modifies the cellular signaling effects mediated by ARNT.
657. The method of claim 32, wherein a mutation of CRBN amino acid H397 and N351 modifies the cellular signaling effects mediated by ARNT.
658. The method of claim 32, wherein a mutation of CRBN amino acid H397 and Y355 modifies the cellular signaling effects mediated by ARNT.
659. The method of claim 32, wherein a mutation of CRBN amino acid H397 and H357 modifies the cellular signaling effects mediated by ARNT.
660. The method of claim 32, wherein a mutation of CRBN amino acid E377 and W400 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO661. The method of claim 32, wherein a mutation of CRBN amino acid E377 and N351 modifies the cellular signaling effects mediated by ARNT.
662. The method of claim 32, wherein a mutation of CRBN amino acid E377 and Y355 modifies the cellular signaling effects mediated by ARNT.
663. The method of claim 32, wherein a mutation of CRBN amino acid E377 and H357 modifies the cellular signaling effects mediated by ARNT.
664. The method of claim 32, wherein a mutation of CRBN amino acid W400 and N351 modifies the cellular signaling effects mediated by ARNT.
665. The method of claim 32, wherein a mutation of CRBN amino acid W400 and Y355 modifies the cellular signaling effects mediated by ARNT.
666. The method of claim 32, wherein a mutation of CRBN amino acid W400 and H357 modifies the cellular signaling effects mediated by ARNT.
667. The method of claim 32, wherein a mutation of CRBN amino acid N351 and Y355 modifies the cellular signaling effects mediated by ARNT.
668. The method of claim 32, wherein a mutation of CRBN amino acid N351 and H357 modifies the cellular signaling effects mediated by ARNT.
669. The method of claim 32, wherein a mutation of CRBN amino acid Y355 and H357 modifies the cellular signaling effects mediated by ARNT.
670. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and E377 modifies the cellular signaling effects mediated by ARNT.
671. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and W400 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO672. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies the cellular signaling effects mediated by ARNT.
673. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and Y355 modifies the cellular signaling effects mediated by ARNT.
674. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies the cellular signaling effects mediated by ARNT.
675. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.
676. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
677. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
678. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
679. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
680. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
681. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
682. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and N351 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO683. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400 and Y355 modifies the cellular signaling effects mediated by ARNT.
684. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
685. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and Y355, modifies the cellular signaling effects mediated by ARNT.
686. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
687. The method of claim 32, wherein a mutation of CRBN amino acid N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.
688. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 modifies the cellular signaling effects mediated by ARNT.
689. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 modifies the cellular signaling effects mediated by ARNT.
690. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397 and N351 modifies the cellular signaling effects mediated by ARNT.
691. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 modifies the cellular signaling effects mediated by ARNT.
692. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397 and H357 modifies the cellular signaling effects mediated by ARNT.
693. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO694. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
695. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
696. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
697. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 modifies the cellular signaling effects mediated by ARNT.
698. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 modifies the cellular signaling effects mediated by ARNT.
699. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 modifies the cellular signaling effects mediated by ARNT.
700. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
701. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
702. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
703. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 modifies the cellular signaling effects mediated by ARNT.
704. The method of claim 32, wherein a mutation of CRBN amino H397, W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO705. The method of claim 32, wherein a mutation of CRBN amino W400, N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.
706. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 modifies the cellular signaling effects mediated by ARNT.
707. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 modifies the cellular signaling effects mediated by ARNT.
708. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 modifies the cellular signaling effects mediated by ARNT.
709. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and H357 modifies the cellular signaling effects mediated by ARNT.
710. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 modifies the cellular signaling effects mediated by ARNT.
711. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 modifies the cellular signaling effects mediated by ARNT.
712. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. H397, W400, and H357 modifies the cellular signaling effects mediated by ARNT.
713. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 modifies the cellular signaling effects mediated by ARNT.
714. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, W400. and Y355 modifies the cellular signaling effects mediated by ARNT.
715. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and H357 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO716. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 modifies the cellular signaling effects mediated by ARNT.
717. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
718. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 modifies the cellular signaling effects mediated by ARNT.
719. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and Y355 modifies the cellular signaling effects mediated by ARNT.
720. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, and H357 modifies the cellular signaling effects mediated by ARNT.
721. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355 and H357 modifies the cellular signaling effects mediated by ARNT.
722. The method of claim 32, wherein a mutation of CRBN amino acid H353 modifies the cellular signaling effects mediated by ARNT.
723. The method of claim 32, wherein a mutation of CRBN amino acid V388 modifies the cellular signaling effects mediated by ARNT.
724. The method of claim 32, wherein a mutation of CRBN amino acid H397 modifies the cellular signaling effects mediated by ARNT.
725. The method of claim 32, wherein a mutation of CRBN amino acid E377 modifies the cellular signaling effects mediated by ARNT.
726. The method of claim 32, wherein a mutation of CRBN amino acid W400 modifies the cellular signaling effects mediated by ARNT.Attorney Docket No.: N2109-7007WO727. The method of claim 32, wherein a mutation of CRBN amino acid N351 modifies the cellular signaling effects mediated by ARNT.
728. Tire method of claim 32, wherein a mutation of CRBN amino Y355 modifies the cellular signaling effects mediated by ARNT.
729. The method of claim 32, 634, or 635, wherein a mutation of CRBN amino acid H357 modifies the cellular signaling effects mediated by ARNT.
730. Tire method of claim 32, wherein a mutation of any CRBN amino acid G151, 1152, F150, H353, F102, H103. Q390, A395, 1371, V388, H397, E377. W386, W400, N351, Y355, H357, or S420 or a combination thereof modifies or reduces the small molecule-induced conformation change of ARNT.
731. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N351, Y355, or H357 or a combination thereof modifies or reduces the small molecule -induced confonnation change of ARNT.
732. The method of claim 32, wherein a mutation of CRBN amino acid H353 and V388 modifies or reduces the small molecule-induced conformation change of ARNT.
733. Tire method of claim 32, wherein a mutation of CRBN amino acid H353 and H397 modifies or reduces the small molecule -induced conformation change of ARNT.
734. The method of claim 32, wherein a mutation of CRBN amino acid H353 and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
735. Tire method of claim 32, wherein a mutation of CRBN amino acid H353 and N351 modifies or reduces the small molecule -induced conformation change of ARNT.
736. The method of claim 32, wherein a mutation of CRBN amino acid H353 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
737. Tire method of claim 32, wherein a mutation of CRBN amino acid H353 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO738. The method of claim 32, wherein a mutation of CRBN amino acid H353 and E377 modifies or reduces the small molecule -induced conformation change of ARNT.
739. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and H397 modifies or reduces the small molecule-induced conformation change of ARNT.
740. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
741. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
742. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
743. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388. and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
744. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
745. The method of claim 32, wherein a mutation of CRBN amino acid V388 and H397 modifies or reduces the small molecule -induced conformation change of ARNT.
746. The method of claim 32, wherein a mutation of CRBN amino acid V388 and E377 modifies or reduces the small molecule -induced conformation change of ARNT.
747. The method of claim 32, wherein a mutation of CRBN amino acid V388 and W400 modifies or reduces the small molecule -induced conformation change of ARNT.
748. The method of claim 32, wherein a mutation of CRBN amino acid V388 and N351 modifies or reduces the small molecule -induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO749. The method of claim 32, wherein a mutation of CRBN amino acid V388 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
750. Tire method of claim 32, wherein a mutation of CRBN amino acid V388 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.
751. The method of claim 32, wherein a mutation of CRBN amino acid H397 and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
752. Tire method of claim 32, wherein a mutation of CRBN amino acid H397 and W400 modifies or reduces the small molecule -induced conformation change of ARNT.
753. The method of claim 32, wherein a mutation of CRBN amino acid H397 and N351 modifies or reduces the small molecule -induced conformation change of ARNT.
754. The method of claim 32, wherein a mutation of CRBN amino acid H397 and Y355 modifies or reduces the small molecule -induced conformation change of ARNT.
755. The method of claim 32, wherein a mutation of CRBN amino acid H397 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.
756. The method of claim 32, wherein a mutation of CRBN amino acid E377 and W400 modifies or reduces the small molecule -induced conformation change of ARNT.
757. The method of claim 32, wherein a mutation of CRBN amino acid E377 and N351 modifies or reduces the small molecule -induced conformation change of ARNT.
758. The method of claim 32, wherein a mutation of CRBN amino acid E377 and Y355 modifies or reduces the small molecule -induced conformation change of ARNT.
759. The method of claim 32, wherein a mutation of CRBN amino acid E377 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO760. The method of claim 32, wherein a mutation of CRBN amino acid W400 and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
761. Tire method of claim 32, wherein a mutation of CRBN amino acid W400 and Y355 modifies or reduces the small molecule -induced conformation change of ARNT.
762. The method of claim 32, wherein a mutation of CRBN amino acid W400 and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
763. The method of claim 32, wherein a mutation of CRBN amino acid N351 and Y355 modifies or reduces the small molecule -induced conformation change of ARNT.
764. The method of claim 32, wherein a mutation of CRBN amino acid N351 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.
765. The method of claim 32, wherein a mutation of CRBN amino acid Y355 and H357 modifies or reduces the small molecule -induced conformation change of ARNT.
766. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
767. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
768. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
769. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
770. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO771. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
772. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
773. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
774. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
775. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
776. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
777. The method of claim 32, wherein a mutation of CRBN amino acid E377, W400, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
778. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
779. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
780. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
781. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and Y355, modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO782. The method of claim 32, wherein a mutation of CRBN amino acid W400, N351, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
783. Tire method of claim 32, wherein a mutation of CRBN amino acid N351, Y355, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
784. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and E377 modifies or reduces the small molecule-induced conformation change of ARNT.
785. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
786. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
787. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
788. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397 and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
789. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, and W400 modifies or reduces the small molecule-induced conformation change of ARNT.
790. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
791. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
792. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO793. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
794. Tire method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
795. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400 and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
796. Tire method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
797. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
798. The method of claim 32, wherein a mutation of CRBN amino acid H397, E377, W400, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
799. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
800. The method of claim 32, wherein a mutation of CRBN amino H397, W400, N351, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
801. The method of claim 32, wherein a mutation of CRBN amino W400, N351, Y355, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
802. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and W400 modifies or reduces the small molecule -induced confonnation change of ARNT.
803. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO804. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
805. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
806. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400 and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
807. Tire method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
808. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, W400, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
809. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and N351 modifies or reduces the small molecule-induced conformation change of ARNT.
810. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, E377, W400, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
811. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. E377, W400, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
812. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397, W400, N351, and Y355 modifies or reduces the small molecule-induced conformation change of ARNT.
813. The method of claim 32, wherein a mutation of CRBN amino acid V388, H397. W400, N351, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
814. The method of claim 32, wherein a mutation of CRBN amino acid H397, W400, N351, Y355, and H357 modifies or reduces the small molecule-induced conformation change of ARNT.Attorney Docket No.: N2109-7007WO815. The method of claim 32, wherein a mutation of CRBN amino acid H353, V388, H397, E377, W400, N3 1, and Y355 modifies or reduces the small molecule -induced conformation change of ARNT.
816. Tire method of claim 32, wherein a mutation of CRBN amino acidH353, V388, H397, E377, W400, N351, and H357 modifies or reduces tire small molecule-induced conformation change of ARNT.
817. The method of claim 32, wherein a mutation of CRBN amino acidH353, V388, H397, E377, W400, N351, Y355 and H357 modifies or reduces the small molecule-induced conformation change of ARNT.
818. Tire method of claim 32, wherein a mutation of CRBN amino acid H353 modifies or reduces the small molecule-induced conformation change of ARNT.
819. The method of claim 32, wherein a mutation of CRBN amino acid V388 modifies or reduces the small molecule-induced conformation change of ARNT.
820. The method of claim 32, wherein a mutation of CRBN amino acid H397 modifies or reduces the small molecule-induced conformation change of ARNT.
821. The method of claim 32, wherein a mutation of CRBN amino acid E377 modifies or reduces the small molecule-induced conformation change of ARNT.
822. The method of claim 32, wherein a mutation of CRBN amino acid W400 modifies or reduces the small molecule-induced conformation change of ARNT.
823. The method of claim 32, wherein a mutation of CRBN amino acid N351 modifies or reduces the small molecule-induced conformation change of ARNT.
824. The method of claim 32, wherein a mutation of CRBN amino Y355 modifies or reduces tire small molecule-induced conformation change of ARNT.
825. The method of claim 32, wherein a mutation of CRBN amino acid H357 modifies or reduces the small molecule-induced conformation change of ARNT.
826. The method of claim 32, wherein the small molecule is a compound of Formula (I):Attorney Docket No.: N2109-7007WOor a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereo isomer, or tautomer thereof, wherein:Ra and Rb are each independently H, D, or (C2-Ce)alkyl;Ri is H, D, -C(O)Rn, -CH2OC(O)Rn, -CH2OC(O)NHRI2. -CH2OC(O)ORJ2, -P(O)(ORI2)2, -CH2OP(O)(OR12)2, -CH2OP(O)(OH)OR12, -CH2OP(O)(R12)2. -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(RI2)NHRI2, -CH2OC(O)(CH2)qC(O)ORi2. or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);R2a, R2b, R2c, and R2dare each independently H or D;R3is H, D, (C2. C3)alkyl, or (C2. C3)dcutcroalkyl;each R4 is independently at each occurrence D or halogen;each R4 is independently at each occurrence H, D, (C2. Ce)alkyl, (C2-Ce)deuteroalkyl, (C2. C,,)haloalkyl. (C2. C6)alkoxy, (C2. C6)haloalkoxy, halogen, -OH, -CN, -SH, -NR9R9, or -S(0)PRi9;R5is H, D, (C2-C6)alkyl, -C(0)RI2, -CH2OC(O)R]2, -CH2OC(O)N(Ri2)2, -CH2OC(O)2Ri2, -P(O)(OR]2)2, -CH2OP(O)(OH)ORI2, or -CH2OP(O)(RI2)2;Rea, Rbb, R'c. and Rbd are each independently H, D, (C2. C2)alkyl, (C2. C2)deuteroalkyl, or (C2. C2)haloalkyl;each Rbe is independently at each occurrence D. (C2C,)alkyl. (C2. C6)deuteroalkyl.(C2. C6)haloalkyl, (C2. Cfi)alkoxy, (C2-Cfi)haloalkoxy, halogen, (C2. C6)hydroxyalkyl, -CN, -OH, -0-(C2. Ce)hydroxyalkyl, (C6-Cio)aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more RI3, the aryl and heteroaryl are optionally substituted with one or more R22. and the carbocyclyl and heterocyclyl are optionally substituted with one or more R23; ortwo Rbe, when on the same carbon atom, together with the carbon atom to which they are attached form a (C3-C7)spirocarbocyclyl or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more RB;Attorney Docket No.: N2109-7007WOwhen R4’ is H. m is 1, n is 0 and R2a, R2b, R2C, R2d, R?, and Rs are all simultaneously H, then R7is (C2-C6)haloalkyl, (C2-Ce)hydroxyalkyl, (C2. C6)halohydroxyalkyl, or (C2-Ce)alkyl optionally substituted with one or more substituents independently selected from D, (C2. Ce)alkoxy, -SFs, -SRiea, -NRieRie-, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-Cvlcarbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S. wherein the phenyl is substituted with one or more Rs. the heteroaryl is optionally substituted with one or more Rs, and the carbocyclyl and heterocyclyl are optionally substituted with one or more Rs- when R is H, m is 0, n is 0, and R2a, R2b, R2C, R2d, R3, and R5are not all simultaneously H or when R4' is H, m is 0 or 1, and n is 1, 2, 3, or 4, then R7is (C2. C6)haloalkyl, (C2. C6)hydroxyalkyl, (C2. C. Jhalohydroxyalkyl. or (C2-C6)alkyl optionally substituted with one or more substituents independently selected from D, (C2. C6)alkoxy, -SF5, -SR^a, -NRieRie, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S. (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R« and the carbocyclyl and heterocyclyl are optionally substituted with one or more R;;when R4’ is (Ci)alkyl, then R7 is (C2. C6)haloalkyl, (C2. C6)hydroxyalkyl, (C2-C6)halohydroxyalkyl, or (C2-C6)alkyl optionally substituted with one or more substituents independently selected from D, (C2. Ce)alkoxy, -SF5. -SRiea, -NRieRie’, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl is substituted with one or more Rg, the heteroaryl is optionally substituted with one or more Rs, and the carbocyclyl and heterocyclyl are optionally substituted with one or more Rs;when R4’ is D, (C2-C4)alkyl, (C2. C6)haloalkyl, (C2. Ce)alkoxy. (C2-C6)haloalkoxy, halogen, -OH, -CN, -SH, -NR9R9, or -S(0)pRi9, thenR7is (C2-C6)haloalkyl, (C2. C6)hydroxyalkyl, (C2. C6)halohydroxyalkyl, or (C2. Cs)alkyl optionally substituted with one or more substituents independently selected from D, (C2. C6)alkoxy, -SF5, -SRiea, -NRieRie-, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Rs and the carbocyclyl and heterocyclyl are optionally substituted with one or more Rs-;Rs and Rs- are each independently at each occurrence D, (C2. Ce)alkyl, (C2. C6)deuteroalkyl, (C2-Ce)haloalkyl, (C2-Ce)alkoxy, (C2. Ce)haloalkoxy, (C2-Ce)hydroxyalkyl, halogen, -OH, -NR30R31, -SFs, -SRM, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-mcmbcrcd hctcroaryl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered hctcroaryl comprising 1 to 4 heteroatomsAttorney Docket No.: N2109-7007WOselected from O, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (C2-C6)alkyl, (C2-Ce)haloalkyl, (C2-Cs)alkoxy, (C2-C.jhaloalkoxv. (C2-Ce)hydroxyalkyl, halogen, -OH. -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SF5, -SR40, and -CN; ortwo Rg, when on adjacent atoms, together with tire atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more Rio;two Rg, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered hctcroar l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Ri0; ortwo R§ together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Rio; ortwo Rg when on the same carbon atom form C=(0);each R9and Ry are each independently at each occurrence H or (C2-Ce)alkyl;Rio is independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl, (C2-C6)haloalkyl, (C2-Cejalkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, or -CN;R11 is independently at each occurrence H, (C2-C6)alkoxy, -NH2, -N(H)(C2-C6)alkyl,-N((C2-C6)alkyl)2, (C2-C6)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)ai 1, (C2-Cs)alkoxy, (C2-C6)hydroxyalkyl, (C2-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Cs-Ciojaryl optionally substituted with one or more substituents independently selected from(Co-Cejalkyl, (C2-C6)alkoxy. (Cz-Cejhydroxyalkyl, (C2-Ce)haloalkyl, halogen, -OH, -NH2, and -CN;R12 is independently at each occurrence H, (C2-C6)alkyl optionally substituted with one or more substituents independently selected from (Cs-Cio)aryl. (C2-C6)alkoxy, (C2-Ce)hydroxyalkyl, (C2-Cjhaloalkyl. halogen, -OH, -NH2. and -CN, or (Cg-Ciojaryl optionally substituted with one or more substituents independently selected from (C2-C6)alkyl, (Ci. C jalkoxy. (C2-C6)hydroxyalkyl, (C2-C6)haloalkyl, halogen, -OH, -NH2, and -CN;Ru- is independently at each occurrence H or (C2-C6)alkyl;each R13 is independently at each occurrence (C2-Ce)alkoxy, (C2-C6)haloalko y, -NRwRw, -CN.Attorney Docket No.: N2109-7007WO(C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (Ce-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein carbocyclyl and heterocyclyl are optionally substituted with one or more R2o and the aryl and heteroaryl are optionally substituted with one or more R21;R14 and R14’ are each independently at each occurrence H or (C2-Ce)alkyl;each Ri? is independently at each occurrence D. (C2. Ce)alkyl, (C2-C6)deuteroalkyl,(C2-C6)haloalkyk (C2-Ce)alkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -C(O)ORi7, -C(O)Ris, or -C(O)NR17RI7;Rie and RI6are each independently at each occurrence H or (C2. C6)alkyl;Ri6a is H, (C2-C6)alkyl or (C2-Ce)haloalkyl;R17 is independently at each occurrence H, (C2-C6)alkyl or (C2-C6)haloalkyl;Ri8 is independently at each occurrence (C2-C6)alkyl or (C2-C6)haloalkyl;Riais (C2-Ce)alkyl or (C2-C6)haloalkyl;each R20 is independently at each occurrence D, (Cz-Csjalkyl, (C2-Ce)haloalkyl, (C2-Ce)alkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR2g, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R20 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S:each R2I is independently at each occurrence D, (C2. C6)alkyl, (C2. C6)haloalkyl, (C2-Ce)alkoxy, (. Cejhaloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R22is independently at each occurrence (C2-C6)alkyl, (C2-C6)haloalkyl, (C2-C6)alkoxy, (C2. C6)haloalkoxy, (C2. C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR2s, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C -C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R22, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R23 is independently at each occurrence (C2. C6)alkyl, (C2. C6)haloalkyl, (C2. C6)alkoxy, (C2_C6)haloalkoxy, (C2C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR29, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S; orAttorney Docket No.: N2109-7007WOtwo R23 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;R24, R25, R26, R27, R28, and R29 are each independently at each occurrence H, (CS C-Jalkyl or (C2-C6)haloalkyl;R30 and R31 are each independently at each occurrence H, (C2-Cs)alkyl, or -C(O)R34;R32, R33. and R34 are each independently at each occurrence H or (C2-Ce)alkyl:R35 and R36 are each independently at each occurrence H, (C2-Ce)alkyL or -C(O)R39;R37, R38, and R39 are each independently at each occurrence H or (C2-C6)alkyl;R40 is H, (C2-C6)alkyl or (C2-C6)haloalkyl;m and p are each independently 0, 1, or 2;q is 1, 2, or 3; andn is 0. 1, 2, 3 or 4.
827. The method of claim 32, wherein the small molecule is a compound of Formula (II):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:Ra and Rb are each independently H or D;Ri is H, D, -C(0)Rn, -CH2OC(O)RII, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(OR12)2, -CH2OP(O)(OH)OR12, -CH2OP(O)(RI2)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(R12 )NHR12. -CH2OC(O)(CH2)qC(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);R2a, R2b, R3c, and R2CI are each independently H or D;R3is H, D, (C3-C3)alkyl, or (C2-C3)deuteroalkyl;each R4 is independently at each occurrence D or halogen;R5is H, D, -C(0)Rn, -CH20C(0)RH, -CH2OC(O)NHRI2. -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(OH)ORi2, or -CH2OP(O)(Ri2)2:Ra. Reb, <. and.d are each independently H, D, (C2-C2)alkyl, (C2-C2)deuteroalkyl, or (C2-C2)haloalkyl;Attorney Docket No.: N2109-7007WOeach Ree is independently at each occurrence D, (C2-C6)alkyl, (C2-Cfi)deuteroalkyl,(C2-C6)haloalkyl, (C2-Ce)alkoxy, (C2-C6)haloalkoxy, halogen, (C2-Ce)hydroxyalkyl, -CN, -OH, -O-(C2-Ce)hydroxyalkyl, (Cg-C io)aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more Ri6. the aryl and heteroaryl are optionally substituted with one or more Ris. and the carbocyclyl and heterocyclyl are optionally substituted with one or more Rig; ortwo Rc. when on the same carbon atom, together with the carbon atom to which they are attached form a (Cb-Cbispirocarbocyclyl or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more RiR7 is (C2-Ce)haloalkyl, (C2-C6)hydroxyalkyl, (C2-C6)halohydroxyalkyl, or (C2-C6)alkyl optionally substituted with one or more substituents independently selected from D, (Ch. C jalkoxy. -SR. -SRua, -NRuRw, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Rs and the carbocyclyl, and heterocyclyl are optionally substituted with one or more Rs-;Rs and Rs- are each independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl, (C2. C6)haloalkyl, (C2-C6)alkoxy, (C2-C6)haloalkoxy, (C2-Cg)hydroxyalkyl, halogen, -OH, -NR27R28, -SR, -SR9, -CN, -C(0)NR29R3o, -C(O)OR29, (C3-C7)carbocyclyl, -O(C.3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (C2-Cg)alkyl, (C2-Cg)haloalkyl, (C2-Cg)alkoxy, (C2-C. Jhaloalkoxy. (C2-C6)hydroxyalkyl, halogen, -OH, -NR32R33, -C(O)NR34R35, -C(0)Rs4, -C(O)OR34, -SF5, -SR37, and -CN; ortwo Rs, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more Rio;Attorney Docket No.: N2109-7007WOtwo Rs, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered hcteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Rio; ortwo Rs- together with the atoms to which they are attached form a (Ci-Cyjcarbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Rio; ortwo Rs when on the same carbon atom form C=(0);Rs is H, (C2-C6)alkyl or (C2-C6)haloalkyl;Rio is independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl, (C2-C6)haloalkyl, (C2. Cejalkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR26, or -CN;Rn is independently at each occurrence H, (C2-Ce)alkoxy, -NH2, -N(H)(C2-C6)alkyl,-N((C2-C6)alkyl)2, (C2-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (C2-Cs)alkoxy, (C2-C6)hydroxyalkyl, (C2-C6)haloalkyl, halogen, -OH, -NH:. and -CN, or (Cs-Ciojaryl optionally substituted with one or more substituents independently selected from(C2-C6)alkyl, (C;. C,,)alkoxy. (Cz-Cejhydroxyalkyl, (C2-Ce)haloalkyl, halogen, -OH, -NH2, and -CN;R12 is independently at each occurrence H, (C2-C6)alkyl optionally substituted with one or more substituents independently selected from (Cs-Cio)aryl. (C2-C6)alkoxy, (C2-Ce)hydroxyalkyl, (C2-CJhaloalkyl. halogen, -OH, -NH2. and -CN, or (Ce-Ciojaryl optionally substituted with one or more substituents independently selected from (C2. C6)alkyl, (C’g. C.jalkoxy. (C2. C6)hydroxyalkyl, (C2. C jhaloalkyl. halogen, -OH, -NH2, and -CN;R12' is independently at each occurrence H or (C2-C6)alkyl;each R13 is independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl,(C2-C6)haloalkyl, (C2-C6)alkoxy. (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -C(0)0Ri5. -C(0)Ri5, or -C(0)NRi5 R15;R14 and Ru are each independently at each occurrence H or (C2-Ce)alkyl;Ri4a is H, (C2-C6)alkyl or (Cg. Cgjhaloalkyl;Ris is independently at each occurrence (C2-C6)alkyl or (C2-C6)haloalkyl;Ri5’ is independently at each occurrence H, (C2-C6)alkyl or (C2-C6)haloalkyl;each Rie is independently at each occurrence (C2-C6)alkoxy. (C2. C6)haloalkoxy, -NR17R17’, -CN. (Cs-C jcarbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (Cg-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein carbocyclyl and heterocyclyl are optionally substituted with one or more R22 and the aryl and hcteroaryl arc optionally substituted with one or more R23;R17 and R17 are each independently at each occurrence H or (C2-C6)alkyl;Attorney Docket No.: N2109-7007WOeach Ris is independently at each occurrence (C2-C6)alkyl, (C2-C6)haloalkyl, (C2-Ce)alkoxy, (C2. C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR20, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo Ris, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S;each Ris is independently at each occurrence (C2-C6)alkyl, (C2-C6)haloalkyl, (C2-C6)alkoxy, (CkC. Jhaloalkoxy. (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR21, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R19 together with the atoms to which they are attached form a (Cs-CNcarbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S;R20 and R21 are each independently at each occurrence H, (C2-C6)alkyl or (C2. C6)haloalkyl; each R22 is independently at each occurrence D, (Cz-Csjalkyl, (C2-C6)haloalkyl, (C2. Ce)alkoxy, (CXC. )haloalkoxy. (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR24, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Cs-Cvjcarbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R22 together with the atoms to which they are attached form a (Cs-Cvjcarbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S:each R23is independently at each occurrence D, (Cz-Csjalkyl, (C2-C6)haloalkyl, (C2. Ce)alkoxy, (. Cejhaloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Cs-Cvjcarbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;R24, R25 and R26 are each independently at each occurrence H, (C2. C6)alkyl or (CNCe.jhaloalkyl: R27 and R2S are each independently at each occurrence H, (C2-C6)alkyl, or -C(O)R3ijR29, R3O, and R3I are each independently at each occurrence H or (C2-C6)alkyl;R32and R33are each independently at each occurrence H, (C2. C6)alkyl, or -C(O)R36;R34, R35, and R3., are each independently at each occurrence H or (C2-Ce)alkyl:R37 is H, (C2. C6)alkyl or (C2. C6)haloalkyl;q is 1, 2, or 3:m is 0, 1 or 2; andn is 0, 1, 2, 3 or 4.
828. Hie method of claim 32, wherein the small molecule is a compound of Formula (III):Attorney Docket No.: N2109-7007WOor a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:Ri is H, D, -C(O)Rn, -CH2OC(O)RU, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORJ2)2, -CH2OP(O)(OR12)2, -CH2OP(O)(OH)ORI2, -CH2OP(O)(RI2)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(RI2)NHRI2, -CH2OC(O)(CH2)qC(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);R2a, R2b, R2c, and R2CI are each independently H or D;R3is H, D, (C2. C3)alkyl, or (C2. C3)deuteroalkyl;each R4 is independently at each occurrence D;R is H, D, (C2. C6)alkyl, -C(0)RI2, -CH2OC(O)RI2, -CH2OC(O)N(RI2)2. -CH2OC(O)2R]2, -P(O)(ORI2)2, -CH2OP(O)(OH)ORI2, or-CH2OP(O)(Ri2)2;R,a. sb, Rbc, and R,-,i are each independently H, D, (C2. C2)alkyl, (C2. C2)deuteroalkyl, or (C2. C2)haloalkyl;each R,, is independently at each occurrence D, (C2. Cg)alkyl, (C2. C6)deuteroalkyl, (C2. C6)haloalkyl, (C2-Ce)alkoxy, (C2. C6)haloalkoxy, halogen, (C2. C6)hydroxyalkyl, -CN, -OH, -0-(C2. Ce)hydroxyalkyl, (C6-Cio)aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S. (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more RQ, the aryl and heteroaryl are optionally substituted with one or more Rig, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R19; ortwo R,e. when on the same carbon atom, together with the carbon atom to which they are attached form a (C3-C7)spirocarbocyclyl or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more R14:R7 is (C2. C6)haloalkyl, (C2. C6)hydroxyalkyl, (C2-Ce)halohydroxyalkyl, or (C2. C6)alkyl optionally substituted with one or more substituents independently selected from D, (C2. C6)alkoxy, -SF5, -SRi5a, -NR16R16', phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, andAttorney Docket No.: N2109-7007WOS, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Rs and the carbocyclyl and heterocyclyl are optionally substituted with one or more Rs;Rs and Rs’ are each independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl, (C2-Ce)haloalkyl, (C2-Ce)alkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NR28R29, -SF5, -SR22, -CN, -C(O)NR30R3I, -C(O)OR30, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered hetcroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O. N, NH. and S), wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (C2. Ce)alkyl, (C2. C6)haloalkyl, (C7. C,.)alkoxy.(C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NR33R34, -C(O)NR35R36, -C(O)R35, -C(O)OR35, -SF5, -SR3S, and -CN; ortwo Rs, when on adjacent atoms, together with tire atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more Rio;two Rs, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Rio; ortwo Rs together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Rio; ortwo Rs when on the same carbon atom form C=(0);each R9 is independently at each occurrence (C2-C6)alkoxy, (C2-C6)haloalkoxy, -NR13R13’, -CN, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S. (Cg-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein carbocyclyl and heterocyclyl are optionally substituted with one or more R20 and the aryl and heteroaryl are optionally substituted with one or more R2I;Rio is independently at each occurrence D, (C2-C6)alkyl, (C2-C6)deuteroalkyl, (C2-C6)haloalkyl, (C2. Cejalkoxy. (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR23, or -CN;R11 is independently at each occurrence H, (C2-Ce)alkoxy, -NH2, -N(H)(C2-C6)alkyl.Attorney Docket No.: N2109-7007WO-N((C2-C6)alkyl)2, ( C C, )alky 1 optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (C2. Cs)alkoxy, (C2-Ce)hydroxyalkyl, (C2-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Cs-Cio)aryl optionally substituted with one or more substituents independently selected from(C2-C6)alkyl, (C2-Ce)alkoxy, (C2-C6)hydroxyalkyl, (C2-C6)haloalkyl, halogen, -OH, -NH2, and -CN;R12 is independently at each occurrence H, (C2-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Ciojaryl. (C2-C6)alkoxy, (C2-Ce)hydroxyalkyl, (C2-C.jhaloalkyl. halogen, -OH, -NH2, and -CN, or (Cs-Cio)aryl optionally substituted with one or more substituents independently selected from (C2-C6)alkyl, (C2. C6)alkoxy, (C2-C6)hydroxyalkyl, (C2. C6)haloalkyl, halogen, -OH, -NH2, and -CN;Ri2’ is independently at each occurrence H or (C^-C. Jalkyl:RB and R 13 are each independently at each occurrence H or (C2-Ce)alkyl;each RM is independently at each occurrence D. (C2-C6)alkyl, (C2-Ce)deuteroalkyl, (C2. C6)haloalkyl, (C2-Ce)alkoxy, (C; C,)haloalkoxy. (C2-C6)hydroxyalkyl, halogen, -C(O)ORi?, -C(O)Ris, or -C(O)NR17Ri7;Ris and R15 are each independently at each occurrence H or (Cz-Cejalkyl;Risa is H, (C2-Ce)alkyl or (C2. C6)haloalkyl;each Rig is independently at each occurrence (C2-C6)alkyl, (C2. C6)haloalkyl, (C2-Ce)alkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR24, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C -C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo Ris, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered hctcroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;R17 is independently at each occurrence H, (C2. C6)alkyl or (C2-C6)haloalkyl;Ris is independently at each occurrence (C2-Ce)alkyl or (C2-Ce)haloalkyl;each Ris is independently at each occurrence (C2-C6)alkyl, (C2_C,,)haloalkyl. (CNC.jalkoxy.(C2-C6)haloalkoxy, ^. Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R19 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R2O is independently at each occurrence D, ( Cejalkyl, (C2-C,6)haloalkyl, (C2-Ce)alkoxy, (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR2e, -CN, phenyl, 5- or 6-membered hctcroaryl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; orAttorney Docket No.: N2109-7007WOtwo R20 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R2I is independently at each occurrence D, (C2-C6)alkyl, (CNC)haloalk l. (CkCOalkoxy. (C2-C6)haloalkoxy, (C2-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C\-C7)carbocyclyl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S;R22, R23, R24, R25, R26, and R27 are each independently at each occurrence H, (C2-C6)alkyl or (C2-C6)haloalkyl;R2S and R29 are each independently at each occurrence H, (C2-C6)alkyl, or -C(O)R32;R30, R31, and R32 are each independently at each occurrence H or (C2-Ce)alkyl;R33 and R34 are each independently at each occurrence H, (C2-Cg)alkyl, or -C(O)R37;R35. R36- and R37 are each independently at each occurrence H or (C2-C6)alkyl:Rss is H, (C2-C6)alkyl or (C2-Ce)haloalkyl;m is 0, 1, or 2;q is 1, 2, or 3; andn is 0, 1, 2, 3, or 4.
829. Hie method of claim 32, wherein the small molecule is a compound of Formula (IV):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:X, is N orCR,;X2is N, N(O), or CR5:X3is N or CRtajX4is N or C tbJX5is N or CRtb;Xg is N orCRs;X7is N orN(O);wherein no more than three of X2, X3, X4, X5, X6and X7is simultaneously N;Attorney Docket No.: N2109-7007WORi is H, D, -C(O)Rn, -CH2OC(O)Rn, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(ORI2)2, -CH2OP(O)(OH)ORI2, -CH2OP(O)(R]2)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(Ri2)NHRI2, -CH2OC(O)(CH2)q-C(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);R2a, Ra.2C, and R2CI are each independently H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, halogen, or -OH, wherein two of R2a, R2b, R2c. and R2d may be taken together with the carbon atom to which they are attached form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl;R3is H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, halogen, or -OH, wherein R3may be taken together with one of R2a, R2b, R2c, and R2d with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl;Rda, Rdb- and R41 are each independently H, D, (Ci-Ce)alkyl, (C -C„)dcutcroalkyl. (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)deuteroalkoxy, (Ci-C6)haloalkoxy, (C3-C7)carbocyclyl. 0(C2-C?)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteoalkoxy, haloalkoxy, and carbocyclyl is optionally substituted with one or more R40;R+, are each independently H, D, (Ci-Cg)alkyl, (Ci-C6)deuteroalkyl, (C-Cjhaloalkyl. or halogen:Rs and Rs- are each independently H, D, (Ci-C6)alkyl, (Ci-Ce)deuteroalkyl, (Ci-Celhaloalkyl, (Ci-Ce)alkoxy, (Ci-C6)deuteroalkoxy, (Ci-Cs)haloalkoxy, (C3-C7)carbocyclyl, O(C3-C7)carbocyclyl, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10;, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteoalkoxy, haloalkoxy, and carbocyclyl is optionally substituted with one or more R40;Rs is H, D, (Ci-Ce)hydroxyalkyl, (Ci-Ce)halohydroxyalkyl, (Ci-C6)aminoalkyl, (Ci-C6)alkyl-0-(Ci-C6)hydroxyalkyl, -C(0)Rn. -CH20C(0)Rn. -CH2OC(O)NHRI2, -CH2OC(O)ORi2, -P(O)(ORi2)2. -CH2OP(O)(OH)ORI2, or -CH2OP(O)(R]2)2;R7a, R7b, R7c, and R7d are each independently H, D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, or (Ci-C2)haloalkyl; ortwo of R?a- R 7b -?c, and R?d are taken together with the carbon atoms to which they are attached form a (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl. or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -C(0)0R, -C(0)RI3, and -C(0)NR;Attorney Docket No.: N2109-7007WOeach R?e is independently at each occurrence D, (Ci -C6)alkyl, (Ci -C,)dcutcroalkyl. (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, halogen, (Ci-Ce)hydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, ( C -C 10) ar l. 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Ci-CMcarbocyclyl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S, wherein the alkyl is optionally substituted with one or more Rig. the aryl and heteroaryl are optionally substituted with one or more R21, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; ortwo R7Ctogether with the carbon atom to which they are attached form a (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (C|-C,.)alk l. (Ci-Celdcutcroalkyl. (Ci-Ce)haloalkyl. (Ci-Ce)alkoxy. (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl. halogen, -C(O)OR13, -C(O)R13, and -C(0)NRI3R13: orone R7C is taken together with any one of R7a, R?b, R7c, and / d and the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22;Rs is (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)hydroxyalkyl, (C -C,.)halohydroxyalkyl. or(C3-C7)carbocyclyl, wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyL and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D, (Ci-Cs)alkoxy, -SF5, -SRua, -NR14R14, -C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S. wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocycly l and heterocyclyl are optionally substituted with one or more R15- R and Rio are each independently at each occurrence H, D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, or (Ci-C6)haloalkyl;Rn is independently at each occurrence H, (Ci-Ce)alkoxy. -NH2, -N(H)(Ci-C6)alkyl,-N((Ci-Ce)alkyl)2. (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (C6-Cm)aryl optionally substituted with one or more substituents independently selected from (Ci-C )alkyl. (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN;R12 is independently at each occurrence H, (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (C6-Cio)aryl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-Attorney Docket No.: N2109-7007WOCjhaloalkyl. halogen, -OH, -NH2, and -CN, or (Cs-Cio)aryl optionally substituted with one or more substituents independently selected from (C -Cjalkyl. (Ci-Cejalkoxy, (Ci-C6)hydroxyalkyl, (Ci-Cejhaloalky 1, halogen, -OH, -NH2, and -CN;Ri2’ is independently at each occurrence H or (Ci-Cs)alkyl;RIB is independently at each occurrence (Ci-C6)alkyl or (Ci-Cs)haloalkyl;Ri3’ is independently at each occurrence H, (Ci-Ce)alkyl or (Ci-Cg) haloalkyl:RM and RM’ are each independently at each occurrence H or (Ci-Ce)alkyl;Ri4a is H, (Ci-Ce)alkyl or (Ci-C6)haloalkyl;Ris and R]5are each independently at each occurrence D, (Ci-C6)alkyl, (Ci-C6)deuteroalky 1, (Ci-C. Jhaloalkyl. (Ci-C6)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR30R31, -SF5, -SR16, -CN, -C(O)NR32R33. -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl. -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein alkyl, alkoxy, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-Cs)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Celhaloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and Ris>; ortwo R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more R17; ortwo Ris, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroary l are optionally substituted with one or more R[7; ortwo Ris’ together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Ri?: ortwo Ris- when on the same carbon atom form C=(0);Ri6 is H, (Ci-Cejalkyl or (Ci-Cejhaloalkyl;R17 is independently at each occurrence D, (Ci-Ce)alky l, (Ci-C. jdciitcroalkyl. (Ci-C )haloalkyl. (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxy alkyl, halogen, -OH, -NH2, -SF5, -SRis, or -CN;Attorney Docket No.: N2109-7007WORi s is H, (Ci-CejalkyL or (Ci-Cfi)haloalkyl;each Rio is independently at each occurrence (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, -NR20R20’, -CN, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Cg-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S. wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R24; orR19 when on the same carbon atom form C=(0); ortwo R19 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R,R20 and R20’ are each independently at each occurrence H or (Ci-Cejalkyl;each R21 is independently at each occurrence (Ci-C6)alkyl, (C -C.)haloalkyl. (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, -CN, phenyl, 5- or 6-membered heteroary 1 comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocycly l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R21. when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15;each R22 is independently at each occurrence (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR26, -CN, pheny l, 5- or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; ortwo R22 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S:each R23 is independently at each occurrence D, (Ci-C6)alky 1, (Ci-C6)haloalky 1, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR27, -CN, pheny l, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or two R23 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S:each R2is independently at each occurrence D, (C’i-C,,)alky 1, (Ci-C,)haloalkyl. (Ci-Cjalkoxy. (Ci-Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR28, -CN, phenyl, 5- or 6-Attorney Docket No.: N2109-7007WOmembered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C-Cvicarbocyclyl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;R25, Rze, R27, R2S, and R29 are each independently at each occurrence H, (Ci-Ce)alkyl, or (Ci-C flialoalkyl:R30 and R31 are each independently at each occurrence H, (Ci-Cg)alkyl, (Ci-C6)haloalkyl, (C3-CNcarbocycIvl. -C(O)R34. phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17:R32, R33, and R3 are each independently at each occurrence H or (Ci-Cjalkyl:R35 and R36 are each independently at each occurrence H, (Ci-Cg)alkyl, or -C(O)R39;R37, R38, and R39 are each independently at each occurrence H or (Ci-Celalkyl;R40 is D, (Ci-C6)alkyl. (Ci-Ce)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen. -OH. -NR30R31, -SR]6, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl:o is 1 or 2;p is 0, 1, 2, 3 or 4;q is 1, 2, or 3; andr is 0 or 1.
830. The method of claim 32, wherein the small molecule is provided in any one of Tables 1 or 2, e.g., or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
831. A method for the design of a compound that causes the degradation of the aryl hydrocarbon nuclear translocator (ARNT) protein, the method comprising:(1) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound:(2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound from step (1) wherein the compound is designed by (i) predicting or identifying potential ligand-protein interactions of the ternary complex with the compound and modifying the compound to form said interactions, (ii) identifying existing ligand-protein interactions of the ternary complex with the compound and modifying the compound to enhance said interactions, (iii) predicting or identifying CRBN / ARNT interactions and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains and modifying the compound to enhance these interactions and to enhance compound / CRBN, CRBN / ARNT interactions, ARNTAttorney Docket No.: N2109-7007WOintramolecular interactions, and / or compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof, (iv) identifying empty cavities in the vicinity of the compound to fill and increase ligand / protein nonspecific interactions and modifying the compound to fill said cavities, (v) identifying areas of the compound that do not fonn interactions or are solvent exposed and modifying the compound in these areas to improve ADME / PK properties, (vi) identifying solvating molecules that are near the compound in the complex to target for destabilization or replacement and modifying the compound to target said areas, and / or, and (vii) use a combination of (i) through (vi) to improve potency and / or ADME / PK properties;(3) synthesizing one or more of the designed compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier; and(4) quantifying the degradation activity of the synthesized compounds with at least one of biochemical assays, cellular assays or molecular dynamics simulations and / or other computational approaches to determine if the one or more designed compounds degrade ARNT or cause the formation of the ternary complex.
832. A method for designing of a chemical library of cereblon (CRBN) binding compounds that form a ternary complex comprising CRBN, the compounds and aryl hydrocarbon nuclear translocator (ARNT) and that are predicted to form ARNT intramolecular interactions between the PAS-1 and PAS-2 domains when ARNT is recruited to cereblon (CRBN), wherein the method comprises:(1) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound;(2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound from step (1) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains of the complex and modifying tire compound to enhance these interactions and to enhance compound / CRBN, CRBN / ARNT interactions, and / or compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof, (ii) identifying empty cavities in the vicinity of the compound to fill and increase ligand / protein nonspecific interactions and modifying the compound to fill said cavities, (iii) identifying areas of the compound that do not form interactions or are solvent exposed and modifying the compound in these areas to improve ADME / PK properties, (iv) identifying solvating molecules that are near the compound in the complex to target for destabilization or replacement and modifying the compoundAttorney Docket No.: N2109-7007WOto target said areas, and (v) use a combination of (i) through (iv) to improve potency and / or ADME / PK properties;(3) synthesizing one or more the designed compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier; and(4) quantifying the degradation activity of the synthesized compounds with at least one of biochemical assays, cellular assays or molecular dynamics simulations and / or other computational approaches to determine if the one or more designed compounds degrade ARNT or enhance ternary complex formation.
833. Tire method of claim 831, wherein the ADME / PK properties are enhanced by modifying the compound (a) to decrease molecular weight, (b) to find areas of the compound that can be rigidified to improve binding; or (c) to find areas of the compound that could be derigidified to improve solubility, or a combination thereof.
834. A method of identifying a compound that degrades ar l hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(2) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound in tire screening assay in step (1);(3) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of said ternary complex comprising CRBN, ARNT, and a compound identified in the screening assay in step (1) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modify ing the compound to form or enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;Attorney Docket No.: N2109-7007WO(4) synthesizing one or more compounds designed in step (3) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(5) testing said compounds synthesized in step (4) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(6) testing said compounds in an assay to assess whether the compounds synthesized in step (4) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein tire compounds that form the complex with ARNT and CRBN via the specific interaction in step (3), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
835. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(2) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;(3) experimentally determining or computationally predicting a three-dimensional atomic structural model of a ternary complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2):(4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151. 1152, F150, H353. F102, H103, Q390, A395. 1371, V388, H397,Attorney Docket No.: N2109-7007WOW386, W400, N351, Y355, H357, or S420, and modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;(5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled fomrat and wherein tire compounds are optionally tagged with an identifier;(6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (4), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
836. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing a compound library comprising one or more compounds in an individual or pooled fonnat, wherein the compounds are optionally tagged with an identifier;(2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2);(4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, andAttorney Docket No.: N2109-7007WOmodifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex;(5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled fomrat and wherein tire compounds are optionally tagged with an identifier;(6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interaction in step (4), (ii) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
837. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing a compound library comprising one or more compounds in an individual or pooled fonnat, wherein the compounds are optionally tagged with an identifier;(2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(3) confirming the screening data from step (2) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;(4) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in tire screening assay in step (2) and confirmed in step (3);(5) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) and confirmed in step (3) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of theAttorney Docket No.: N2109-7007WOcomplex and modifying the compound to enhance said interactions, and (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151, I152, F150, H353, F102, H103, Q390, A395, I371, V388, H397, W386, W400, N351, Y355, H357, or S420, and modifying the compound to enhance said specific interactions in between ARNT, CRBN and the compound in the complex:(6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(8) testing the compounds in an assay to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein tire compounds that form the complex with ARNT and CRBN via the specific interaction in step (5), (ii) between tire ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
838. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(2) experimentally determining or computationally predicting tire atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (i);(3) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step ( 1) wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, (ii) determining whether said compound identified in the screening assay in step (1) induces a change in the confonnation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNTAttorney Docket No.: N2109-7007WOwherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2), and (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;(4) synthesizing one or more compounds designed in step (3) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(5) testing said compounds synthesized in step (4) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(6) testing said compounds in an assay to assess whether tire compounds synthesized in step (4) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (3), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (3), (iii) result in degradation of ARNT.
839. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) screening a compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;(2) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in the presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;(3) experimentally determining or computationally predicting tire atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (1) and confirmed in step (2);(4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN),Attorney Docket No.: N2109-7007WOARNT, a compound identified in the screening assay in step (1) and confmued in step (2) wherein the compound is designed by (i) predicting and identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound enhance said interactions, (ii) determining whether said compound identified in tire screening assay in step (1) and confinned in step (2) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2), (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;(5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (4), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (4), (iii) result in degradation of ARNT.
840. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing a compound library comprising one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;(2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;Attorney Docket No.: N2109-7007WO(3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2);(4) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, a compound identified in the screening assay in step (2) wherein the compound is designed by (i) determining whether said compound identified in the screening assay in step (2) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO. 2), and (ii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the complex;(5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (4), (ii) between the ARNT amino acids result in degradation of ARNT.
841. A method of identifying a compound that degrades ar l hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing a compound library comprising one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;(2) screening the compound library in a compound screening assay, in an individual or pooled format, wherein the compounds are optionally tagged and wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation, degradation, or disappearance of ARNT;Attorney Docket No.: N2109-7007WO(3) confirming the screening data from step (1) by testing the individual compounds in a biochemical or cellular ARNT degradation assay wherein the ubiquitination or degradation activity is confirmed by (i) testing said individual compounds in tire presence of an inhibitor of the ubiquitination or degradation or (ii) testing said individual compounds in biochemical ternary complex formation assays or in vitro ubiquitination assays;(4) experimentally determining or computationally predicting tire atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound identified in the screening assay in step (2) and confirmed in step (3);(5) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally detennined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, a compound identified in the screening assay in step (2) and confirmed in step (3) wherein the compound is designed by (i) identifying the ARNT / CRBN / compound interactions of the complex and modifying the compound to enhance said interactions, (ii) determining whether said compound identified in the screening assay in step (2) and confirmed in step (3) induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.2), (iii) identifying the specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compound to enhance said specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex;(6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(8) testing tire compounds in an assay to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (5), (i) between the ARNT amino acids and the CRBN amino acids and that induce a change in the conformation of the ARNT via the specific intramolecular interactions in step (5), (iii) result in degradation of ARNT.Attorney Docket No.: N2109-7007WO842. A method of identifying a compound that degrades and hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound;(2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the ARNT degrader compound is designed by predicting or identifying the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex, and modifying the compounds to (a) to enhance said ARNT intramolecular interactions of the PAS-1 and PAS-2 domains and (b) to optionally cause additional ARNT intramolecular interactions of the PAS-1 and PAS-2 domains;(3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;(4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in the complex comprising cereblon (CRBN), ARNT, and the compound result in degradation of ARNT.
843. A method of identifying a compound that degrades and hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound;(2) performing structural modeling, using a suitably programmed computer, to identify a compound that degrades ARNT using the experimentally detemrined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the compound is designed by (i) identifying the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in tire complex, (ii) determining if the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of the ARNT in the complex occur through the specific interaction of ARNT 1372 and ARNT L237; ARNT 1372 and ARNT L239;Attorney Docket No.: N2109-7007WOARNT T374 and ARNT 1236; ARNT T374 and ARNT L237; ARNT T374 and ARNT L239; ARNT F375 and ARNT T233; ARNT F375 and ARNT G234; ARNT F375 and ARNT R235; ARNT F375 and ARNT 1236; ARNT F375 and ARNT L237; ARNT F375 and ARNT E247; ARNT L392 and ARNT R235; ARNT L392 and ARNT 1236; ARNT L392 and ARNT L237; or ARNT L392 and ARNT V244, and (iii) modifying the compound to (a) enhance said ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in (ii) and (b) optionally cause additional ARNT intramolecular interactions of the PAS- 1 and PAS-2 domains in the complex;(3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;(4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the ARNT intramolecular interactions of the PAS-1 and PAS-2 domains in step (2) result in degradation of ARNT.
844. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound;(2) performing structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and an ARNT degrader compound, wherein the compound is designed by (i) predicting or identifying the ARNT / CRBN / compound interactions of the complex, (ii) determining whether the ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240. L239, or L237 with at least one of the CRBN amino acids G151. 1152, F150, H353. F102, H103. Q390, A395. 1371, V388, H397, W386, W400, N351, Y355, H357, or S420, and (iii) modifying the compound to (a) enhance said specific interactions between ARNT, CRBN and the compound, (b) optionally cause additional ARNT / CRBN / compound interactions and (c) optionally increase ARNT / CRBN / compound nonspecific interactions in the complex;Attorney Docket No.: N2109-7007WO(3) synthesizing one or more compounds designed in step (2) wherein the compounds are synthesized in an individual or pooled format;(4) testing said compounds synthesized in step (3) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(5) testing the compounds in an assay to assess whether the compounds synthesized in step (3) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in step (2) between the ARNT amino acids and the CRBN amino acids result in degradation of ARNT.
845. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing one or more compounds in an individual or pooled format, wherein the compounds are optionally tagged with an identifier;(2) testing said compounds synthesized in step (1) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, engineered protein domain swaps, saturating mutagenesis assays, phenotypic screening assays or evaluation of the downregulation or disappearance of ARNT;(3) experimentally determining or computationally predicting the atomic structure model of a complex comprising cereblon (CRBN), ARNT, and a compound tested in step (2) having ARNT modulation activity;(4) perforating structural modeling, using a suitably programmed computer, to design a compound that degrades ARNT using the experimentally determined or computationally predicted atomic structural coordinates of a three-dimensional atomic structure of a complex comprising cereblon (CRBN), ARNT, and a compound tested in step (2) having ARNT modulation activity, wherein the compound is designed by (i) identifying the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains formed in tire complex, (ii) determining whether ARNT / CRBN / compound interactions in the complex occur through the specific interaction of at least one of the ARNT amino acids E398, N395, G393, 1372, K245, G242, T241, K240, L239, or L237 with at least one of the CRBN amino acids G151. 1152. F150, H353. F102, H103. Q390, A395. 1371, V388. H397, W386, W400, N351. Y355, H357. or S420. (hi) modifying the compound to enhance said specific interactions between ARNT, CRBN and the compound and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains and optionally cause additional ARNT / CRBN / compound interactions and ARNT intramolecular interactions between the PAS-1 and PAS-2 domains of the complex;Attorney Docket No.: N2109-7007WO(5) synthesizing one or more compounds designed in step (4) wherein the compounds are synthesized in an individual or pooled format and wherein the compounds are optionally tagged with an identifier;(6) testing said compounds synthesized in step (5) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(7) testing the compounds in an assay to assess whether the compounds synthesized in step (5) are modulating ARNT via CRBN mediated degradation of the ARNT protein;wherein the compounds that form the complex with ARNT and CRBN via the specific interactions in between the ARNT amino acids and the CRBN amino acids and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains in step (4) result in degradation of ARNT.
846. The method of claim 831, wherein the experimentally determined atomic structure coordinates of the ternary complex is determined from cryo-electron microscopy single particle analysis, X-ray cry stallography, negative stain EM, cryo-electron tomography, NMR, hydrogen-deuterium exchange mass spectrometry’, chemical footprinting, engineered protein construct fusions, protein mutagenesis, CRISPR base editing or tiling screens, sloppy PCR, or HTRF, or a combination thereof.
847. The method of anyone of claims 831-846, wherein the computationally predicted atomic structural coordinates of the ternary complex is determined by using structure prediction methods, protein docking prediction methods, ternary complex prediction model generation methods, or computer-assisted protein complex methods, or a combination thereof.
848. The method of claim 831, wherein the structural modeling is performed using computational chemistry design software, protein docking prediction methods, ternary complex prediction model generation methods, or computer-assisted protein complex methods, or a combination thereof.
849. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format; and(2) screening said one or more compounds from step (1) in an individual or pooled format using a screening method comprising proteomics, cellular proximity screen, AlphaLisa / Alpha Screen, orAttorney Docket No.: N2109-7007WOluciferase-based proximity screens, or a combination thereof to determine the ability of the compounds to modulate ARNT;(3) evaluating whether said one or more compounds induces a change in the conformation of the CRBN or otherw ise alters the properties of the CRBN surface such that a ternary’ complex is formed between the CRBN, the ARNT and the small molecule;(4) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.2); and(5) testing said one or more compounds in a biochemical or cellular assay, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded;wherein a CRBN confirmational change or alteration results in recruitment of ARNT, wherein ARNT intramolecular interactions and the interactions between the ARNT and the CRBN mediate the formation of the E3 ubiquitin ligase ternary complex and ubiquitination of ARNT, and wherein ARNT is not ubiquitinated by an E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
850. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format; and(2) screening said one or more compounds from step (1) in an individual or pooled format using a screening method comprising proteomics, cellular proximity screen, AlphaLisa / Alpha Screen, or luciferase-based proximity' screens, or a combination thereof to determine the ability of the compounds to modulate ARNT;(3) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.2);(4) testing said one or more compounds in a biochemical or cellular assay, wherein said assay determines whether ARNT levels arc reduced or ARNT is degraded;Attorney Docket No.: N2109-7007WOwherein ARNT intramolecular interactions mediate the formation of the E3 ubiquitin ligase ternary complex and ubiquitination of ARNT, and wherein ARNT is not ubiquitinated by an E3 ubiquitin ligase complex to a sufficient level to reduce cellular ARNT protein levels in the absence of said small molecule.
851. The method of 858 or 859, wherein tire luciferase -based proximity screens is NanoBit or NanoBRET.
852. A method of identifying a compound that degrades ar l hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format;(2) contacting said one or more compounds with cereblon (CRBN);(3) testing in a biochemical or cellular assay in an individual or pooled format, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded;(4) evaluating whether said one or more compounds induces a change in the conformation of the CRBN or otherw ise alters the properties of the CRBN surface such that a ternary’ complex is fonned between the CRBN, the ARNT and the small molecule;(5) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.2);(6) modifying said one or more compounds to (i) enhance said specific interactions between the ARNT, CRBN and the compound, and the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains, (ii) optionally cause additional ARNT / CRBN / compound interactions, ARNT intramolecular interactions, or enhance compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof; and (iii) optionally increase ARNT / CRBN / compound nonspecific interactions;(7) synthesizing one or more compounds designed in step (6) wherein the compounds are synthesized in an individual or pooled format;(8) testing said compounds synthesized in step (7) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of tire dow nregulation or disappearance of ARNT; andAttorney Docket No.: N2109-7007WO(9) testing the compounds in step (7) in a biochemical or cellular assay in an individual or pooled format to assess whether tire compounds synthesized in step (7) are modulating ARNT via CRBN mediated degradation of the ARNT protein.
853. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) synthesizing one or more compounds, wherein the compounds are synthesized in an individual or pooled format;(2) contacting said one or more compounds with cereblon (CRBN);(3) testing in a biochemical or cellular assay in an individual or pooled fomiat, wherein said assay determines whether ARNT levels are reduced or ARNT is degraded;(4) evaluating whether said one or more compounds induces a change in the conformation of the ARNT that results in ARNT amino acids interacting to form specific ARNT intramolecular interactions of the PAS-1 and PAS-2 domains of ARNT wherein said PAS-1 domain comprises amino acids 173-344 of ARNT (SEQ ID NO. 1) and said PAS-2 domain comprises amino acids 362-464 of ARNT (SEQ ID NO.2);(5) modifying said one or more compounds to (i) enhance said the ARNT intramolecular interactions between the PAS-1 and PAS-2 domains, and (ii) optionally cause additional ARNT intramolecular interactions, or enhance ARNT / CRBN / compound interactions, and / or cause compound / ARNT / CRBN-damage specific DNA binding protein 1 (DDB1) interactions, or a combination thereof;(6) synthesizing one or more compounds designed in step (5) wherein the compounds are synthesized in an individual or pooled fomiat:(7) testing said compounds synthesized in step (6) in one or more assays to evaluate whether said compounds modulate ARNT, wherein said assay can include proteomic analysis, binding assay, ubiquitin transfer assay, or evaluation of the downregulation or disappearance of ARNT; and(8) testing the compounds in step (6) in a biochemical or cellular assay in an individual or pooled fonnat to assess whether the compounds synthesized in step (6) are modulating ARNT via CRBN mediated degradation of the ARNT protein.
854. A method of identifying a compound that degrades aryl hydrocarbon nuclear translocator (ARNT), wherein the method comprises:(1) developing is a biochemical or cellular assay to identify compounds that induce an ARNT-CRBN interaction wherein said biochemical or cellular assay can measure a compound’s ability toAttorney Docket No.: N2109-7007WOdownregulate ARNT, to degrade ARNT, to ubiquitinate ARNT, to reduced protein levels wherein said reduced protein levels are measured by proteomics, fluorescence / luminescence read-out, or western blot, or to promote ARNT-CRBN proximity7;(2) screening one or more compounds in an individual or pooled fomiat in an assay developed in step (1) wherein the compounds are optionally tagged with an identifier;(3) analyzing the data from screening the compounds in step (2) to identify molecules that induce an ARNT-CRBN interaction in the assay:(4) confirming the screening data from step (2) by testing the individual compounds in the same biochemical or cellular assay or additional biochemical and cellular assays;(5) using the data obtained in step (2) and confirmed in step (4) to create a ternary complex model; and(6) using said ternary complex model created in step (5) to design compounds compatible with the binding mode of ARNT.
855. A small molecule (e.g., an ARNT degrader compound) that interacts with:(A) one or more of cereblon amino acid residues (1) H353, (2) P352, (3) N351, (4) S375, (5) E377, (6) H378, (7) S379, (8) W380, (9) F402, (10) W400. (11) W386, (12) F381. (13) H357. and (14) R373; and / or(B) one or more of ARNT amino acid residues (1) Q389, (2) E390, (3) L392, (4) G393, (5) K394, (6) L237, (7) D238, (8) L239, (9) K240, (10) T241, (11) G242, and (12) V244.
